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Cellular glucose uptake and metabolism 
In order to survive and perform vital cellular processes such as migration, 
transport, and cell division, cells require energy. Monosaccharides, amino acids, 
and fatty acids derived from food are taken up by cells and the energy stored in 
these biomolecules is used to produce adenosine triphosphate (ATP), the energy 
currency of cells. The monosaccharide glucose is one of the main energy sources 
for our body. In the majority of cells, glucose crosses the plasma membrane by 
facilitated diffusion along the glucose-gradient. This equilibrative glucose 
transport is mediated by glucose transporters (GLUTs). On the contrary, in cells of 
the intestine and renal proximal tubule, glucose is actively transported against a 
concentration gradient. This accumulative glucose transport is mediated by 
sodium-glucose linked transporters (SGLTs), which use the potential energy stored 
in the sodium-gradient to co-transport glucose. In this thesis we will focus on 
GLUT-mediated glucose uptake. 
 
GLUT isoforms 
GLUTs are integral membrane glycoproteins which belong to the Solute Carrier 
Family 2 (SLC2), which is part of the Major Facilitator Superfamily (MFS). The SLC2 
family comprises 14 members, which all contain 12 transmembrane (TM) α-
helices, with intracellular facing N- and C-termini, and a large intracellular loop 
between TM domain 6 and 7 (Mueckler et al., 1985). GLUTs can be divided in 3 
classes based on sequence similarities (Augustin, 2010). Class I comprises the 
‘classic’ and well-characterized transporters GLUT1-4 and GLUT14. Class II 
comprises GLUT5, 7, 9, 11, which transport fructose. Class III comprises GLUT6, 8, 
10, 12, 13, which contain an internalization signal and are mostly localized 
intracellular (Augustin, 2010). Class I and II GLUTs contain a relatively large 
extracellular loop between TM domain 1 and 2, which has an N-glycosylation site 
(Fig. 1A). In Class III GLUTs the N-glycosylation site is localized in a relatively large 
extracellular loop between TM domain 9 and 10 (Fig. 1B). The GLUT isoforms differ 
in their substrate specificity, kinetic parameters, tissue distribution, and mode of 
regulation (Table 1).  
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Figure 1. Predicted topology of class I and II (panel A) and class III (panel B) GLUTs. The N-glycosylation site is 
positioned in the relatively larger extracellular loop between TM domain 1 and 2 (class I and II) or between 
TM domain 9 and 10 (class III).  
 
 
Table 1. Characteristics of class I GLUTs. Data compiled from (Augustin, 2010) and the UniProtKB database. 
 
 
2-DG, 2-deoxy-D-glucose; aa, amino acids; Km(app), apparent Km. 
 
The tissue-specific expression of GLUTs, allows for a tissue-specific regulation of 
glucose uptake (Bell et al., 1990, Gould and Holman, 1993). For example, upon 
differentiation of the murine skeletal muscle-derived C2C12 myoblast cell line into 
multinucleated myotubes, Glut1 is down-regulated and Glut4 is upregulated (Fig. 
  Introduction 13 
2). This change in Glut expression during myogenesis was also observed in 
primary fetal rat myoblasts and the rat skeletal muscle-derived myoblasts cell line 
L6 (Mitsumoto and Klip, 1992, Guillet-Deniau et al., 1994). Under basal conditions, 
the majority of GLUT4 in muscle cells is retained in intracellular vesicles that are 
derived from the trans-Golgi network. Retention of these vesicles requires the 
activity of the Rab GTPase activating proteins TBC1D1 and TBC1D4 (Eguez et al., 
2005, Larance et al., 2005, Sano et al., 2003). Stimulation by insulin or exercise 
induces translocation of these vesicles to the plasma membrane. Although the full 
signaling cascade regulating vesicle translocation is still incompletely understood, 
Akt-mediated inhibition of TBC1D1/TBC1D4 plays an essential role (Eguez et al., 
2005, Funaki et al., 2004, Kohn et al., 1998, Larance et al., 2005, Sano et al., 2003, 
Ng et al., 2008).  
 
 
 
Figure 2. mRNA levels of Glut1 and 4 were analyzed by qPCR. C2C12 myoblasts express Glut1. Culturing for 5 
days in low serum differentiation medium induces myotube formation and Glut4 expression. Primer 
sequences are listed in the ‘material and methods’ section of chapter 3. 
 
GLUT1 is expressed during all stages of embryonic development (Hogan et al., 
1991). After birth, GLUT1 expression decreases, but most cell types still express 
low levels of GLUT1 to mediate basal glucose uptake. However, GLUT1 expression 
remains high in cells that primarily depend on glycolysis for ATP generation such 
as erythrocytes and certain tumor cells. In the latter, GLUT1 is frequently up-
regulated (Baer et al., 1997, Brown and Wahl, 1993, Nishioka et al., 1992), which is 
associated with poor survival in various malignant tumors (Szablewski, 2013). 
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Under basal conditions, a substantial amount of GLUT1 is stored in the 
endoplasmic reticulum (ER), the Golgi, and endosomes (Luiken et al., 2004, Holman 
et al., 1990, Farrell and Pardridge, 1991, Cornford et al., 1994). Stimulation by 
growth factors increases GLUT1 plasma membrane abundance by decreasing the 
rate of internalization and by promoting recycling of intracellular GLUT1 in a 
serum/glucocorticosteroid regulated kinase 1 (SGK1)- and Akt-dependent manner 
(Wieman et al., 2007, Palmada et al., 2006). In addition, protein kinase C (PKC) 
stimulates translocation of GLUT1 to the plasma membrane by phosphorylating 
Ser226, which is localized in the largest intracellular loop (Lee et al., 2015, Cooper 
et al., 1999). The affinity of GLUT1 depends on the glycosylation status at Asn45. 
Mutation of this residue leads to a 2-fold increase in the Km for 2-deoxy-D-glucose 
(2-DG) (Asano et al., 1991). Glucose depletion for more than 12 hours renders 
GLUT1 hypoglycosylated, which decreases its affinity for glucose but greatly 
increases the protein half-life of GLUT1. Re-addition of glucose restores 
glycosylation and reduces the protein half-life to normal (McMahon and Frost, 
1995). The above regulatory mechanisms can help cells to cope with differences 
in energy demand and available energy sources, respectively.  
 
GLUT transport mechanism 
Based on homology-modeling and the structure of GLUT1, the transport 
mechanism of GLUTs was proposed to be an alternating access model in which 
the carrier cycles between four different conformations (Jardetzky, 1966, Deng et 
al., 2014, Krupka and Deves, 1981, Lieb and Stein, 1974). Crystalized human GLUT1 
revealed that the N- and C-terminal domains are connected by an intracellular 
helical bundle, which comprises 4 short α-helices (Deng et al., 2014). Interactions 
between this intracellular helical bundle and the TM domains was proposed to 
maintain the carrier in an outward-open conformation in the absence of substrate. 
Binding of substrate to the exofacial binding site, drives a conformational change 
from an occluded-occupied to an inward-open conformation, in which the 
endofacial sugar binding site is exposed (Fig. 3; 1→2→3). This part of the cycle is 
termed translocation. The lower substrate concentration inside the cell shifts 
equilibrium towards dissociation and the substrate is released. Next, the carrier is 
able to return to the outward-open conformation, which in the absence of 
substrate is termed relaxation (Fig. 3; 3→4→1).  
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Figure 3. GLUT transport mechanism. GLUT cycles between 4 conformations: 1) outward-open, 2) occluded-
occupied, 3) inward-open, and 4) occluded-empty. 
 
GLUT1 kinetics are asymmetric, meaning that the Vmax and Km for glucose uptake 
are lower than the Vmax and Km for glucose efflux (Baker and Widdas, 1988, Batt 
and Schachter, 1973). At physiological temperature this asymmetry is observed as 
a 2.5-fold higher affinity for glucose uptake compared to glucose efflux (Lowe and 
Walmsley, 1986). This asymmetry is at least in part mediated by binding of ATP to 
GLUT1, which induces a 4-fold reduction in Km and 2.4-fold reduction in Vmax for 
glucose uptake (Carruthers, 1986). Another important feature of GLUT1 is trans-
acceleration, which means that glucose transport is faster when glucose is present 
on the opposite (trans)-side of the membrane. Based on the above described 
model this means that glucose translocation is faster than relaxation. This slower 
relaxation is mediated by TM domain 6, which was proposed to inhibit relaxation 
(Vollers and Carruthers, 2012). Although each GLUT1 molecule represents a fully 
functional catalytic unit, reduced GLUT1 is a dimer and non-reduced GLUT1 is a 
tetramer (Graybill et al., 2006, Sogin and Hinkle, 1978, Hebert and Carruthers, 
1992, Zottola et al., 1995). Dimeric GLUT1 comprises two structurally associated 
but functionally independent GLUT1 subunits (Gorga and Lienhard, 1981). 
Tetrameric GLUT1 comprises a dimer of GLUT1 dimers in which subunits 
functionally interact in an anti-parallel manner so that, at any time two carriers are 
in the outward-open conformation and two carriers are in the inward-open 
conformation (Cloherty et al., 2001, Hamill et al., 1999, Hebert and Carruthers, 
1992, Zottola et al., 1995). Reorientation of two carriers in one direction induces 
reorientation of the coupled carriers in the opposite direction. When translocation 
is faster than relaxation, translocation of two carriers could accelerate the 
relaxation of the coupled two carriers, thereby inducing trans-acceleration. 
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Glucose metabolism 
Once inside the cell, glucose is phosphorylated by hexokinase (HK) to form 
glucose-6-phosphate (G6P). Phosphorylated glucose can be used anabolic to form 
NADPH and nucleotide precursors via the pentose phosphate pathway (PPP) or to 
be stored as glycogen. Alternatively, glucose can be used catabolic via the 
glycolytic pathway, which comprises 10 enzymes that oxidize glucose in a step-
wise manner (Fig. 4). The net yield of glycolysis is 2 molecules of pyruvate, 2 
molecules of ATP, and 2 molecules of reduced nicotinamide adenine dinucleotide 
(NADH). In the absence of oxygen, pyruvate is converted to lactate by lactate 
dehydrogenase (LDH) and secreted out of the cell (Fig. 4). Alternatively, when 
sufficient oxygen is available, pyruvate enters the mitochondria where it is 
converted by pyruvate dehydrogenase (PDH) into acetyl-coenzyme-A (AcCoA), 
which is further oxidized by the tricarboxylic acid (TCA) cycle (Fig 4). Oxidation of 1 
molecule of AcCoA by the TCA cycle yields 1 molecule of ATP, 4 molecules of NADH, 
and 1 molecule of reduced flavin adenine dinucleotide (FADH2). The latter two 
serve as electron donors for mitochondrial complex I (CI or NADH:ubiquinone 
oxidoreductase) and complex II (CII or succinate:ubiquinone oxidoreductase) of 
the electron transport chain (ETC). The electrons are subsequently transported by 
ubiquinone to complex III (CIII or ubiquinol:cytochrome-c oxidoreductase) and by 
cytochrome-c to complex IV (CIV or cytochrome-c oxidase) where they react with 
oxygen to form water. At CI, CIII and CIV protons are expelled from the 
mitochondrial matrix across the mitochondrial inner membrane (MIM). This 
proton pumping establishes an inward-directed proton motive force (PMF) that 
consists of a chemical (ΔpH) and electrical (Δψ) component. Via complex V (CV or 
F1Fo-ATP synthase), protons are allowed to flow back into the matrix to fuel 
generation of ATP from ADP and inorganic phosphate (Pi) (Fig. 4). Together with 
the ETC, CV constitutes the mitochondrial oxidative phosphorylation (OXPHOS) 
system. Under optimal conditions, OXPHOS yields 30 molecules of ATP per 
glucose. However, due to the presence of uncoupling-proteins and other Δψ-
consuming processes, the actual ATP yield is lower.     
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Figure 4. Schematic representation of glucose catabolic metabolism. Glucose (GLC) is taken up by GLUT 
and phosphorylated by hexokinase (HK) to glucose-6-phosphate (G6P). Next, G6P is converted by 
phosphoglucose isomerase (PGI) to fructose-6-phosphate (F6P). F6P is phosphorylated by 
phosphofructokinase (PFK) to fructose 1,6-bisphosphate (FBP). FBP is broken down by fructose 1,6-
bisphosphate aldolase (FBA) to dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate (G3P). 
DHAP is converted by triose phosphate isomerase (TPI) to G3P. G3P is converted by glyceraldehyde-3-
phosphate dehydrogenase (GPDH) to 1,3-bisphosphoglycerate (BPG), yielding NADH. BPG is phosphorylated 
by phosphoglycerate kinase (PGK) to 3-phosphate glycerate (3PG), yielding ATP. 3PG is converted by 
phosphoglycerate mutase (PGM) to 2-phosphate glycerate (2PG). 2PG is converted by endolase (En) to 
phosphoenolpyruvate (PEP). Finally, PEP is converted by pyruvate kinase (PK) to pyruvate (PYR), yielding ATP. 
PYR can be converted by lactate dehydrogenase (LDH) to lactate (LAC), consuming NADH, or imported into 
the mitochondria by the mitochondrial pyruvate carrier (MPC), where it is converted by pyruvate 
dehydrogenase (PDH) to acetyl coenzyme A (AcCoA). AcCoA is oxidized within the tricarboxylic acid (TCA) cycle, 
yielding NADH and FADH2, which serve as electron donors for complex I (CI) and complex II (CII). The electrons 
are transported by ubiquinone (UQ) to complex III (CIII) and by cytochrome-c (Cyt c) to complex IV (CIV) where 
they react with O2. At CI, CIII and CIV protons are pumped across the mitochondrial inner membrane, which 
results in an inward-directed proton motive force. Via complex V (CV), protons flow back into the matrix to 
fuel generation of ATP. ATP is exported from the mitochondrial matrix by the adenine nucleotide translocator 
(ANT). 
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Mitochondrial oxidative phosphorylation dysfunction 
To date, mutations in more than 240 genes encoding mitochondrial proteins have 
been linked to a wide variety of both multi-systemic and tissue-specific 
mitochondrial disorders (Thorburn, 2004, Koopman et al., 2012). The incidence of 
mitochondrial disease is about 1-5 in 10.000 live births (Thorburn, 2004) and the 
majority of mutations affect the complexes of OXPHOS system (Wallace, 1999). 
Isolated CI deficiency is the most common OXPHOS disorder and often presents 
as Leigh or Leigh-like syndrome, which is a progressive, subcortical 
encephalopathy (Leigh, 1951, Rahman et al., 1996). CI consist of 37 nuclear 
encoded and 7 mitochondrial encoded proteins, which are assembled into a ~1 
MDa holo-complex. Pathogenic mutations causing isolated CI deficiency can reside 
in the structural components or assembly factors. Fully assembled CI comprises a 
peripheral NADH dehydrogenase module, an electron conducting hydrogenase 
module, and an integral proton pumping module (Balsa et al., 2012, Hunte et al., 
2010). In the peripheral arm, electrons derived from NADH are accepted by flavin 
mononucleotide (FMN), transported through 8 iron-sulfur (FeS) clusters, and 
donated to ubiquinone. In primary skin fibroblasts from patients baring mutations 
in different CI subunits, the activity of this complex ranges from 5-82% of the 
lowest control value (Koene et al., 2012, Verkaart et al., 2007b, Voets et al., 2012). 
Interestingly, this residual CI activity does not correlate with clinical features in 
patients. This can at least in part be attributed to differences in genetic 
background, the presence of compensatory mechanisms, and differences in 
energy demand (Koopman et al., 2012). Besides inherited disorders, OXPHOS 
dysfunction has been linked to a number of age-related diseases such as 
Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), 
diabetes type II, and cancer (Breuer et al., 2013a, Chandra and Singh, 2011, Martin, 
2011, Ritov et al., 2010, Swerdlow, 2012).  
Cellular biochemical consequences of OXPHOS dysfunction are among others 
reduced mitochondrial membrane potential (ΔΨ), aberrant calcium and ATP 
homeostasis, aberrations in mitochondrial structure, and increased mitochondrial 
reactive oxygen species (ROS) levels (Blanchet et al., 2011). Correlation of these 
and other biochemical parameters obtained from primary CI patient skin 
fibroblasts revealed that fibroblasts from patients with a lower age of disease 
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onset and death, displayed a larger reduction in CI activity, a larger increase in 
mitochondrial fragmentation, lower cellular levels of OXPHOS proteins, and a 
larger increase in ROS levels (Blanchet et al., 2011). In the following sections, 
mitochondrial ROS production and its role in the regulation of glucose uptake will 
be discussed.  
 
Mitochondrial ROS production 
To prevent generation of excessive mitochondrial ROS and induction of oxidative 
stress, mitochondria possess powerful antioxidant systems. One of these consists 
of manganese-dependent superoxide dismutase (MnSOD or SOD2), an enzyme 
that is localized in the mitochondrial matrix and rapidly converts superoxide to 
hydrogen peroxide. This conversion is also catalyzed by the copper/zinc-
dependent superoxide dismutase (Cu/ZnSOD or SOD1), which is localized in the 
cytosol, nucleus and mitochondrial intermembrane space (Murphy, 2009, Tyler, 
1975, Weisiger and Fridovich, 1973). In turn, hydrogen peroxide can be converted 
into water by the action of catalases that are mainly located in the peroxisomes 
and also in mitochondria (Salvi et al., 2007). However, within mitochondria, 
hydrogen peroxide is mainly removed by the action of glutathione peroxidase-1 
(Gpx1) (Cox et al., 2010, Esposito et al., 2000, Esworthy et al., 1997), peroxiredoxins 
3 and 5 (Prx3 and Prx5) and the thioredoxin-2 (Trx2) system (Chae et al., 1999, 
Chang et al., 2004, Cox et al., 2010), which require glutathione (GSH). Oxidized GSH 
(GSSG) is recycled to GSH by the action of glutathione reductase. Similarly, oxidized 
Trx2 is recycled by Trx reductase. Both of these systems require NADPH (Arner, 
2009, Carlberg and Mannervik, 1985), which is regenerated in the cytosol by 
glucose-6-phosphate-dehydrogenase (G6PDH) via the PPP (Le Goffe et al., 2002). 
Alternatively, NADPH can be regenerated in the mitochondrial matrix by 
nicotinamide nucleotide transhydrogenase (NNT), which uses NADH and the PMF 
(Hatefi and Yamaguchi, 1996, Rydstrom, 2006, Yin et al., 2012). When 
mitochondrial ROS production exceeds the capacity of the cell’s antioxidant 
systems or when the latter systems are less active, increased ROS levels can induce 
cell damage (oxidative stress). In principle, superoxide can react with protein FeS 
clusters (Liochev and Fridovich, 1994), which, in the presence of hydrogen 
peroxide, induce generation of hydroxyl radicals (Fenton reaction). The latter are 
highly reactive and can damage lipids, proteins, and DNA (Martinez-Reyes and 
Cuezva, 2014, Valko et al., 2006). Given the fact that iron is effectively sequestered 
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(Kakhlon and Cabantchik, 2002), the relevance of the Fenton reaction is not fully 
established in vivo. Superoxide can react with NO to form peroxynitrite (ONOO−) 
(Pacher et al., 2005). When rising too high, hydrogen peroxide can induce over-
oxidization of cysteine residues from sulfenic acid (–SO−) to sulfinic acid (–SO2H) 
and sulfonic acid (–SO3H). In case of CI, such over-oxidation is associated with 
irreversible deactivation of CI (Hurd et al., 2008, Mailloux et al., 2014). In general, 
if ROS levels exceed a certain threshold, they will impair OXPHOS complexes and 
further stimulate ROS production (Galloway and Yoon, 2012). In the light of the 
above, it is not surprising that increased ROS levels, although not always oxidative 
stress, are observed during various pathological conditions. For example, primary 
fibroblasts derived either from CI deficient mice or patients show increased ROS 
levels, but no obvious signs of oxidative stress (Koopman et al., 2007, Valsecchi et 
al., 2013, Verkaart et al., 2007a, Verkaart et al., 2007b). Increased ROS levels also 
have been observed in multiple types of cancer (e.g., prostate, colorectal, ovarian, 
pancreatic, breast, liver, bladder, melanoma, glioma), neurogenerative diseases 
(e.g., Alzheimer’s disease and Parkinson’s disease), and during insulin-resistance 
and diabetes (Afanas'ev, 2011, Freeman et al., 2006, Kumar et al., 2008, Pi and 
Collins, 2010, Sabens Liedhegner et al., 2012, Sanchez-Gomez et al., 2013).  
 
Regulation of glucose uptake by mitochondrial ROS 
Mitochondrial OXPHOS dysfunction triggers several adaptive responses. One of 
these is an increase in the rate of glucose uptake and glycolysis (Wu and Wei, 
2012). Stimulation of cellular glucose uptake is frequently observed during 
conditions of oxidative stress. Exogenous addition of hydrogen peroxide 
stimulates glucose uptake in skeletal muscle (Higaki et al., 2008, Jensen et al., 2008, 
Kim et al., 2006), C2C12 myoblasts, clone 9 liver cells, and 3T3 fibroblasts (Prasad 
and Ismail-Beigi, 1999). Upon electrical stimulation, endogenous ROS also induced 
an increase in glucose uptake in muscle cells (Merry et al., 2010, Pinheiro et al., 
2010). Below we will discuss the role of ROS in the regulation of glucose uptake at 
the level of GLUT transcription, GLUT translocation, and GLUT activation.  
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Transcriptional regulation of GLUT expression by ROS 
Protein expression levels of human GLUT1 are controlled by a promoter region 
and several putative enhancer regions that contain binding sites for various 
transcription factors including specificity proteins (Sp1) (Vinals et al., 1997) and 
hypoxia-inducible factor-1 (HIF-1) (Ebert et al., 1995). Mild oxidative stress induced 
by either glucose/glucose oxidase (Glc/GO) or xanthine/xanthine oxidase (Xan/XO) 
has been shown to up-regulate GLUT1 expression by increasing the transcription 
rate and mRNA stability leading to increased GLUT1 protein and glucose transport 
activity (Kozlovsky et al., 1997). As far as we know, there is no experimental 
evidence demonstrating the involvement of Sp1 in ROS-induced stimulation of 
GLUT1 expression, and therefore, we here focus on the role of HIF-1. 
HIF-1 consists of two subunits, HIF-1α and HIF-1β. Under normoxic conditions, 
prolines within the oxygen-dependent degradation domains (ODDs) of HIF-1α are 
hydroxylated by prolyl-4-hydroxylases (PHDs) (Ivan et al., 2001). This hydroxylation 
acts as an ubiquitination signal leading to proteasomal degradation of HIF-1α. In 
the absence of oxygen, HIF-1α ubiquitinylation is inhibited allowing its interaction 
with HIF-1β to drive transcription of various target genes, including GLUT1 
(Hayashi et al., 2004, Iyer et al., 1998, Ouiddir et al., 1999, Wood et al., 1998). During 
hypoxia, ROS levels increase and play an important role in HIF-1α stabilization 
(Brunelle et al., 2005, Chandel et al., 2000, Guzy et al., 2005, Mansfield et al., 2005, 
Sanjuan-Pla et al., 2005, Schroedl et al., 2002). Preventing ROS-mediated HIF-1α 
stabilization represses GLUT1 expression and glucose uptake in Lewis lung 
carcinoma, HT-29 colon, and T47D breast cancer cells (Jung et al., 2013). Upon 
mitochondrial DNA depletion (Chandel et al., 2000, Mansfield et al., 2005) and in 
mouse embryonic fibroblasts (MEFs) lacking cytochrome-c (Mansfield et al., 2005), 
hypoxia-induced HIF-1α stabilization is abrogated. This suggests that hypoxia-
induced ROS are of mitochondrial origin. Knockout of the Rieske iron–sulfur 
protein (RISP) in mitochondrial CIII decreases ROS production during hypoxia and 
attenuates hypoxic stabilization of HIF-1α (Guzy et al., 2005). Therefore, RISP-
mediated mitochondrial ROS production appears to be involved in HIF-1α 
stabilization during hypoxia. At the RISP site, electrons are transferred one-by-one 
from ubiquinol to cytochrome-c1. This one-electron donation generates a highly 
reactive ubisemiquinone, which can act as a source for superoxide generation. 
Over-expression of catalase (Chandel et al., 2000, Guzy et al., 2005) or GPx1 
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(Brunelle et al., 2005, Emerling et al., 2005) abolishes HIF-1α stabilization during 
hypoxia, whereas over-expression of SOD1 or SOD2 does not (Brunelle et al., 2005, 
Guzy et al., 2005). In addition, exogenous hydrogen peroxide is sufficient to 
stabilize HIF-1α under normoxic conditions (Chandel et al., 2000, Jung et al., 2008, 
Mansfield et al., 2005). This suggests that the stabilization of HIF-1α primarily 
involves hydrogen peroxide via inactivation of PHDs (Fig. 5) and subsequent 
reduction of HIF-1α ubiquitinylation (Chandel et al., 1998, Guzy and Schumacker, 
2006). However, HIF-1α ubiquitinylation is incompletely blocked by exogenous or 
hypoxia-derived hydrogen peroxide (Guzy et al., 2005), suggesting the involvement 
of additional mechanisms. 
Alternatively, ROS-induced HIF-1α stabilization was proposed to be mediated by 
specific signaling routes. Phosphoinositide 3-kinase (PI3K) appears to be involved 
in HIF-1α stabilization by mitochondrial ROS in Hep3B cells (Fig. 5; arrow 1) 
(Chandel et al., 2000). Compatible with this mechanism, PI3K inhibition lowered 
GLUT1 transcription under hypoxic and normoxic conditions (Chen et al., 2001). In 
addition, both p38 mitogen-activated protein kinase (MAPK p38) and its upstream 
kinases MKK3/6 are activated by hypoxia-derived ROS and are essential in HIF-1α 
stabilization and the ensuing increase in GLUT1 mRNA levels (Emerling et al., 
2005). Activation of MAPK p38 by ROS is mediated by apoptosis signal-regulating 
kinase 1 (ASK1), which is normally bound to Trx. Oxidation of Trx releases ASK1 
leading to activation of its downstream targets MKK3, MKK4, MKK6 and MMK7 and 
subsequently JNK and MAPK p38 (Nagai et al., 2007). Also, AMP-activated protein 
kinase (AMPK) can be activated by ROS during hypoxia (Emerling et al., 2009). This 
protein plays a key role in energy metabolism and cellular adaptation to ROS (Wu 
et al., 2014). Various metabolic stress conditions can activate AMPK through 
phosphorylation of Thr172 by upstream kinases such as LKB1 (Hardie, 2011). In 
addition, AMP-interaction stimulates AMPK activation by promoting AMPK 
phosphorylation, preventing AMPK dephosphorylation, and inducing allosteric 
activation of AMPK (Davies et al., 1995, Hardie and Ashford, 2014). Oxidative stress 
can inhibit the ETC, potentially leading to an increased AMP:ATP ratio (Hawley et 
al., 2010). However, under hypoxic conditions, AMPK is also activated by 
mitochondrial ROS in an LKB1-dependent and AMP:ATP-independent manner 
(Emerling et al., 2009, Mungai et al., 2011). In muscle cells, AMPK activation 
stimulated GLUT1 expression and twofold increased cellular glucose uptake (Fryer 
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et al., 2002). Besides activation of HIF-1α, AMPK can up-regulate GLUT1 via 
degradation of thioredoxin-interacting protein (TXNIP) (Fig. 5; arrow 1). TXNIP 
reduces the level of GLUT1 mRNA in the nucleus. TXNIP is degraded upon Ser308 
phosphorylation by AMPK, leading to increased GLUT1 mRNA and protein levels 
(Wu et al., 2013). 
 
 
Figure 5. Glucose uptake can be regulated by: (1) altering the expression level of GLUTs, (2) stimulating 
translocation of GLUTs from internal vesicles to the plasma membrane and (3) changing the intrinsic activity 
of GLUTs at the plasma membrane. Proteins that are activated by ROS are depicted in yellow. ATM, ataxia 
telangiectasia mutated; GIPC, Gα-interacting protein-interacting protein C-terminus; HIF-1, hypoxia-inducible 
factor 1; P-AMPK, phosphorylated (activated) AMP-activated protein kinase; PHD, prolyl hydroxylase domain; 
P-p38, phosphorylated (activated) p38 mitogen-activated protein kinase; PI3K, phosphoinositide 3-kinase, 
ROS, reactive oxygen species, TXNIP, thioredoxin-interacting protein. 
 
Regulation of GLUT-vesicle translocation to the plasma membrane by ROS 
The cellular capacity for glucose uptake is co-determined by the abundance of 
functional GLUTs at the plasma membrane. This means that glucose uptake can 
be regulated by GLUT trafficking between the cytosol and the plasma membrane. 
During exercise, muscle contraction is associated with increased ROS levels, 
believed to represent a fast adaptive response to an increase in energy demand 
(Chambers et al., 2009, Murrant et al., 1999, Wretman et al., 2001). In these cells, 
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endogenous (i.e., those induced by contraction) and exogenous ROS stimulate 
glucose uptake via a mechanism involving activation of Akt and/or AMPK (Higaki 
et al., 2008, Sandstrom et al., 2006, Toyoda et al., 2004). ROS can activate Akt 
(Fernandes et al., 2011, Niwa et al., 2003), which probably involves inactivation of 
cysteine-based phosphatases (Okoh et al., 2011). ROS can activate AMPK by 
modification of cysteine residues on its α-catalytical subunit (Zmijewski et al., 
2010). Once activated, Akt and AMPK phosphorylate TBC1D4 and TBC1D1, leading 
to GLUT4 translocation (Geraghty et al., 2007, Kramer et al., 2006, Taylor et al., 
2008, Thong et al., 2007). 
Translocation of GLUT1 to the plasma membrane (Fig. 5; arrow 2) is regulated by 
ataxia telangiectasia mutated (ATM) (Andrisse et al., 2013). This protein is a 
member of the family of phosphatidylinositol-3-kinase-related protein kinases 
(PIKKs) and plays an important role in the response to DNA damage after which it 
becomes phosphorylated. However, ATM can also localize to the cytosol where it 
is activated by ROS and involved in cytosolic signaling (Alexander and Walker, 
2010). ATM is thiol-oxidized by ROS to form an active dimer of two covalently linked 
monomers (Guo et al., 2010). Activated ATM localizes near mitochondria and 
mitochondria are necessary for ROS-induced ATM activation (Morita et al., 2014). 
This suggests that ATM dimerization and activation are stimulated by 
mitochondrial ROS. Evidence was provided that ATM is activated by ROS during 
treatment with the chemotherapeutic agent doxorubicin (Kurz et al., 2004). In 
muscle, ATM activation by doxorubicin mediates targeting of GLUT1 to the cell 
surface by phosphorylation of GLUT1 at S490. This serine residue is part of a C-
terminal PDZ motif, and phosphorylation of this residue induces interaction of 
GLUT1 with the PDZ-interacting protein, Gα-interacting protein and C-terminus 
(GIPC1) (Andrisse et al., 2013). GIPC1 interaction promotes GLUT1 trafficking to the 
cell surface and stimulates glucose uptake (Fig. 5; arrow 2) (Wieman et al., 2009). 
 
Regulation of GLUT1 activity at the plasma membrane by ROS 
Regulation of glucose uptake can also occur directly at the plasma membrane. This 
type of regulation occurs on a relatively short-term time scale (i.e., within 1 hour) 
and represents a relatively fast mechanism that allows the cells to cope with 
metabolic stress (Fig. 5; arrow 3). The intrinsic activity of GLUTs can be modulated 
by conformational changes or posttranslational modifications that increase 
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glucose affinity (Asano et al., 1991, Levine et al., 2002). In addition, Vmax can be 
modulated by activation or deactivation of GLUTs at the plasma membrane. A 
number of metabolic inhibitors and AMPK activators acutely stimulate glucose 
uptake without increasing the amount of GLUT molecules at the plasma 
membrane (Abbud et al., 2000, Barnes et al., 2002, Hamrahian et al., 1999, Shetty 
et al., 1993, Shi et al., 1995). It was proposed that this increase is due to the release 
of ‘masking proteins’, which display an inhibitory interaction with the GLUT 
cytoplasmic domain under basal conditions (Shi et al., 1995). Stomatin was 
proposed being a masking protein as it interacts with the C-terminus of GLUT1, 
and its over-expression reduces GLUT1 intrinsic activity (Rungaldier et al., 2013, 
Zhang et al., 2001). Another potential masking protein is TXNIP, which displays an 
inhibitory interaction with GLUT1 (Wu et al., 2013). AMPK-induced degradation of 
TXNIP (see previous section) would unmask GLUT1 leading to enhancement of 
GLUT1-mediated glucose influx (Fig. 5; arrow 3). Although stimulation of GLUT 
intrinsic activity is often observed during metabolic stress, the role of ROS in this 
pathway is still incompletely understood. In a leukemic cell line, ROS generated by 
NAD(P)H oxidase (Nox) stimulated glucose uptake via Src-mediated 
phosphorylation of GLUT1 (Prata et al., 2008). On the other hand, antioxidants 
were ineffective in preventing GLUT1 activation during azide-induced CIV 
inhibition (Hamrahian et al., 1999). Taken together, various signaling pathways 
have been implied in the stimulation of glucose uptake as an adaptive response 
during oxidative stress (Fig. 5). At a relatively slow timescale, ROS-induced signals 
stimulate glucose uptake via up-regulation of GLUT protein expression. Rapid 
stimulation of glucose uptake can occur at the level of GLUT translocation and 
regulation of GLUT intrinsic activity. Interestingly, several of the signaling proteins 
are ROS-sensitive (i.e., AMPK and TXNIP) and involved in both slow and fast 
responses. This suggests that ROS-induced stimulation of glucose uptake is part 
of a (adaptive) mechanism triggered by oxidative and/or metabolic stress. 
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The role of glucose in ROS scavenging 
The above evidence supports the conclusion that increased ROS levels stimulate 
cellular glucose uptake both at slow and fast time scales. However, inhibition of 
GLUT1 activity in myoblasts was paralleled by increased ROS levels (Andrisse et al., 
2014). This might indicate that glucose uptake also plays a role in regulating the 
balance between ROS production and scavenging, suggesting that glucose uptake 
must be tightly controlled to maintain cellular energy homeostasis and redox 
status. Glucose entry into the PPP is protective against hydrogen peroxide-
induced cytotoxicity (Le Goffe et al., 2002). Mechanistically, this protection is 
probably due to an increased PPP flux, leading to a higher NADPH/NADP+ ratio 
and GSH level. Compatible with this hypothesis, skin fibroblasts derived from 
patients with myoclonic epilepsy with ragged red fibers (MERRF; a syndrome that 
has been associated with a mutation in the tRNALys gene of mtDNA) displayed 
GLUT1 up-regulation and increased NADPH and GSH levels (Wu and Wei, 2012). 
Preventing this NADPH increase induced ROS over-production and cell death (Wu 
and Wei, 2012). Glucose entry into the PPP and subsequently increased levels of 
NADPH is stimulated by ATM-induced activation of G6PD, which is the first and 
rate determining enzyme of the PPP (Cosentino et al., 2011). In a Drosophila model 
for Huntington’s disease, which is particularly vulnerable to oxidative stress, 
overexpression of G6PD in neurons increased the tolerance to hydrogen peroxide 
(Besson et al., 2015). This increased tolerance was proposed to be mediated by 
increased activity of NADPH-dependent antioxidant systems because 
overexpression of Drosophila homologues of Prx2 and Trx significantly extended 
the flies lifespan. Moreover, GLUT1 contributes to ROS scavenging by mediating 
the transport of dehydroascorbic acid (DHA), the oxidized form of vitamin C, which 
is recycled back to vitamin C inside the cell (Rumsey et al., 1997, Guaiquil et al., 
2001). Vitamin C is a potent antioxidant, which can prevent oxidative cell death 
(Guaiquil et al., 2001). Experimental evidence suggests that GLUT1 also co-localizes 
with mitochondria to facilitate mitochondrial uptake of DHA and quench ROS 
induced by mitochondrial uncoupling (Kc et al., 2005). In summary, enhanced PPP 
glucose entry and GLUT-mediated antioxidant uptake appear to be relevant for 
cellular ROS removal.  
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Aim and outline of this thesis 
The aim of this thesis is to assess the role of cellular glucose uptake in 
mitochondrial OXPHOS dysfunction. This aim was addressed by studying: (i) the 
effect of pharmacologically or genetically induced CI dysfunction on the rate of 
glucose uptake and consumption, (ii) how glucose uptake stimulation affects the 
glycolytic ATP production, and (iii) the mode of regulation of glucose uptake in 
CI/CIII-inhibited myoblasts. Chapter 2 provides an overview of available 
fluorescent glucose sensors and their applications. In Chapter 3 the development 
of a microscopy protocol for live-cell quantitative glucose uptake measurements 
is presented. Using this protocol, the kinetic parameters of glucose uptake and 
consumption in CI- and CIII-inhibited C2C12 myoblasts are determined and used 
to construct a mathematical model, which allows prediction of the glycolytic flux 
and ATP production. Chapter 4 focusses on glucose uptake in primary skeletal 
muscle myoblasts from Ndufs4 knockout mice and how this parameter is affected 
by different culturing conditions. Chapter 5 explains the mechanism by which CI- 
and CIII-inhibition regulates glucose uptake in C2C12 myoblasts. In Chapter 6, the 
obtained results are integrated and discussed in a broader perspective.   
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
CHAPTER 2 
Quantitative glucose sensing in mammalian cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from:  
Dania C. Liemburg-Apers, Hiromi Imamura, Marleen Forkink, Marco 
Nooteboom, Herman G. Swarts, Roland Brock, Jan A. M. Smeitink, Peter H. G. 
M. Willems and Werner J. H. Koopman 
Pharm Res. (2011) 28(11):2745-5
30  Chapter 2 
Abstract 
The functioning and survival of mammalian cells requires an active energy 
metabolism. The monosaccharide glucose constitutes a key source of cellular 
energy. Following its import across the plasma membrane glucose is converted 
into pyruvate by the glycolysis pathway. Pyruvate oxidation supplies substrates for 
the ATP-generating mitochondrial oxidative phosphorylation (OXPHOS) system. To 
gain cell-biochemical knowledge about the operation and regulation of the cellular 
energy metabolism in the healthy and diseased state, quantitative knowledge is 
required about (changes in) metabolite concentrations under (non) steady-state 
conditions. This information can for instance be used to construct more realistic 
in silico models of cell metabolism, which facilitates understanding the 
consequences of metabolic dysfunction as well as on- and off-target effects of 
mitochondrial drugs. Here we review the current state-of-the-art concerning the 
live-cell quantification of the key cellular metabolite glucose, using protein-based 
sensors that apply the principle of FRET (fluorescence resonance energy transfer). 
We further summarize the properties and applications of the FRET-based sensors, 
their calibration, pitfalls and future perspectives.  
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Introduction  
Energy availability in a living cell depends on the balance between energy 
production by breakdown of biomolecules (catabolism) and energy demand. This 
balance constitutes part of a cell’s metabolism, which involves a large collection of 
molecular intermediates (metabolites). The concentration of metabolites 
continually changes in time and/or space in response to alterations in the cellular 
environment and metabolic activity. Within cells, adenosine triphosphate (ATP) is 
the most important energy currency. ATP hydrolysis yields adenosine diphosphate 
(ADP) and inorganic phosphate (Pi), providing the energy that fuels numerous 
cellular processes. In most cells, ATP is generated by the metabolic conversion of 
the monosaccharide glucose, which is taken up from the extracellular 
environment. In this sense, glucose is a key player in cellular metabolism. We 
present how protein-based sensors can be used to quantify the (sub)cellular 
concentration of glucose and discuss sensor calibration, possible pitfalls and 
future perspectives.  
 
Quantification of glucose levels in living cells  
Principles of FRET 
For the purpose of quantifying glucose in different cellular compartments, a 
variety of protein-based metabolite sensors are available (Deuschle et al., 2006, 
Deuschle et al., 2005a, Deuschle et al., 2005b, Fehr et al., 2003, Fehr et al., 2005). 
Sensors that are based on the same principle are available for lactate, pyruvate, 
maltose, ribose, citrate, glutamate, and ATP (Berg et al., 2009, Ewald et al., 2011, 
Imamura et al., 2009, Okumoto et al., 2008, San Martin et al., 2014, San Martin et 
al., 2013, Tsuboi et al., 2004, Deuschle et al., 2005b). The detection principle of 
most of these reporter molecules is based on the principle of Fluorescence 
Resonance Energy Transfer (FRET). FRET is the distance- and orientation-
dependent (non-radiative) transfer of energy, which can occur between a 
fluorescent donor molecule and a fluorescent acceptor molecule. FRET 
(donor→acceptor) only takes place if donor and acceptor are very close to each 
other (i.e. within 1-10 nm). For FRET to happen, the emission spectrum of donor 
needs to partially overlap with the absorption spectrum of the acceptor. FRET 
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efficiency (E) is given by E = R06/(R06+r6), with r being the distance between donor 
and the acceptor, and R0 (the Förster distance) being the distance of half-maximal 
FRET efficiency. If the wavelength is expressed in cm and J(λ) is in units of M-1·cm3, 
the Förster distance (in Å) for a FRET pair is given by: R0 = 9.78·103·[κ2·n-4·QD·J(λ)]1/6 
(Lakowicz, 2006). In this equation κ2 is a factor describing the relative orientation 
in space of the transition dipoles of the FRET pair (typically assumed to be 2/3), n 
is the refractive index, QD is the quantum-yield of the donor (i.e. the ratio of the 
number of photons emitted to the number absorbed), and J(λ) represents the 
overlap-integral, which accounts for the degree of overlap between the emission 
and absorption spectra of the donor and acceptor, respectively.  
A 'good' FRET pair contains a donor with a high quantum-yield, contains an 
acceptor with a large molecular extinction coefficient, displays maximal overlap 
between the donor emission and acceptor absorption spectrum, and displays 
minimal excitation of the acceptor at the maximal excitation wavelength of the 
donor. In many biosensors, (variants of) enhanced cyan fluorescent protein (ECFP) 
and yellow fluorescent protein (EYFP) are used as (donor→acceptor) FRET pairs. 
The ECFP-EYFP pair has an R0 of ~5.5 nm. By fusing ECFP and EYFP to the N- and 
C-termini (or vice versa) of a suited metabolite-sensing protein, metabolite-induced 
conformational changes in the sensing protein will induce changes in the 
ECFP→EYFP FRET signal. In this sense, metabolite binding and unbinding are 
associated with opposite changes in FRET efficiency that can be visualized as 
changes in ECFP and EYFP emission intensity by fluorescence microscopy. For 
instance, in case of a sensor in which metabolite binding increases FRET efficiency, 
increased FRET is associated with a lower ECFP and higher EYFP fluorescence 
intensity, and decreased FRET is associated with higher ECFP and lower EYFP 
fluorescence intensity. By taking the ratio between the EYFP and ECFP emission 
signals, a quantitative measure of FRET is obtained.  
When using FRET-based biosensors for single cell imaging, it is critical to obtain a 
signal with a high signal-to-noise ratio. This means that the donor and acceptor 
fluorescence signals need to be well above aspecific (background) fluorescence 
levels, which can arise from cellular autofluorescence, to prevent that small FRET 
changes are obscured by background noise. Additionally, the biosensor will 
display large FRET changes upon concentration changes of the to-be-detected 
biomolecule. This means that maximizing the dynamic range of the FRET sensor is 
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of crucial importance. To achieve the latter, one strategy is the use of ‘improved’ 
versions of CFP (e.g., Cerulean, super-enhanced CFP) and YFP (e.g., Venus, Citrine) 
because the FRET efficiency generally depends on the photo-physical properties 
of the donor and acceptor fluorophores.  
 
FRET-based biosensors for glucose sensing 
Bacterial periplasmic binding proteins (PBPs) have been applied as sensing 
proteins in FRET-based biosensors. PBPs display a high affinity for specific 
metabolites and possess considerable similarity at the level of their tertiary 
structure. PBPs consist of two globular domains that are connected by a hinge 
region. Substrate binding occurs in the cleft between the two domains and the 
substrate is engulfed via a hinge-twist motion, leading to a major conformational 
change in the protein. By flanking the PBP with a donor and acceptor fluorescent 
protein, the conformational change occurring in the PBP is translated into a 
change in FRET. The PBP family can be divided into two classes. In type I PBPs, the 
N- and C-terminus are located at the proximal ends of the globular domains. Upon 
substrate binding, the termini and fluorophores in the sensor, move further apart 
from each other and FRET is decreased (Fehr et al., 2003). In type II PBPs, the 
termini are located at the distal ends of the globular domains and move closer to 
each other upon substrate binding, leading to an increase in FRET. The majority of 
the FRET-based glucose biosensors use the periplasmic glucose/galactose-binding 
protein (GGBP) from the bacterium E. coli for glucose sensing. GGBP is a type I PBP 
and is involved in chemotaxis towards glucose and galactose in many bacteria. So 
GGBP is able to detect both glucose and galactose, but its affinity for glucose is 
approximately two times higher compared to galactose (Fehr et al., 2003). 
Although the precise galactose concentration in cells is not firmly established, the 
plasma galactose concentration in healthy humans (0.17 mM) is far below that of 
blood glucose (5 mM). GGBP-based glucose sensors do not respond to the 
glycolysis-inhibitor 2-deoxy-D-glucose (2-DG) (Fehr et al., 2003). 
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One of the first FRET-based glucose sensors consisted of a GGBP flanked by ECFP 
and EYFP and was designated "fluorescence indicator protein for glucose with an 
in vitro Kd of 170 nM" ("FLIPglu-170n"; Table 1). This sensor contains the wild-type 
GGBP, displaying a relatively high affinity for glucose. However, the blood glucose 
concentration is much higher (see previous section) and, therefore, intracellular 
glucose levels might be far above the Kd of FLIPglu-170n.  
To allow quantification of higher glucose levels, Phe16 in GGBP was mutated into 
an alanine. This reduced the substrate affinity of GGBP, resulting in a sensor with 
a Kd of 590 μM, (FLIPglu-600μ; Table 1). Relative to FLIPglu-170n, FLIPglu-600μ also 
displayed a somewhat higher maximum EYFP/ECFP ratio change and increased 
glucose specificity. A "control" sensor was generated by mutating aspartic acid at 
position 236 in GGBP to an alanine, leading to greatly decreased glucose sensitivity 
("FLIPglu-control (CT)"; Kd ≥100 mM; Table 1).  
To further increase the maximum ratio change of FLIPglu-600μ, two strategies 
were applied to reduce the rotational freedom of its two fluorophores (Deuschle 
et al., 2005b). In a first approach, the sensor-structure was made more rigid by 
deleting various amino acids of the 'composite linkers', being the less well-
structured sequences connecting the fluorophores to the GGBP. The mutant with 
a deletion of 15 amino acids in the N-terminal linker and 16 amino acids in the C-
terminal linker, named FLIPglu-600μΔ13, showed the highest increase in 
maximum ratio change relative to FLIPglu-600μ (Table 1). The second approach 
involved the insertion of ECFP into the backbone of GGBP to decrease its rotational 
freedom. Additionally, EYFP was replaced by Citrine, a YFP mutant which is less 
pH- and chloride-sensitive than EYFP and displays an increased in vivo folding 
efficiency (Griesbeck et al., 2001). The resulting sensor, 'fluorescent indicator - 
ECFP insertion at position 12 - protein for glucose with an in vitro Kd of 590 μM' 
(FLII12Pglu-600μ), displayed the highest increase in maximum ratio change 
compared to FLIPglu-600μ (Table 1).  
In an attempt to increase the maximum ratio change even further, various amino 
acid deletions were created in the composite linker between GGBP and Citrine of 
FLII12Pglu-600μ (Takanaga et al., 2008). The mutant in which only the six amino 
acids of the synthetic linker between GGBP and Citrine were removed (FLII12Pglu-
700μδ6), displayed the highest in vivo ratio change relative to FLII12Pglu-600μ 
(Table 1). Furthermore, by mutating the GGBP a range of affinity mutants was 
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engineered (i.e. FLIPglu-170nΔ13, FLIPglu-2μΔ13, FLIPglu-3.2mΔ13, FLIPglu-
30μΔ13) to cover a wide range of glucose affinities (Table. 1). In case of FLIPglu-
30μΔ13, EYFP was replaced by a mutant variant (Venus), which displays improved 
in vivo maturation (Nagai et al., 2001). 
 
Application of FRET-based glucose sensors  
The glucose sensors introduced above have been applied in a collection of 
mammalian cell lines to assess steady-state glucose levels and flux rates under a 
variety of experimental conditions. For instance, FLIPglu-600μ was used to analyze 
glucose dynamics in the cytosol of COS-7 cells (Fehr et al., 2003). It was found that 
this sensor responded rapidly to changes in extracellular glucose concentration in 
a reversible manner. Using the in vitro Kd of FLIPglu-600μ, the cytosolic glucose 
concentration in COS-7 was estimated to be generally 50% lower than the 
extracellular glucose concentration. This suggests that glucose is metabolized at a 
high rate in these cells. In C2C12 muscle cells, the FLIPglu-600μ sensor revealed a 
higher glucose concentration near the plasma membrane and a lower perinuclear 
concentration (John et al., 2008). The latter might be due to the presence of 
hexokinase (HK) bound to perinuclear mitochondria. When C2C12 cells were 
cultured in a medium with a high-glucose concentration (25 mM), cytosolic glucose 
levels were lower than when cells were cultured in a low-glucose medium (<5 mM). 
High external glucose levels reduced the rate of glucose uptake in Chinese 
hamster ovary (CHO) cells, suggesting downregulation of GLUT1. In these cells, the 
cytosolic glucose concentration was maintained at ~1 mM when extracellular 
glucose concentration equaled 10 mM (John et al., 2008). In CHO cells displaying a 
low glucose uptake rate, cytosolic glucose accumulation was observed upon 
glycolysis inhibition by iodoacetate (IAA). Glucose uptake was not affected by 
glycolysis inhibition. Upon removal of extracellular glucose there was little glucose 
clearance, suggesting that glucose efflux is absent. In contrast, in cells displaying 
a high glucose uptake rate, less glucose accumulation was observed upon 
inhibition of glycolysis (John et al., 2008). When human embryonic kidney (HEK) 
cells were cultured in a high-glucose medium, the rate of decrease in cytosolic 
glucose concentration was increased in response to acute changes in extracellular 
glucose concentration, suggesting that glycolytic enzymes are more active in these 
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cells (John et al., 2008). When cells were pre-cultured in a high-glucose medium, 
acute lowering of the extracellular glucose concentration increased cytosolic 
glucose levels, possibly by stimulating the generation of glucose from non-
carbohydrate carbon substrates (i.e. gluconeogenesis) (John et al., 2008). 
Conversely, cells pre-cultured in a low-glucose medium displayed a decrease in 
intracellular glucose level upon acutely increasing the extracellular glucose level, 
suggesting that glycolysis is stimulated by low external glucose. Taken together, 
the above findings suggest a mechanism in which glucose homeostasis is 
dynamically controlled by alterations in glucose transport and metabolism. This 
mechanism might serve to prevent toxic effects of too high cytosolic glucose as 
well as to prevent the glucose level from dropping below the Km of HK.  
FLIPglu-600μ was also applied to measure glucose fluxes between the 
endoplasmic reticulum (ER) and cytosol (Fehr et al., 2005). To this end, FLIPglu-
600μ was modified to contain ER targeting and retention signals. No differences 
between the cytosolic and ER glucose concentration were observed. Similarly, the 
glucose flux rate across the ER membrane and plasma membrane did not differ. 
However, when a high-affinity glucose sensor was used (FLIPglu-30μΔ13) and 
measurements were carried out in low-glucose medium, the steady state glucose 
concentration, as well as the glucose flux rate across the ER membrane and 
plasma membrane were different (Takanaga and Frommer, 2010). The latter study 
also revealed that, following their biosynthesis in the ER, GLUTs were active during 
their transport to the plasma membrane and mediated glucose transport over the 
ER membrane. In 3T3-L1 fibroblasts, FLIPglu-600μ was used to monitor cytosolic 
glucose dynamics under conditions of inhibited glycogen synthesis (Chowdhury et 
al., 2014). The increase in cytosolic free glucose induced by insulin was 
approximately 10-fold higher in cells with inhibited glycogen synthase activity, 
which was proposed to be mediated by an imbalance between the glucose uptake 
and the use of glucose for glycogen synthesis. 
Using FLI12Pglu-700μδ6, the glycolytic rate was investigated in fibroblasts, 
adipocytes, myoblasts, astrocytes, neurons, and HeLa cells (Bittner et al., 2010). To 
this end, glucose transport across the plasma membrane was reduced either by 
lowering the extracellular glucose concentration or by specifically inhibiting 
GLUTs. Average glycolytic rates were demonstrated to be higher in 
undifferentiated cells (C2C12 myoblasts and 3T3-L1 fibroblasts) and tumor cell 
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lines (HeLa cells) than in astrocytes, neurons, and differentiated 3T3-L1 adipocytes. 
Moreover, the variability in glycolytic rate between individual cells was higher for 
astrocytes, 3T3-L1 fibroblasts, C2C12 myoblasts, and HeLa cells, when compared 
to neurons and 3T3-L1 adipocytes. Finally, Hou and colleagues provided a detailed 
protocol for monitoring glucose levels in the cytosol of mammalian cell cultures 
through the use of FRET-based glucose sensors (Hou et al., 2011). 
  
Calibration and pitfalls of FRET-based glucose sensors  
Calibration 
Using FRET-based sensors, alterations in glucose concentration are reflected by 
changes in emission ratio between the respective fluorophores. In general, this 
approach allows comparison of glucose levels within the same cell (type) between 
individual experiments if the fluorescence recordings have been carried out under 
standardized conditions (e.g. temperature, excitation source, fluorescence filters). 
However, a proper cell-biochemical understanding of glucose metabolism 
requires knowledge about absolute concentrations. This means that the 
measured ratio (changes) need(s) to be translated into exact concentrations by 
means of calibration.  
A method has been described that makes use of the in vitro Kd of the sensor (Fehr 
et al., 2003, Fehr et al., 2005, Takanaga et al., 2008, Takanaga and Frommer, 2010). 
A point of concern with this approach is that the in vitro Kd does not necessarily 
equal the in vivo 'apparent' Kd due to effects of the cellular environment. 
Nevertheless, an estimate of the in vivo 'apparent' Kd of the sensor can be obtained 
by varying the external glucose concentration and plotting the ratio signal of the 
cytosolic sensor as a function of external glucose concentration. However, this 
strategy does not provide information about the absolute intracellular glucose 
concentration. 
In addition, a more general protocol can be used for calibration of glucose. This 
strategy relies on controlled plasma membrane permeabilization, followed by 
clamping the cytosolic glucose concentration with different levels of external 
glucose. Typically, cells are permeabilized using a detergent like digitonin, which 
interacts with plasma membrane cholesterol, or the pore-forming bacterial toxin 
Streptolysin O. To prevent morphological cell changes, damage to intracellular 
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compartments, and cell detachment, the optimal permeabilization conditions 
need to be experimentally established for each cell type. Key parameters to 
consider are cell density, detergent concentration, detergent incubation time, and 
temperature. During permeabilization, the ionic composition and pH of the 
extracellular medium should closely mimic the intracellular situation. Another 
point of concern is the possible loss of intracellular proteins including the sensor 
itself from the cell. To prevent this from happening, permeabilization should be as 
mild as possible and holes in the plasma membrane should prevent passage of 
molecules >5 kDa. The calibration of organelle-targeted FRET sensors is still 
problematic. In case of the ER, one possible strategy might involve isolation of the 
ER from the cell, followed by calibration using appropriate media and a 
spectrofluorometer.  
 
Pitfalls 
To facilitate signal detection, the discussed FRET sensors are often expressed 
using a strong promoter. If expression levels are too high, the sensor might act as 
a buffer and thereby influence glucose homeostasis. Buffering effects become 
particularly important if a sensor with a low Kd is expressed at a high level to detect 
a substrate that is present at a low concentration. To check for buffering effects, 
the ratio of the sensor can be plotted as a function of its expression level for 
individual cells. If buffering is absent, there should be no correlation between 
these parameters. 
Another potential problem associated with high expression levels and/or the 
exogenous nature of the sensor protein is its breakdown by proteolysis. This can 
be investigated by Western blotting of (native) gels using an FP-specific antibody 
or in-gel fluorescence analysis (Dieteren et al., 2008). We have applied an insect 
(baculoviral) transfection system, as well as stable cell lines, to allow (controlled) 
expression of the sensor at relatively low levels.  
Obviously, it is crucial to use a sensor with a detection range matching the 
expected range of metabolite concentrations in the cellular compartment. To 
validate the obtained results, parallel experiments with low- and high-affinity 
sensors might be relevant, as well as determining the detection range of the 
sensor by in situ calibration. 
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To rule out a-specific effects on the signal of the FRET sensor, the best option is to 
carry out parallel experiments in which a ‘control’ sensor (unable to bind the 
substrate) is used (Table 1; CT). For the presented glucose sensors, genuine 
alterations in metabolite concentration will induce opposite changes in the CFP 
and YFP emission intensity. In contrast, a pH change will increase or decrease the 
CFP and YFP signals in the same direction.  
 
Summary and future perspectives 
Glucose constitutes a main source for ATP production in most mammalian cells, 
either directly by glycolysis (e.g. in cancer cells) or through the combined action of 
glycolysis and oxidative phosphorylation. In addition to its role as a substrate, 
glucose also acts as regulator of metabolic pathways, placing this metabolite at 
the centre of cell metabolism. Metabolic dysfunction occurs during normal human 
aging and a large variety of pathological conditions including type II diabetes, 
muscular dystrophies, inherited metabolic disorders, Parkinson's disease, 
Alzheimer's disease, metabolic syndrome, certain forms of cancer, and ischemia-
reperfusion injury. Development of rational treatment strategies for these 
metabolic diseases requires a comprehensive understanding of how metabolic 
homeostasis is maintained and how cells respond to alterations in metabolic 
homeostasis. This information is also crucial to understand the consequences of 
metabolic dysfunction induced by off-target drug effects (Wallace, 2008). Because 
cell metabolism is dynamic and highly compartmentalized, experimental 
strategies are required that allow visualization of glucose concentration in time 
and space. Here we presented how quantitative live cell microscopy of FRET-based 
protein sensors can be used for this purpose. We expect that this technology will 
be of great value to understand the cell biological mechanism and consequences 
of metabolic dysfunction in patient-derived cells. Moreover, obtaining quantitative 
and spatiotemporal data is essential for construction of realistic mathematical 
models of metabolism (Chapter 3). The latter will allow a systems level 
understanding of metabolism in healthy and diseased cells and can be used to 
guide development of specific intervention strategies.  
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Mitoenergetic dysfunction triggers a rapid 
compensatory increase in steady-state glucose flux 
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Abstract 
ATP can be produced in the cytosol by glycolytic conversion of glucose into 
pyruvate. The latter can be metabolized into lactate, which is released by the cell, 
or taken up by mitochondria to fuel ATP production by the tricarboxylic acid (TCA) 
cycle and oxidative phosphorylation (OXPHOS) system. Altering the balance 
between glycolytic and mitochondrial ATP generation is crucial for cell survival 
during mitoenergetic dysfunction, which is observed in a large variety of human 
disorders including cancer. To gain insight into the kinetic properties of this 
adaptive mechanism we here determined how acute (30 min) inhibition of 
OXPHOS affected cytosolic glucose homeostasis. Glucose dynamics were analyzed 
in single living C2C12 myoblasts expressing the fluorescent biosensor FLII12Pglu-
700μδ6 (FLII). Following in situ FLII calibration, the kinetic properties of glucose 
uptake (V1) and glucose consumption (V2) were determined independently and 
used to construct a minimal mathematical model of cytosolic glucose dynamics. 
After validating the model, it was applied to quantitatively predict V1 and V2 at 
steady-state (i.e. when V1=V2=Vsteady-state) in the absence and presence of OXPHOS 
inhibitors. Integrating model predictions with experimental data on lactate 
production, cell volume and O2 consumption revealed that glycolysis and 
mitochondria equally contribute to cellular ATP production in control myoblasts. 
Inhibition of OXPHOS induced a 2-fold increase in Vsteady-state and glycolytic ATP 
production flux. Both in the absence and presence of OXPHOS inhibitors, glucose 
was consumed at near maximal rates, meaning that glucose consumption is rate-
limiting under steady-state conditions. Taken together, we here demonstrate that 
OXPHOS inhibition increases steady-state glucose uptake and consumption in 
C2C12 myoblasts. This activation fully compensates for the reduction in 
mitochondrial ATP production, thereby maintaining the balance between cellular 
ATP supply and demand.  
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Introduction  
Glucose is among the prime substrates for cellular energy production and serves 
as a precursor for various biomolecules such as glycoproteins and glycolipids. 
Hence, the capacity of a cell for glucose uptake and conversion greatly impacts on 
its energetic and functional state. Glucose uptake is mediated by specific 
facilitative glucose transporters (Gluts). These integral plasma membrane proteins 
belong to the Solute Carrier (SLC) 2A subfamily, which consists of 14 different 
members that differ in their substrate specificity, transport kinetics, tissue 
distribution, and mode of regulation. The rate of Glut-mediated cellular glucose 
uptake depends on the amount of active Gluts on the plasma membrane, their 
kinetic properties, and the magnitude of the trans-plasma membrane glucose 
gradient, which co-depends on the extracellular free glucose concentration 
([GLC]ext) and the cytosolic free glucose concentration ([GLC]c). Once taken up, 
glucose is phosphorylated by the glycolysis enzyme hexokinase (HK) to form 
glucose-6-phosphate (G6P). Subsequently, G6P is converted into pyruvate and 
imported into mitochondria to fuel the tricarboxylic acid (TCA) cycle. The latter 
produces NADH (reduced nicotinamide adenine dinucleotide) and FADH2 (reduced 
flavin adenine nucleotide), which serve as substrates for the mitochondrial 
oxidative phosphorylation (OXPHOS) system. Alternatively, pyruvate can be 
reversibly converted into lactate by lactate dehydrogenase (LDH) that is released 
by the cell into the extracellular medium. The OXPHOS system consists of five 
multiprotein complexes (CI-CV) that generate ATP by chemiosmotic coupling 
(Mitchell, 1961). CI-CIV constitute the electron transport chain (ETC) that extracts 
electrons from NADH (at CI) and FADH2 (at CII). Subsequently, the electrons are 
transported to CIII and from thereon to CIV where they react with molecular 
oxygen (O2). At CI, CIII and CIV protons (H+) are transported from the mitochondrial 
matrix across the mitochondrial inner membrane to generate an inward-directed 
proton-motive force (PMF). Driven by the PMF, controlled H+ back-flux via CV (i.e. 
the FoF1-ATP synthase) is used to synthesize ATP from ADP and inorganic 
phosphate (Pi). ATP is generated by glucose breakdown during glycolysis (2 ATP per 
glucose molecule), by the TCA cycle (2 ATP per glucose molecule) and by the 
OXPHOS system (32 ATP per glucose molecule). The relative contribution of these 
systems to cellular ATP production depends on many parameters including the cell 
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type and the nature/availability of energy substrates. In practice, the actual 
number of ATP molecules generated probably lies within the range of 29-30 ATP 
molecules per oxidized glucose molecule (Rich, 2003). 
In case of mitochondrial dysfunction, increased extracellular lactate levels were 
observed in fibroblasts from patients with mitochondrial disease (Pitkanen and 
Robinson, 1996), mouse embryonic fibroblasts (MEFs) from Nduf4 knockout (KO) 
mice with isolated CI deficiency (Valsecchi et al., 2012), skin fibroblasts from 
patients with Myoclonic Epilepsy with Ragged Red Fibers (MERRF) syndrome (Wu 
and Wei, 2012), myotubes overexpressing the mitochondrial uncoupling protein 3 
(Huppertz et al., 2001), polymerase gamma mutator mice (Saleem et al., 2015), and 
human embryonic kidney 293 cells (HEK293) with a knock-down of the CI subunit 
NDUFS3 (Suhane et al., 2013). In addition, drug-induced mitochondrial dysfunction 
stimulated glucose uptake in Clone 9 cells (Barnes et al., 2002, Shetty et al., 1993, 
Shi et al., 1995, Jing et al., 2008, Hamrahian et al., 1999) and Glut1 upregulation 
and enhanced glucose uptake was demonstrated in cancer cells (Gambhir, 2002, 
Young et al., 2011). These results suggest that glycolysis-mediated ATP generation 
is activated by mitochondrial dysfunction (Wu and Wei, 2012). Currently, the 
balance and interactions between glucose uptake, glycolysis- and OXPHOS-
mediated ATP production, as well as their regulation, is a subject of intense study 
(Patergnani et al., 2014, Haran and Gross, 2014, Drozdowicz-Tomsia et al., 2014, 
Dott et al., 2014, Jose et al., 2011). However, the various components of this 
dynamic system cannot be simultaneously accessed by experimental studies in 
single living cells. This necessitates the use of mathematical models (Lowe and 
Walmsley, 1986, Fehr et al., 2005, Barros et al., 2007, Wu et al., 2007, van Eunen et 
al., 2011, Marin-Hernandez et al., 2011, Alam et al., 2015).  
In this study we aimed to demonstrate how acute OXPHOS dysfunction affects 
steady-state glucose uptake and consumption, lactate production, O2 
consumption and ATP production in C2C12 myoblasts. To this end we integrated 
experimental results with in silico predictions of a minimal model of glucose 
dynamics. This model correctly predicted the glycolytic flux in control and 
OXPHOS-inhibited cells and revealed that glycolysis and mitochondria equally 
contribute to ATP production when OXPHOS is active. We demonstrate that acute 
OXPHOS inhibition 2-fold increases glucose uptake and consumption, thereby fully 
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compensating for the loss in OXPHOS-mediated ATP generation and maintaining 
steady-state ATP homeostasis.  
 
Materials and methods 
Chemicals  
Sodium iodoacetic acid (IAA), Cytochalasin B (CytoB), Cytochalasin D (CytoD), 
Antimycin A (AA), and p-trifluoromethoxy carbonyl cyanide phenyl hydrazone 
(FCCP) were obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands). 
Piericidin A (PA) was obtained from Enzo Life Sciences (Raamsdonksveer, The 
Netherlands).  
 
Cell culture  
C2C12 myoblasts were cultured at 37o C (95% air, 5% CO2) in Dulbecco’s modified 
eagle’s medium (DMEM-32430; Life Technologies – Invitrogen, Bleiswijk, The 
Netherlands), supplemented with 10% (v/v) fetal bovine serum (FBS). C2C12 
myoblasts were seeded in fluorodishes® (#FD35-100, World Precision 
Instruments, Sarasota, USA) at a density of 40,000 cells/dish.   
 
Transfection  
One day after seeding, C2C12 cells were at 40% confluence. 1 μg DNA was mixed 
with 6 μl lipofectamine (Invitrogen) in 0.5 ml FBS-free DMEM. Following 20 min 
incubation at room temperature the transfection mix was added to the cells in 
FBS-free DMEM. After 6 hours this medium was replaced by DMEM containing 10% 
FBS. The glucose sensor FLII12Pglu-700μδ6 (Addgene Plasmid #17866; (Takanaga 
et al., 2008)) and its high affinity variant FLIPglu-170nΔ13V (Addgene Plasmid 
#18018; (Takanaga and Frommer, 2010)) were a gift from Dr. Wolf Frommer 
(Department of Plant Biology, Carnegie Institution for Science, CA, USA). 
 
Single cell microscopy of cytosolic glucose dynamics  
At 24 hours post-transfection the C2C12 myoblasts were at 80% confluence. Cells 
were washed and incubated for 3 min in HEPES-Tris (HT) buffer (adjusted to pH 7.4 
with Tris) containing 4.2 mM KCl, 132 mM NaCl, 10 mM HEPES, 1.2 mM MgCl2 and 
1 mM CaCl2. Next, the HT buffer was replaced with HT buffer containing 500 μM 
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iodoacetic acid (IAA) and incubated for another 15 min. Subsequently the 
fluorodish® was mounted on an inverted microscope (Nooteboom et al., 2012) 
(Axiovert 200 M, Carl Zeiss BV, Sliedrecht, The Netherlands), equipped with a 
x40/1.3 NA Plan NeoFluar objective (Carl Zeiss) and a CoolSNAP HQ monochrome 
CCD-camera (Roper Scientific, Vianen, The Netherlands). Microscopy hardware 
was controlled using Metafluor 6.0 software (Universal Imaging Corporation, 
Downingtown, PA, USA). FLII12Pglu-700μδ6 and FLIPglu-170nΔ13V were excited at 
430 nm (CFP) for 300 ms using a Polychrome IV monochromator system (TILL 
Photonics, Gräfelfing, Germany). CFP fluorescence was detected using a 455DRLP 
dichroic mirror (XF2034, Omega Optical Inc, Brattleboro, VT, USA) and a 480AF30 
(XF3075; Omega) emission filter. Citrine emission (CitrineFRET) was measured using 
430 nm excitation light (during 200 ms) and emission was detected using the 
455DRLP dichroic mirror and a 535AF26 emission filter (XF3079; Omega). Time-
lapse recordings were performed using an acquisition interval of 2.5 s.  
 
Lactate measurements  
C2C12 myoblasts were seeded in a T25 culture flask and cultured for one day, as 
described above. Next, cells were incubated in 1 ml HT buffer containing 2 mM 
glucose and either vehicle or mitochondrial inhibitors for 60-90 min. The buffer 
was collected and centrifuged for 5 min at 600g. Lactate levels were quantified 
using an Architect chemical analyzer (Abbott B.V., Hoofddorp, The Netherlands). 
For each sample, the cell number was determined using a Burker Turk 
hemocytometer. 
  
O2 consumption measurements  
For respirometry analysis (Hutter et al., 2004) C2C12 myoblasts were counted 
using a Scepter® cell counter (Millipore, Billerica, USA) and 1.5·106 cells were 
transferred to the temperature-controlled (37°C) chamber of an Oxygraph-2k 
controlled by Datlab 5 recording (2 s time interval) and analysis software (Gnaiger, 
2001) (Oroboros Instruments, Innsbruck, Austria). To measure O2 consumption, 
cells were either resuspended in HT buffer containing 2 mM glucose or culture 
medium. After adding the cells to the respiration chamber, the O2 consumption 
trace was allowed to stabilize for 10 minutes until routine respiration (routine-
value) could be measured in the coupled state of respiratory control. Next, the 
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complex V (CV) inhibitor oligomycin A (2.5 μM) was added to determine the leak 
respiration (leak-value). The maximal capacity of the ETC (ETS-value) was 
determined by subsequent titration with the mitochondrial uncoupler p-
trifluoromethoxy carbonyl cyanide phenyl hydrazone (FCCP). Finally, minimal 
respiration (ROX-value) was assessed after adding a maximal concentration of the 
complex I (CI) inhibitor rotenone (ROT; 0.5 μM) and of the complex III inhibitor 
antimycin A (AA; 0.5 μM). This ROX-value was subtracted from the other respiratory 
rates to correct them for non-mitochondrial respiration.  
 
Cellular ATP level measurements   
The total amount of cellular ATP was measured after 24 hours using an ATP 
bioluminescence assay kit according to the manufacturer’s protocol (CLS II; Roche 
Applied Science, Mannheim, Germany). Briefly, cells were harvested and counted 
using a Scepter® cell counter (Millipore, Billerica, USA) after which cellular ATP was 
released by adding the cell suspension to a boiling Tris-EDTA buffer (100 mM Tris, 
4 mM EDTA, pH 7.75) for 2 min. Part of this solution was diluted 1:1 (v/v) with 
luciferase reagent, followed by measurement of the bioluminescence signal. ATP 
concentrations were calculated using a standard curve, and divided by cell count 
to obtain ATP values.  
 
Q-PCR analysis  
RNA was extracted from C2C12 cells according to the manufacturer’s protocol 
(PureLinkTM RNA Mini Kit, Invitrogen). cDNA was generated from 1 μg RNA using 
the IScript cDNA synthesis kit (Biorad, Hercules, CA, USA) according to the 
manufacturer’s protocol. Quantitative real-time PCR was performed in a final 
volume of 25 μl containing 12.5 μl SYBR®Green Supermix (Bio-Rad), 5 μl (10x 
diluted) cDNA, 4.5 μl RNAse-free water, 1.5 μl forward primer (2.5 μM) and 1.5 μl 
reverse primer (2.5 μM). Primers for actin and Glut1-4 were obtained from 
Biolegio, Nijmegen, The Netherlands (see below). Amplification of cDNA was 
performed using a C1000 Thermal Cycler (Bio-Rad) and fluorescence was analyzed 
using the CFX96TM Real-Time System (Bio-Rad). The PCR conditions were 95 ºC for 
3 minutes (1 cycle), 95 ºC for 15 s and 60 ºC for 30 seconds (39 cycles), and finally 
a temperature increase starting at 65 ºC to 95 ºC with 0.5 ºC intervals. RNA 
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expression was normalized against the mRNA level of actin (DCt) and represented 
as 2-DC(t). 
Glut1 TGCAGTTCGGCTATAACACTG and GGTGGTTCCATGTTTGATTG 
Glut2 TGTGATCAATGCACCTCAAG and TCATAGTTAATGGCAGCTTTCC 
Glut3 ACTCTTTGTCAACCGCTTTG and ATCTTGGCGAATCCCATAAG 
Glut4 CTTGGCTCCCTTCAGTTTG and CACGTTGCATTGTAGCTCTG 
Actin CTAAGGCCAACCGTGAAAAG and TACGACCAGAGGCATACAGG 
 
Single cell pH measurements  
For cytosolic pH analysis, C2C12 myoblasts were loaded with the pH-sensitive 
reporter molecule BCECF (2',7'-Bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein) 
(Life Technologies - Molecular Probes, Bleiswijk, The Netherlands) by incubating 
them with 5 μM of the BCECF acetoxy-methyl (AM) ester form (BCECF-AM) in HT 
buffer for 15 min at 37 oC in the dark. Subsequently, cells were washed 3 times 
with HT buffer and imaged using an inverted microscope (see above). The H+-
bound form of BCECF was excited at 440 nm (100 ms) using a 505DRLPXR dichroic 
mirror (XF2031; Omega). The H+-unbound form of BCECF was excited at 490 nm 
(100 ms) using the same dichroic mirror. Fluorescence images were recorded at 
530 nm using a 535AF45 emission filter (XF3084; Omega). The ratio between the 
emission signal obtained at 490 nm and at 440 nm excitation was used as a 
measure of cellular pH (Ozkan and Mutharasan, 2002). Time-lapse recordings were 
performed using an acquisition interval of 6 s. 
 
P/O ratio analysis  
To determine the P/O ratio we slightly modified a previously described approach 
(De Rasmo et al., 2011). Briefly, cells were resuspended in mitochondrial 
respiration medium MiR05 (Krumschnabel et al., 2015) containing: 110 mM 
sucrose, 60 mM K+-lactobionate, 0.5 mM EGTA, 3 mM MgCl2, 20 mM taurine, 10 
mM KH2PO4, 20 mM HEPES adjusted to pH 7.1 with KOH at 30 °C, and 1 g/l BSA 
essentially fatty acid-free. Routine O2 consumption was recorded as described in 
the Materials and Methods section. Next, the plasma membrane was 
permeabilized using digitonin (10 μg / 1·106 cells) and malate (2 mM) and pyruvate 
(5 mM) were added. Upon addition of ADP (220 nM), the O2 consumption rate was 
allowed to decrease to a stable level, indicating a complete conversion of ADP into 
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ATP. As a quality control (Kuznetsov et al., 2008), mitochondrial integrity was 
assessed by adding 10 μM cytochrome-c (cyt-c). The P/O ratio was calculated by 
dividing the amount of ADP used by the amount of oxygen used by the 
mitochondria to consume all the ADP.  
 
Image processing, statistical analysis and mathematical modeling  
Microscopy images were stored in native Metafluor format (Universal Imaging 
Corporation) and analyzed off-line using Image Pro Plus 6.1 software (Media 
Cybernetics, Rockville, USA). Individual images were background corrected for the 
individual wavelengths by subtracting the average intensity in an extracellular 
region of interest (ROI). Next, cell-derived fluorescence signals were quantified 
using cytosolic circular regions of interest (ROIs).  Average values are presented as 
mean ± standard error of the mean (SEM). Curve fitting and statistical analysis was 
performed using Origin Pro 6.1 (OriginLab Corp., Northampton, USA) and 
GraphPad Prism 5 (Graphpad Software Inc., La Jolla, USA). Unless stated otherwise, 
statistical significance was assessed using an unpaired Student’s t-test and 
expressed as: ***(p<0.001), **(p<0.01), and *(p<0.05) relative to the indicated 
condition. Mathematical modeling was performed using MATLAB/Simulink 6.1 
(The Mathworks Inc., Natick, USA). 
 
Results 
In situ calibration of the FLII12Pglu-700μδ6 glucose sensor in C2C12 
myoblasts  
In this study we used the glucose biosensor FLII12Pglu-700μδ6 (FLII) (Takanaga et 
al., 2008), which is based on the fluorescence resonance energy transfer (FRET) 
principle, to monitor dynamic changes in free cytosolic glucose concentration 
([GLC]c). As described in Chapter 2, FLII consists of a glucose binding domain 
sandwiched between cyan fluorescent protein (CFP) and the yellow fluorescent 
protein mutant Citrine). The glucose binding domain is derived from a periplasmic 
protein expressed in E.coli (Fehr et al., 2003). When glucose binds, the emission of 
Citrine upon CFP excitation (“CitrineFRET”) increases. Simultaneously, the CFP 
emission upon CFP excitation (“CFP”) will decrease (Fig. 1A). Glucose unbinding will 
induce the reverse effect and the emission ratio (CitrineFRET/CFP) can be used as a 
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readout of [GLC]c. Manipulation of [GLC]c by changing the extracellular glucose 
concentration ([GLC]ext; see next section for details) induced antiparallel changes 
in CitrineFRET and CFP in FLII-expressing C2C12 myoblasts (Fig. 1B; upper panel). No 
alterations in cellular volume upon [GLC]ext manipulation were observed, as 
indicated by the lack of parallel changes in the individual CFP and CitrineFRET 
emission signals (Fig. 1B; upper panel). Inspection of the CitrineFRET/CFP signal 
revealed identical dynamic emission ratio in different subcellular regions of 
interest (ROIs; Fig. 1A; inset) and the whole cell (Fig. 1B; lower panel). For 
quantitative analysis and mathematical modeling of [GLC]c dynamics, calibration 
of the FLII emission ratio is required. Using a cell permeabilization strategy with β-
Escin (a triterpenoid saponin) was not useful since it induced a shift in FLII signals 
(data not shown), as reported previously for C2C12 cells ( John et al., 2008). 
Therefore, the in situ calibration curve was generated by incubating FLII-expressing 
C2C12 myoblasts with different [GLC]ext concentrations in the presence of the 
glucose consumption inhibitor iodoacetic acid (IAA; 500 μM). IAA inhibits the 
glycolysis enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) leading 
to G6P accumulation and allosteric HK inhibition (Bittner et al., 2010). Following a 
30 min incubation with various [GLC]ext and IAA, the FLII emission ratio was stable 
(Fig. 1C). This demonstrates that [GLC]ext and [GLC]c are fully equilibrated, allowing 
calibration of the FLII emission ratio (Bittner et al., 2010). For each [GLC]ext the 
measured (CitrineFRET/CFP) emission ratio was corrected for the emission ratio 
obtained in the absence of extracellular glucose (“CitrineFRET/CFP0mMGLC”). This 
corrected emission ratio was termed Rcorr. 
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Figure 1. In situ calibration of the glucose sensor. (A) The glucose sensor FLII12Pglu-700μδ6 (FLII) consists 
of a glucose binding domain that is sandwiched between CFP and Citrine. Fluorescence resonance energy 
transfer (FRET) increases and decreases upon glucose (GLC) binding and unbinding to the sensor, respectively. 
The inset depicts a typical FLII-expressing C2C12 myoblast revealing the cytosolic localization of the sensor 
(Citrine image shown). Regions of interest (ROIs) used for temporal analysis of FLII fluorescence are marked 
by numerals. (B) Response of FLII to a stepwise increase in extracellular glucose ([GLC]ext) in the presence of 
the glucose consumption inhibitor iodoacetic acid (IAA). The top panel shows the individual Citrine (open 
symbols) and CFP (filled symbols) average fluorescence intensity per pixel (background corrected) for the two 
ROIs indicated in panel A. In addition, the average fluorescence intensity per pixel (background corrected) for 
the total cell was determined by creating a cellular mask (binary image) of the cell and superimposing this 
mask onto the background corrected image. Calculation of the FLII emission ratio (CitrineFRET/CFP) revealed 
identical ratio-unit (RU) changes in all signals (lower panel). (C) Stability of the FLII ratio signal following 30 min 
incubation at various [GLC]ext in the presence of 500 μM IAA. FLII images of different cells were acquired. The 
mean CitrineFRET/CFP signal (±SD) of all cells within individual images were plotted as a function of time for 0.2 
mM, 2 mM, and 7 mM [GLC]ext. For each concentration, no significant differences were detected between time 
points (one-way ANOVA). (D) Average CitrineFRET/CFP signal (±SEM) as a function of [GLC]ext (20 cells analyzed 
for each [GLC]ext). Data was corrected by subtracting the FLII emission ratio obtained at [GLC]ext=0. A Michaelis-
Menten equation was used to fit the calibration curve (R2=0.96).  
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The experimental in situ calibration curve was fitted using a Michaelis Menten 
equation: 
 
       (1)
  
with [GLC]c in mM, Rcorr equaling the corrected FLII emission ratio (as defined 
above) and Km representing the in situ FLII glucose affinity (in mM).   
 
Fitting yielded a maximal FLII emission ratio (Rmax) of 3.6±0.4 and a Km of 1.9±0.5 
mM (Fig. 1D). To allow calculation of [GLC]c(t) from the measured Rcorr(t) Eq.1 was 
rearranged into: 
 
       (2) 
 
Analysis of glucose uptake and consumption in C2C12 myoblasts   
In the most simple case, (Fig. 2A) dynamic changes in [GLC]c (i.e.[GLC]c(t)) depend 
on the rate of glucose entry (V1) across the plasma membrane and the rate of 
glucose consumption in the cell (V2):  
 
        (3) 
 
Cellular glucose entry is mediated by glucose transporters (Augustin, 2010). Q-PCR 
analysis revealed that Glut isoform 1 (Carruthers et al., 2009) is highly expressed 
in C2C12 myoblasts whereas Glut2, Glut3 and Glut4 were not detected (Fig. S1). 
This suggests that V1 is dominated by Glut1-mediated glucose entry in our cell 
model. To dissect the contribution of V1 and V2 in determining [GLC]c, we adapted 
a strategy previously described for cultured mouse astrocytes (Bittner et al., 2010). 
Quantification of V1 requires inhibition of glucose consumption, which was 
achieved using IAA (Fig. 2A).  Conversely, glucose entry was inhibited using 
Cytochalasin B (CytoB) (Fig. 2A), a noncompetitive and membrane-permeable 
inhibitor of Glut uniporters (Deves and Krupka, 1978, Fehr et al., 2003, Bittner et 
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al., 2010, Haran and Gross, 2014, Ulanovskaya et al., 2011). CytoB inhibits glucose 
transport by binding close to the glucose efflux site on the cytoplasmic domain of 
Gluts. Removal of extracellular glucose induced a drop in [GLC]c to zero within 3 
min (Fig. 2B), indicating that cytosolic glucose is actively consumed. When CytoB 
treatment was carried out on IAA-pretreated cells, the decrease in [GLC]c was 
blocked in a dose- and time-dependent manner. It was found that 15 min pre-
treatment with 500 μM IAA fully blocked glucose consumption (Fig. 2C). The 
experimental strategy to measure V1 in C2C12 myoblasts is schematically 
summarized in Figure 2D and allows analysis of glucose entry under zero-trans 
conditions (i.e. when [GLC]c is virtually zero prior to external glucose re-addition). 
It consists of cell seeding and transfection (Fig. 2D-a and 2D-b), optional treatment 
with a mitochondrial inhibitor (Fig. 2D-c; see below), removal of extracellular 
glucose (Fig. 2D-d), IAA treatment (Fig. 2D-e) and re-addition of external glucose 
(Fig. 2D-g). In the absence of IAA, increasing [GLC]ext from 0 to 2 mM induced a bi-
phasic increase in [GLC]c in glucose-depleted myoblasts (Fig. 2E and F; open 
symbols/bars) consisting of a fast (V1,No-IAA) and slow component (V1slow,No-IAA).  In 
myoblasts pre-incubated with IAA (500 μM, 15 min) the rate of fast [GLC]c increase 
(V1,IAA) was significantly higher than V1,No-IAA, whereas the rate of increase of the 
slow phase (V1slow,IAA vs. V1slow,No-IAA) was not affected (Fig. 2E and F). This 
demonstrates that in the absence of IAA, V1 is underestimated due to glucose 
consumption, primarily during the fast phase. In the absence of IAA, CytoB 
induced an acute drop in [GLC]c at a rate V2,No-IAA (Fig. 2E and F). In contrast, no 
significant decrease in [GLCc] was observed (i.e. V2,IAA equaled zero) when CytoB 
was added to IAA-treated cells (Fig. 2E and F). Supported by the results presented 
in Fig. 2C, these findings demonstrate that glucose is not consumed in IAA-treated 
C2C12 cells. Applying Eq. 3 to the data presented in Fig. 2F suggests that: (i) in the 
presence of IAA: V2≈0 so d[GLC]c/dt=V1=V1,IAA=0.26±0.07(SD) mM/min, (ii) in the 
absence of IAA, V1 is underestimated by an amount of V2,No-IAA, so d[GLC]c/dt=V1,No-
IAA+ V2,No-IAA = 0.12±0.03(SD) + 0.08±0.06(SD) = 0.20±0.07(SD) mM/min. The fact that 
V1,IAA is ≈ V1,No-IAA+ V2,No-IAA strongly suggests that the effect of IAA on V1 is due to 
inhibition of V2 rather than an aspecific effect of this inhibitor on Glut1.  
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Figure 2. Experimental strategy for analysis of glucose uptake and consumption. (A) Principle of the 
approach. Glucose (GLC) enters from the extracellular space ([GLC]ext) into the cytosol ([GLC]c) via facilitative 
glucose transport (Glut) across the plasma membrane (PM) and is subsequently consumed. Glucose enters at 
a rate V1 and is consumed at a rate V2.  Cytochalasin B (cytoB) and iodoacetic acid (IAA; acting on hexokinase; 
HK) are used to inhibit V1 and V2, respectively. (B) Boxplot of the average time required (±SD) for lowering 
[GLC]c to zero upon removal of [GLC]ext (n=10 cells; N=2 independent experiments). (C) Analysis of the 
concentration and duration of IAA treatment required for full inhibition of glucose consumption. Graph 
presents the mean (±SEM) of 15 cells per condition (N=3 independent experiments). Statistical significance 
was determined using the Kruskal-Wallis test. (D) Flowchart of the experimental approach. After cell seeding 
and FLII transfection, cells are optionally treated with mitochondrial inhibitors for 30 min. Subsequently, 
([GLC]ext was removed and V2 inhibited by IAA, followed by microscopy imaging. (E) Representative example 
of a glucose uptake experiment in the absence (filled symbols) and presence (open symbols) of IAA. After a 3 
min incubation in the absence of extracellular glucose, [GLC]ext was increased to 2 mM followed by addition 
of CytoB. Both in the absence and presence of IAA, [GLC]c displayed a biphasic increase at rates V1,No-IAA and 
V1,IAA  and V1slow,No-IAA and V1slow,IAA upon external glucose addition. The effect of CytoB was reflected by the 
rates V2,No-IAA and V2,IAA. (F) Average values (±SD) for the various rates depicted in panel E (determined from 
linear regression analysis; n=12 cells; N=3 independent experiments). #Not significantly different from zero 
determined by a one-way Student’s t-test. 
 
Control experiments demonstrated that glucose influx was inhibited by CytoB but 
not by CytoD, suggesting Glut-mediated glucose uptake in our cell system (Fig. 
S2A). Because proteinaceous FRET sensors can exhibit sensitivity to their local 
environment including pH (Borst et al., 2005, Willemse et al., 2007, Moussa et al., 
2014), the high-affinity glucose sensor described in Chapter 2 (FLIPglu-170nΔ13V; 
Km= 0.17 μM) (Takanaga and Frommer, 2010) was used as a control. In C2C12 
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myoblasts expressing this control sensor, no changes in fluorescence ratio signal 
upon manipulation of the extracellular glucose level were observed (Fig. S2B). This 
suggests that this cytosolic sensor is fully in its glucose-bound state (“saturated”) 
and that the observed changes in FLII ratio are unlikely caused by glucose-
independent alterations in FRET efficiency. Moreover, in agreement with the data 
presented in Figure 1B (upper panel), the lack of effect on the high-affinity glucose 
sensor fluorescence signals, directly after glucose addition, demonstrates that 
[GLC]ext changes do not induce cell-volume changes.  
 
Effect of mitochondrial inhibition on cellular glucose uptake and 
consumption in C2C12 myoblasts 
Using the strategy in Fig. 2D, we next investigated the effect of short-term 
mitochondrial dysfunction on cellular glucose uptake and consumption. To this 
end, cells were incubated with mitochondrial inhibitors for 30 min prior to 
microscopy analysis. In these experiments piericidin A (PA) was used to inhibit 
complex I (CI) of the OXPHOS system. In parallel experiments, cells were treated 
with antimycin A (AA) to inhibit OXPHOS complex III (CIII). Respirometry analysis 
revealed that both inhibitors dose-dependently inhibited CI and CIII (Fig. S3). Full 
inhibition of mitochondrial O2 consumption in intact C2C12 cells required a 
minimal concentration of 100 nM PA (IC50=8.4±0.2 nM) and 20 nM AA (IC50=8.5±0.2 
nM). These concentrations were used during the remainder of the study. First, we 
quantified the effect of 30 min mitochondrial inhibition on the maximal rate of 
glucose entry for various [GLC]ext in IAA-treated cells (Fig. 3A). This was performed 
by calculating the maximal linear rate of [GLC]c increase from single-cell recordings 
(Fig. 3B), which increased as a function of [GLC]ext in vehicle-, PA- and AA-treated 
cells (Fig. 3C). Curve fitting using a Hill-equation revealed that the V1-associated Km-
value (Fig. 3D; Table 1-A1) and cooperativity factor n (Fig. 3E) were not affected in 
PA- and AA-treated cells. In contrast, inhibitor-treated cells displayed a large 
increased in maximal value of V1 (V1,max) (Fig. 3F; Table 1-A1).  
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Although IAA did not alter cytosolic pH, PA- and AA-treatment acidified the cytosol 
to a similar extent (Fig. S2C). Therefore, we determined whether pH changes 
affected the fluorescence ratio signal of FLII by transient addition of extracellular 
ammonium chloride (Ozkan and Mutharasan, 2002). Using the pH-sensor BCECF 
we observed that NH4Cl addition and removal induced cytosolic alkalinization and 
acidification, respectively (Fig. S2D; upper panel). However, no changes in the FLII 
ratio signal were observed upon acidification (Fig. S2D; lower panel). These results, 
combined with the observation that CFP and CitrineFRET emission changed 
antiparallel (Fig. 1B), make it unlikely that FLII signals were affected by cytosolic 
acidification in our experiments.   
 
 
 
Figure 3. Effect of mitochondrial inhibition on cellular glucose uptake kinetics. (A) Inhibition of the 
glucose (GLC) consumption flux (V2) allows analysis of glucose uptake (V1). (B) Typical glucose uptake in cells 
pretreated with vehicle, PA or AA for 30 min. The maximal rate of linear increase of these curves was used as 
a measure of V1. (C) Mean (±SEM) of the maximal rate of [GLC]c increase as a function of [GLC]ext in vehicle-
treated cells and cells treated with PA or AA (n=20 cells per condition; N=4 independent experiments). A Hill 
equation was used for curve fitting (Vehicle: R2=0.85; PA: R2=0.68; AA: R2=0.94). (D) Average value (±SD) of Km 
for vehicle-, PA- or AA-treated cells. (E) Similar to panel D, but now for the cooperativity parameter n. (F) Similar 
to panel D, but now for Vmax.   
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Table 1. Experimental results, model parameters and model predictions. 
 
PARAMETER VEHICLE PA AA 
A. MODEL DIRECTLY BASED UPON EXPERIMENTAL PARAMETERS (DEFAULT MODEL)  
1. GLUCOSE UPTAKE RATE (V1) PARAMETERS$ 
Experimental Km,V1 (mM) 1.4±0.3 1.0±0.4   1.5±0.4  
Experimental V1,max (mM/min) 0.32±0.05  2.8±0.7 2.9±0.5 
2. GLUCOSE CONSUMPTION RATE (V2) PARAMETERS@ 
Experimental V2,max (mM/min) 0.67±0.07   1.23±0.12  1.7±0.3  
Km,V2 (mM) 0.06 0.06 0.06 
3. [GLC]C AT STEADY-STATE 
Experimental (mM) 0.49±0.11 0.66±0.09 0.51±0.07 
Predicted (mM) 0.02 0.40 0.20 
B. MODEL WITH ADJUSTED V1,MAX (OPTIMAL MODEL) 
1. GLUCOSE UPTAKE RATE (V1) PARAMETERS 
Adjusted V1,max (mM/min) 1.86 4.20 4.80 
2. [GLC]C AT STEADY-STATE 
Predicted (mM) 0.49 0.66 0.51 
3. GLUCOSE, PYRUVATE, LACTATE AND ATP RATES AT STEADY-STATE& 
Predicted V1=V2=Vsteady-state (mM/min) 0.60  1.14 1.50 
Predicted pyruvate production rate   
V3=2·Vsteady-state (mM/min) 
1.20 2.28 3.00 
Predicted rate of lactate release  
V7=V4=V3 (mM/min)# 
1.20 2.28 3.00 
Experimental rate of lactate release V7   
(mM/min/cell) 
1.8±0.6 (SD) 4.1±1.1 (SD) 3.5±1.6 (SD) 
Predicted glycolytic ATP production rate  
2·Vsteady-state (mM/min) 
1.20 2.28 3.00 
Experimental ATP-linked O2 consumption rate 
(mM/min) 
0.43±0.08 (SD) 0 0 
Experimental P/O ratio  2.7±0.4 (SD) n.d. n.d. 
Predicted mitochondrial ATP production rate 
(mM/min) 
1.2±0.2 (SD) 0 0 
Predicted total ATP production (mM/min) 2.39 (100%) 2.28 (95%) 3.00 (126%) 
Experimental total ATP (pmol/cell) 30±13 (SD) 19±5 (SD) 30±18 (SD) 
All experiments and model predictions were performed at an extracellular free glucose concentration 
([GLC]ext) of 2 mM.  
$Measured under conditions of IAA-blocked glucose consumption. 
@Measured under conditions of CytoB-blocked glucose uptake. 
&Average C2C12 cell volume equaled 2.1·10-12±0.4·10-12 (SD) liter (n=14 cells).  
Lactate production was measured during 60-90 min in three independent experiments. Routine O2 
consumption and P/O ratio were determined in at least four independent experiments. Total ATP after 24h 
incubation with vehicle, PA, or AA was measured in three independent experiments, performed in duplo. 
#Assuming a negligible value for V5 
Km,V1, affinity (Km) of glucose uptake; Km,V2, affinity (Km) of glucose consumption; V1,max, maximal rate (Vmax) of 
glucose uptake; V2,max, maximal rate (Vmax) of glucose consumption; V2,n, cooperativity (n) of glucose 
consumption.  
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Next, we analyzed the resting [GLC]c and the maximal linear rate of [GLC]c decrease 
upon acute CytoB treatment (Fig. 4A-B). In the literature a Km value of 60 μM was 
reported for HK (Bertram and Pernarowski, 1998, Lowe and Walmsley, 1986). Since 
the steady-value of [GLC]c was 7- to 10-fold higher than this value, we considered 
the maximal linear rate of [GLC]c decrease upon acute CytoB treatment to reflect 
the maximal value of V2 (V2,max). Inhibitor treatment did not significantly alter the 
resting [GLC]c at 2 mM [GLC]ext (Fig. 4C; Table 1-A3) whereas V2,max was 1.8- and 2.5-
fold higher in PA- and AA-treated cells respectively (Fig. 4D; Table 1-A2). Taken 
together, our results demonstrate that inhibition of CI and CIII increase the 
maximal rates of cellular glucose uptake (V1,max) and consumption (V2,max) within 
30 min. 
 
 
Figure 4. Effect of mitochondrial inhibition on cellular glucose consumption kinetics. (A) Inhibition of 
the glucose (GLC) uptake flux (V1) allows analysis of glucose consumption (V2). (B) Typical glucose consumption 
experiment in cells treated with vehicle, PA or AA for 30 min. (C) Average value (±SD)  of resting [GLC]c for 2 
mM [GLC]ext in the absence of CytoB for vehicle-, PA-, or AA- treated cells (D) The average value (±SD) of the 
maximal rate of linear decrease upon cytoB addition in panel B. V2 (n=20 cells; N=4 independent experiments). 
N.s. not significant. 
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A minimal mathematical model for glucose uptake and consumption in 
C2C12 myoblasts  
To gain insight into how V1 and V2 quantitatively contribute to the kinetics of the 
[GLC]c signal, we developed a mathematical model using Eq. 3. Since cellular 
volume changes were not observed (see above), cell volume in the model was 
assumed to be constant. Glut-mediated glucose influx (V1) was modeled using an 
equation (Bertram and Pernarowski, 1998) that was previously used for 
quantitative prediction of Glut1-mediated glucose influx in HepG2 cells (Fehr et al., 
2005):  
 
   (4) 
 
With V1,max being the measured maximal value of V1 (Table 1-A1; in mM/min), Km,V1 
the measured affinity (Table 1-A1; in mM), [GLC]ext the extracellular free glucose 
concentration (in mM) and [GLC]c the cytosolic free glucose concentration (in mM). 
We modeled cytosolic glucose consumption (V2) using a Michaelis-Menten 
equation (Deichmann et al., 2014) that quantitatively predicted HK-mediated 
glucose consumption in HepG2 cells (Fehr et al., 2003):  
 
       (5) 
 
With V2,max being the measured maximal value of V2 (Table 1-A2; in mM/min), Km,V2 
the affinity (in mM), and [GLC]c the cytosolic free glucose concentration (in mM). 
Under conditions that glucose influx is blocked, the rate at which [GLC]c drops will 
reflect maximal HK action (see above) so we used a Km,V2 value of 60 μM (Table 1A-
2) as described in the literature (Lowe and Walmsley, 1986, Wilson, 2003).  
 
Parameter optimization and validation of the mathematical model  
Using the experimental parameter values for V1 and V2 (Table 1) we performed a 
set of explorative simulations for the vehicle condition at 2 mM [GLC]ext. This 
‘default model’ quantitatively matched (not shown) the experimental data 
obtained in vehicle-, PA- and AA-treated cells, with respect to maximal rate of 
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[GLC]c decrease (Fig. 4D). This suggests that the kinetic parameters measured for 
V2 were correct for all three conditions. However, the default model predicted a 
much lower steady-state [GLC]c (i.e. 0.02 mM) than the experimental value (0.49 
mM) (Table 1A-3).  In order to gain insight into why the predicted steady-state 
[GLC]c was much lower, various parameters (i.e. Km,v1, Km,v2, V1,max, V2,max) were 
manually varied in the default model to fit the experimental steady-state [GLC]c. 
This revealed that only when V1,max was increased (i.e. from 0.32 to 1.86 mM/min), 
the predicted steady-state [GLC]c matched its experimental value. Also for the PA- 
and AA-treated condition, the steady-state [GLC]c predicted by the default model 
was too low (Table 1A-3). Similarly, this discrepancy disappeared when V1,max was 
increased from 2.8 to 4.2 mM/min (PA-treated cells) and from 2.9 to 4.8 mM/min 
(AA-treated cells). In this way, ‘optimal’ models were obtained (Table 1-B). The too 
low V1,max values reported in our experiments could be due to the fact that the rate 
of cellular glucose uptake was determined under the condition that [GLC]c is 
virtually zero (‘zero-trans’ condition; (Cloherty et al., 1996). This would lead to an 
underestimation of V1,max since [GLC]c stimulates Glut-mediated glucose influx by 
a mechanism called ‘trans-acceleration’ (Carruthers, 1990, Liu et al., 2001). Indeed 
(Fig. S4A), the maximal rate of [GLC]c increase was much higher when [GLC]c 
equaled 0.4 mM (i.e. when glucose uptake was trans-accelerated) than when [GLC]c 
was virtually zero (zero-trans condition). In this sense, the model-predicted 
underestimation of V1,max in our experiments is very likely due to the use of zero-
trans conditions.  
Simulating the calibration procedure with the optimal model (vehicle-condition) 
predicted that [GLC]c fully equilibrated with [GLC]ext within 30 min for [GLC]ext ≤ 4 
mM (Fig. S5A). For [GLC]ext > 4 mM this model predicted that [GLC]c did not fully 
equilibrate with [GLC]ext within this time period (Fig. S5A). However, correcting 
[GLC]c for this effect did not significantly affect the FLII calibration curve and its Km 
and Rmax value (Fig. S5B).  
 
Model prediction of steady-state glucose uptake and consumption  
In a first set of simulations we used the optimal model to simulate the experiment 
in Figure 4B. Model predictions (Fig. 5A) quantitatively matched the experimental 
data obtained in vehicle, PA- and AA-treated cells, with respect to resting [GLC]c 
(Fig. 4C) and maximal rate of [GLC]c decrease (Fig. 4D). Next, we simulated the 
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experiment in Figure 2E, to predict the steady-state values of V1 and V2 (Fig. 5B). In 
the presence of 2 mM [GLC]ext, V1 and V2 steady-state values (i.e. when V1=V2= 
Vsteady-state) increased from 0.60 mM/min (vehicle) to 1.14 mM/min (PA) to 1.50 
mM/min (AA), without significantly affecting steady-state [GLC]c (Fig. 4C). To 
quantify the effect of V1 and V2 upon the overall steady-state glucose flux we 
calculated flux control coefficients in the vehicle, PA- and AA- model (Fig. 5C-D). 
This was performed by determining the steady-state glucose flux values at various 
magnitudes of V1,max or V2,max (Rossignol et al., 2000, Alam et al., 2015).  The arrows 
in Figure 5C indicate the values of V1,max (left panel) and V2,max (right panel) in the 
three optimal models. At each arrow we calculated the derivative to obtain the flux 
control coefficient (i.e. (dFlux/Flux)/(dVmax/Vmax) = (dFlux/dVmax) . (Vmax/Flux)). For all 
three steady-state conditions, the flux control coefficient was much larger for V2 
than for V1 (Fig. 5D), demonstrating that the steady-state glucose flux is primarily 
determined by the steady-state value of V2.  
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Figure 5. A minimal model of glucose uptake and consumption in C2C12 myoblasts. (A) [GLC]c dynamics 
predicted by the optimal model mimicking the experiments in Figure 4B for vehicle-, PA- and AA-treated cells. 
Glucose influx (V1) was set to zero to simulate Glut inhibition by CytoB. Both resting [GLC]c (y-axis) and maximal 
linear rate of [GLC]c decrease (numerals) were predicted correctly. (B) Simulated experiment of Figure 2E to 
predict the steady-state values (numerals) of glucose influx (V1; dotted lines) and consumption (V2; continuous 
lines) in vehicle-, PA- and AA-treated cells. Glucose influx (V1) was set to zero to simulate Glut inhibition by 
CytoB. SS indicates the steady-state situation. (C) Flux variation as a function of V1,max and V2,max. The steady-
state flux at 2 mM [GLC]ext was predicted for different values of V1,max (left panel) and V2,max (right panel). Arrows 
mark the Vmax value in the respective models. (D) Flux control coefficients for V1 and V2 determined by 
calculating the derivatives of the traces in panel C (see Results for details). (E) Schematic representation of the 
various fluxes (V1, V2, V3, V4, V5, V6, V7; see Results and Discussion for details). (F) Comparison between the 
predicted single-cell lactate (LAC) production flux (x-axis) and measured average (±SD) of LAC production flux 
(y-axis) in cells treated with vehicle, PA or AA in HT buffer containing 2 mM glucose (N=3 independent 
experiments). A linear equation was used for fitting (R2=0.90; slope=1.49±0.29; dotted lines indicate 95% 
confidence limits).  
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Model prediction of steady-state lactate production  
Mitochondrial O2 consumption was fully blocked in inhibitor-treated cells (Fig. S3). 
This suggests (Fig. 5E) that the rate of mitochondrial pyruvate entry (V5) is close to 
zero and that pyruvate (generated by glycolysis at a rate V3) is converted into 
lactate at a rate V4 and subsequently released by the cells at a rate V7. Assuming 
that all consumed glucose is converted into lactate that is transported out of the 
cell, we used the predicted Vsteady-state to calculate V7. At 2 mM [GLC]ext the optimal 
model predicts (Table 1-B3) that Vsteady-state equals 1.14 mM/min (PA) and 1.50 
mM/min (AA). Because glycolytic conversion yields two pyruvate molecules for 
each glucose molecule that is consumed, the predicted rates of pyruvate 
generation (V3) and lactate release (V7) equal V3=V7=2·Vsteady-state, yielding 2.3 
mM/min (PA) and 3.0 mM/min (AA). Experimental analysis (using the same 
medium used for FLII imaging) yielded lactate fluxes of 3.7±1.1 (SD) fmol/min/cell 
(vehicle), 8.7±1.5 (SD) fmol/min/cell (PA) and 7.5±3.0 (SD) fmol/min/cell (AA). In 
order to compare these experimental values with the predictions of the 
mathematical model (which simulates a single cell) information about C2C12 
myoblast volume is required. To this end, we first determined the area of FLII-
expressing cells (using the CitrineFRET image), yielding an average value of 
1.2·103±0.4·103 (SD) μm2 (n=14 cells). Using data from the literature (Slomka and 
Gefen, 2011) it was found that C2C12 area and volume display a highly linear 
correlation (Fig. S6). From this correlation we estimated that the average C2C12 
volume in our experiments equaled 2.1·10-12±0.4·10-12 (SD) liter, compatible with a 
previous estimate obtained by 3D microscopy analysis (Peeters et al., 2004). In 
case of PA-treated cells the measured value of V7 equaled (8.7±1.5 
fmol/min/cell)/(2.1·10-12±0.4·10-12 liter) = 4.1±1.1 mM/min/cell. A similar calculation 
yields 1.8±0.6 mM/min/cell and 3.5±1.6 mM/min/cell for vehicle- and AA-treated 
cells, respectively. Quantitative comparison of these measured lactate fluxes with 
model predictions revealed a linear correlation (Fig. 5F). The fitted line did not 
significantly differ from y=x (i.e. the latter fell within the 95% confidence limits of 
the fitted line), suggesting that the model correctly predicted lactate fluxes (V7) for 
vehicle- and inhibitor-treated cells.  
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Model predictions of steady-state ATP production  
Finally, we integrated model predictions and experimental results to analyze the 
balance between glycolytic and mitochondrial ATP production in C2C12 cells. For 
vehicle-treated cells the amount of ATP derived from glycolysis equaled 2·Vsteady-
state (i.e. 1.20 mM/min). To compare this flux with mitochondrial ATP production, we 
measured routine O2 consumption (Fig. 6A). Following correction for leak 
respiration, the ATP-linked O2 consumption rate equaled 15.4±2.7 pmol/s/106 cells. 
Considering C2C12 cell volume, this yields an ATP-linked O2 flux of 0.43±0.08 (SD) 
mM/min (Table 1-B3). Next, the ATP production rate was calculated from this O2 
flux using the phosphorus/oxygen ratio (P/O ratio). The latter was determined by 
measuring the amount of O2 required to convert 220 nmol ADP to ATP in 
permeabilized cells supplemented with pyruvate and malate (De Rasmo et al., 
2011). This strategy revealed a P/O ratio of 2.7±0.4 (SD) (Table 1-B3 and Fig. S7), 
meaning that ATP is produced by mitochondria at a rate of (2.7±0.4)·(0.43±0.08 
mM/min) = 1.2±0.2 (SD) mM/min. Therefore, vehicle-treated C2C12 cells derive 
50% of their cellular ATP from glycolysis and 50% from OXPHOS (Fig. 6B, Table 1-
B3). For inhibitor-treated cells we assumed that ATP is exclusively generated by 
glycolysis, yielding fluxes of 2.28 mM/min (PA) and 3.00 mM/min (AA). Therefore, 
the total steady-state ATP production flux is virtually identical for vehicle- and 
inhibitor-treated cells (Fig. 6B): 2.39 mM/min (vehicle, set at 100%), 2.28 mM/min 
(PA; 95%) and 3.00 mM/min (AA; 126%). In line with these predictions, 24 hours 
treatment with vehicle-, PA and AA did not significantly affect total cellular ATP level 
(Fig. 6C, Table 1-B3) or the total number of cells (data not shown). This suggests 
that increased steady-state glucose uptake and consumption fully compensates 
for the loss of mitochondrial ATP production in PA- and AA-treated cells.  
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Figure 6. Analysis of O2 consumption and total ATP concentration in C2C12 myoblasts. (A) Average 
values (±SEM) for routine, leak, maximal (ETS) and residual respiration (ROX) in C2C12 cells (N=6 independent 
experiments). (B) Prediction of the balance between glycolytic and mitochondrial ATP production in vehicle- 
and inhibitor-treated cells. See Results for details. (C) Average values (±SEM) of total ATP levels in cells treated 
for 24 hours with vehicle, PA or AA (N=3 independent experiments). Statistical significance was assessed using 
the Kruskal-Wallis test. 
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Discussion  
This study focuses on gaining a quantitative understanding of the balance 
between steady-state glucose uptake/consumption, glycolytic and mitochondrial 
ATP production, and the effect of mitoenergetic dysfunction on this system. We 
provide integrated experimental and in silico evidence that the glycolytic pathway 
and mitochondria equally contribute to total ATP production in C2C12 myoblasts. 
Acute (30 min) OXPHOS inhibition induced a 2-fold increase in steady-state glucose 
uptake and consumption, which fully compensated for the drop in mitochondrial 
ATP production. Our results suggest a mechanism in which mitoenergetic 
dysfunction triggers compensatory activation of the glycolysis pathway, allowing 
metabolic flexibility.  
 
In situ calibration and validation of the FLII glucose sensor  
Predictive mathematical modeling requires a quantitative measure of [GLC]c. 
Therefore, we calibrated the emission ratio of the FLII sensor by incubating the 
cells with different [GLC]ext concentrations in the presence of the V2 inhibitor IAA. 
The in situ FLII calibration curve displayed Michaelis-Menten kinetics and a Km of 
1.9 mM, which was 2.7-fold higher than its in vitro Km-value (Bermejo et al., 2010). 
This illustrates the importance of in situ calibration (Moussa et al., 2014) and 
demonstrates that FLII most sensitively reports [GLC]c when [GLC]c is near 1.9 mM. 
Of note, discrepancies between in situ and in vitro Km-values are not uncommon, 
as illustrated by the 8-fold increase in Km for the proteinaceous Ca2+ sensor 
“PericamR” when expressed in the mitochondrial matrix (Filippin et al., 2003). We 
demonstrated that the FLII ratio is not affected by cytosolic acidification in our 
experiments, compatible with previous findings in yeast cultures (Bermejo et al., 
2010). Taken together, we provided evidence that the employed calibration 
procedure and experimental conditions are suited for quantitative measurement 
of [GLC]c(t) using the FLII sensor.   
 
Quantification of cellular glucose uptake and consumption  
In previous studies cellular glucose uptake (V1) was measured using a radio-labeled 
variant of glucose (i.e. 2-deoxy-D-glucose or 2-DG), which inhibits HK and is 
phosphorylated by this enzyme (Kletzien and Perdue, 1973, Purich and Fromm, 
1971). However, this approach cannot be used to study the relatively rapid 
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temporal glucose dynamics at the (sub)cellular level. In addition, fluorescently 
labeled glucose analogues such as 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-
2-deoxyglucose (2-NBDG) and 6-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-6-
deoxyglucose (6-NBDG) have been used to quantify V1 (Zou et al., 2005, Jung et al., 
2011). However, these glucose analogues display a different affinity for Glut 
transporters than glucose (Barros et al., 2009). Here we experimentally dissected 
the contribution of V1 to [GLC]c dynamics, by removing [GLC]ext and preventing 
cytosolic glucose consumption (V2) using IAA. Measurements of zero-trans glucose 
uptake were performed by extracellular addition of glucose to cells with zero 
glucose on the trans (i.e. intracellular) site. Upon glucose addition, the rate of 
change in [GLC]c (i.e. d[GLC]c/dt) was determined by quantifying the maximal slope 
of the calibrated FLII signal. This slope was then used as a measure of the initial 
rate of glucose uptake. Because the sum of V1 and V2 in the absence of IAA is 
similar to the experimental value of V1 in the presence of IAA, it appears that IAA 
does not affect glucose uptake. Q-PCR analysis revealed that Glut1 is expressed, 
whereas Glut2, Glut3 and Glut4 transcripts were not detected. This suggests that 
V1 primarily reflects Glut1-mediated glucose uptake. In vehicle-treated cells the 
maximal rate of V1 (V1,max) was 0.32±0.05 mM/min and its Km-value (Km,V1) equaled 
1.4±0.3 mM. Similar Km,V1 values (i.e. 0.38-2.00 mM) were reported in previous 
studies (Cloherty et al., 1996, Fehr et al., 2005, Takanaga et al., 2008, Naftalin, 
2008), suggesting that our experimental strategy to determine Km,V1 is valid. The 
maximal value of V2 (V2,max) was determined in the presence of the V1-blocker 
CytoB (Bittner et al., 2010). Because HK displays a glucose-affinity of ~60 μM 
(Saleem et al., 2015, Wilson, 2003) it operates (near) it’s Vmax at the measured [GLC]c 
concentrations.  
 
OXPHOS inhibition stimulates cellular glucose uptake  
Thirty min treatment with PA or AA did not significantly affect the affinity of glucose 
uptake (Km,V1) but induced an 8-fold increase in V1,max, compatible with previous 
results in OXPHOS-inhibited cells (Barros et al., 2007, Cloherty et al., 2001, Bonder 
and Mooseker, 1986, Barnes et al., 2002, Jing and Ismail-Beigi, 2007). Similar to 
another study (Behrooz and Ismail-Beigi, 1997), qPCR analysis revealed that 
inhibitor treatment did not alter Glut mRNA levels (data not shown). Although PA 
and AA are chemically dissimilar and target different OXPHOS complexes, they 
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equipotentially stimulated glucose uptake. This suggests that the latter is due to 
OXPHOS inhibition rather than off-target effects of PA and AA, supporting a 
mechanism in which acute mitochondrial dysfunction stimulates Glut1-mediated 
glucose uptake in C2C12 myoblasts. A similar phenomenon was induced by 
extracellular alkalinization, possibly by modification of Glut cysteine residues 
(Gunnink et al., 2014). However, here we measured that OXPHOS inhibition 
lowered cytosolic pH and increased extracellular lactate levels, which argues 
against involvement of alkalinization-induced Glut1 activation. Alternatively, 
OXPHOS inhibition might induce a drop in ATP level leading to reduced ATP-
induced inhibition of Glut1 activity (Blodgett et al., 2007, Levine et al., 2002). Our 
results argue against such a mechanism since: (i) they suggest that the drop in 
OXPHOS-mediated ATP production is fully compensated for by increased glycolytic 
activity, and (ii) they demonstrate that total cellular ATP amount is not significantly 
reduced in cells treated with OXPHOS inhibitors for 24 h. Glut1 activity might also 
be increased by a mechanism involving AMP-activated protein kinase (AMPK), 
activation (phosphorylation) of which was linked to stimulation of glucose 
transport during OXPHOS inhibition (Barnes et al., 2002, Ozkan and Mutharasan, 
2002, Wu et al., 2013). Alternatively, Glut1 redox modification and oligomerization 
were demonstrated to regulate Glut1 activity (Hebert and Carruthers, 1992, 
Zottola et al., 1995, De Zutter et al., 2013, Kuipers et al., 2013) and the amount of 
active Glut1 at the plasma membrane might be increased by stimulation of Glut1 
translocation from internal storage vesicles to the plasma membrane or by 
activation of plasma membrane-localized Glut1 by OXPHOS inhibition (Barnes et 
al., 2002, Shi et al., 1995, Shetty et al., 1993, Hamrahian et al., 1999). In Chapter 5 
the mechanism by which OXPHOS inhibition stimulates glucose uptake will be 
discussed in more detail. 
 
OXPHOS inhibition stimulates cellular glucose consumption  
OXPHOS inhibition induced a 2-fold increase in the maximal rate of glucose 
consumption (V1,max). Genomic expression profiling 
(http://www.ncbi.nlm.nih.gov/geo/; GEO accession: GDS2420) suggests that C2C12 
myoblasts express HK isoforms I and II. HK-mediated phosphorylation of glucose 
leads to formation of G6P, which allosterically inhibits HKI and HKII. In case of HKI 
this inhibition is antagonized by Pi, whereas the latter activates HKII (Wilson, 1995). 
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This suggests that increased glucose consumption might be explained by Pi-
induced activation of HKII during OXPHOS inhibition. However, as discussed 
above, our results argue against such a mechanism since glycolytic activity fully 
compensated for the loss in OXPHOS-mediated ATP production in PA- or AA-
treated cells and total cellular ATP was not affected after 24 hours inhibitor 
treatment. Glucose consumption might also be increased in OXPHOS-inhibited 
cells by activation of glucokinase, a low-affinity (Km=8 mM) HK isozyme (Meglasson 
and Matschinsky, 1983). However: (i) the above expression profile suggests that 
glucokinase is not expressed in C2C12 myoblasts (confirmed in (Otaegui et al., 
2002)), and (ii) the steady-state resting [GLC]c was 10-fold lower than the Km of 
glucokinase in vehicle-treated and OXPHOS-inhibited cells. In addition to HK 
activation, increased glucose consumption likely involves stimulation of other 
(glycolytic) enzymes including phosphofructokinase and pyruvate kinase.  
 
A minimal model of cytosolic glucose dynamics  
To predict steady-state glucose uptake and consumption fluxes, we constructed a 
minimal mathematical model that consisted of two equations: (i) a reversible 
Michaelis-Menten equation for glucose uptake (V1) and (ii) an irreversible 
Michaelis-Menten equation for glucose consumption (V2). The glucose uptake 
equation does not account for asymmetry (i.e. different kinetic parameters for 
glucose influx and efflux) or trans-accelerated transport. The kinetic parameters 
for V1 (Km,V1 and V1,max) and V2 (V2,max) were experimentally determined and 
included in the model. In case of V2, we used a glucose-affinity (Km,V2) of 60 μM 
compatible with values previously reported for HK and HK-mediated glucose 
consumption in C2C12 cells (Wilson, 2003, Fehr et al., 2005, Bittner et al., 2010). 
Initially, the model predicted a too low steady-state [GLC]c in vehicle- and inhibitor-
treated cells (default model). Manual parameter optimization revealed that our 
experimental strategy systematically underestimated V1,max, which had to be 
increased from 0.32 to 1.86 mM/min (vehicle), from 2.8 to 4.20 mM/min (PA) and 
from 2.9 to 4.80 mM/min (AA) to generate quantitatively correct predictions 
(optimal model). Triggered by these model predictions, we provided experimental 
evidence suggesting that our experimental method underestimates the rate of 
glucose uptake due to a lower [GLC]c. Importantly, the adjusted V1,max values in the 
72 Chapter 3  
optimal model fell within a similar range as those reported for Glut1-mediated 
glucose entry in HepG2 cells (i.e. 7.2 mM/min; (Fehr et al., 2005)).  
 
Predicting the glycolytic flux at steady-state   
Model predictions yielded a steady-state value of V1=V2=Vsteady-state of 0.60 mM/min 
in vehicle-treated cells. Vsteady-state was 2-fold higher in PA- and AA-treated cells. 
Under all three conditions V2 displayed the largest flux control coefficient (i.e. ~ 
0.6), indicating that the glucose flux was primarily determined by the steady-state 
value of V2. The flux control coefficient of V1 was below 0.1 for all three conditions. 
In comparison, the flux control coefficient of glucose uptake upon oxygen 
consumption ranged between 0.3-0.5 and increased upon lowering external 
glucose in T. brucei (Bakker et al., 1999). In PA- and AA-treated cells mitochondrial 
O2 consumption was fully blocked, meaning that mitochondrial pyruvate entry (V5) 
is negligible. Under these conditions, we assumed that all the glucose (consumed 
at rate Vsteady-state) is converted into lactate and released from the cell at a predicted 
rate V7. The latter prediction agreed with lactate release measurements, 
supporting the validity of our minimal model and suggesting that the contribution 
of alternative pathways branching off or feeding into to the glycolytic pathway is 
relatively low. Interestingly, also in the absence of inhibitors (i.e. when V5 was not 
zero) the predicted V7 was close to the measured lactate release. This strongly 
suggests that the magnitude of steady-state mitochondrial pyruvate uptake (V5) is 
much smaller than the rate of pyruvate-to-lactate conversion (V4) and subsequent 
lactate release (V7) in vehicle-treated cells. Since the lactate release predicted using 
Vsteady-state matched with the experimental lactate release rate it appears that Vsteady-
state is a good measure of glucose flux. The fact that the measured lactate release 
was higher than the predicted lactate release for all three conditions might be due 
to hydrolysis of glycogen to G6P, thereby increasing V3 and V7. In addition, we 
cannot exclude that glucogenic amino acids contribute to pyruvate and lactate 
production in our experiments. For analysis of the glycolytic flux, our strategy 
provides an alternative to measurement of the extracellular acidification rate 
(ECAR), which might not always provide a reliable estimate of glycolytic flux 
(Mookerjee et al., 2015). 
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Balancing glycolytic and mitochondrial ATP production   
Analysis of ATP-linked mitochondrial O2 consumption and P/O ratio in vehicle-
treated cells suggested that ATP was generated by the OXPHOS system at a rate of 
1.20 mM/min. Since Vsteady-state also equaled 1.20, this means that under vehicle 
conditions 50% of the total ATP is generated by glycolysis and 50% by OXPHOS. As 
a consequence, a 2-fold increase in Vsteady-state under conditions of OXPHOS 
inhibition fully compensates for the loss in OXPHOS-mediated ATP production. 
Indeed, model predictions suggested that the total cellular ATP production rate 
under steady-state conditions equaled 100% (vehicle), 95% (PA) and 126% (AA). 
Following 24 hours treatment, total cellular ATP content and total cell number were 
similar for vehicle- and inhibitor-treated cells. This is compatible with a mechanism 
in which glycolytic ATP production fully compensates for the loss in mitochondrial 
ATP production. A similar lack of effect on total ATP content was demonstrated in 
MEFs from NDUFS4-/- mice with isolated CI deficiency (Valsecchi et al., 2012) and in 
fully glycolytic skin fibroblasts treated for 72 hours with the CI-inhibitor rotenone 
(Distelmaier et al., 2015). C2C12 myoblasts displayed a relatively high glycolytic 
and low mitochondrial pyruvate influx. This allowed a 2-fold increase in glycolytic 
flux to fully compensate for the lack of mitochondrial ATP production in PA- and 
AA-treated cells. This suggests that cells displaying a more oxidative metabolism 
would require a larger increase in glycolytic flux to maintain overall ATP 
production.  
 
Conclusions  
By combining experiments and mathematical modeling we here demonstrate that 
mitoenergetic dysfunction triggers a rapid compensatory increase in steady-state 
glucose uptake and consumption in C2C12 myoblasts. This mechanism maintains 
the balance between cellular ATP supply and demand, thereby preventing energy 
crisis in cells which mitochondrial ATP generation is compromised.  
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Figure S1. mRNA levels of Glut family members in C2C12 myoblasts and respirometry analysis. A qPCR 
with primers against mouse Glut1, Glut2, Glut3, and Glut4 was performed on cDNA generated from C2C12 
myoblasts. Only mRNA of Glut1 was detected.   
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Figure S2. Validation of the experimental strategy for analysis of glucose uptake and consumption. (A) 
Typical glucose uptake in cells pretreated with CytoB (open symbols) or CytoD (filled symbols). Because CytoB 
might induce F-actin depolymerization, the structural analogue Cytochalasin D (CytoD), which has no effect 
on Gluts was used. In contrast to CytoB, glucose entry was not blocked by CytoD in IAA-treated cells. (B) Typical 
glucose uptake in cells expressing a high-affinity glucose sensor (FLIPglu-170nΔ13V). (C) Effect of the various 
treatments on cytosolic pH. Cells were pretreated for 30 min with vehicle, PA or AA. Subsequently, cells were 
loaded with the pH sensor BCECF using a [GLC]ext of 0 mM in the absence or presence of IAA. Statistical 
significance was determined using the Kruskal-Wallis test: N.s. not significant. (D) Effect of cytosolic pH 
changes on FLII fluorescence. Cytosolic pH was manipulated by transient extracellular addition ammonium 
chloride and monitored using the pH sensor BCECF (upper panel). In parallel experiments the response of FLII 
to these changes was determined (lower panel).  
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Figure S3. Dose-dependent inhibition of O2 consumption by piericidin A and antimycin A in intact C2C12 
cells. O2 consumption rates of C2C12 cells in culture medium upon titration with piericidin A (PA) and 
antimycin A (AA). Respiration rates were normalized to basal respiration in the absence of inhibitor. The IC50 
value was determined by fitting a logistic equation (y=[(A1-A2)/(1+(x/IC50)p)]-A2 to the data (R2>0.95), with A1 
being the initial respiration (i.e. 100%) and A2 being the lowest respiration. Residual respiration (ROX) after 
rotenone (ROT) and antimycin A (AA) was displayed as percentage of basal respiration. 
 
 
 
 
 
Figure S4. Effect of [GLC]c on the maximal rate of [GLC]c increase. (A) Typical kinetics of [GLC]c upon acutely 
increasing [GLC]ext from 0 to 1 mM (left part) and from 1 mM to 2 mM (after a 15 min waiting period; break). 
The experiment was carried out in the presence of IAA to block glucose consumption. The maximal rate of 
[GLC]c increase was quantified using a linear fit (red lines). (B) Average maximal rate of [GLC]c increase for the 
experiment depicted in panel A (N=2 experiments, n=18 cells).  
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Figure S5. Effect of the magnitude of [GLC]ext on [GLC]c equilibration kinetics as predicted by the 
optimal model. (A) Simulations with the vehicle model were carried out to reflect the conditions during the 
FLII calibration protocol: At t=t0 [GLC]ext increases to values (X) used during calibration (see Fig. 1C); the 
simulation time is 30 min to reflect the incubation time. Initial conditions: [GLC]ext=25 mM, [GLC]c=2.4 mM, 
V2=0 to reflect the presence of IAA. After 30 min, full equilibration is predicted (i.e. [GLC]ext=[GLC]c) for X=0.1 
mM, 1.0 mM, 1.5 mM, 2.0 mM, 3.0 mM and 4.0 mM. Partial equilibration was predicted for X=5.0 mM ([GLC]c 
equals 94% of [GLC]ext), X=6.0 mM ([GLC]c equals 90% of [GLC]ext) and X=7.0 mM ([GLC]c equals 86% of [GLC]ext). 
The predicted partial equilibration at higher [GLC]ext did not affect the FLII calibration curve, since identical 
values for R2, Rmax and Km were obtained (panel B). 
 
 
 
 
 
Figure S6. Area-volume relationship of C2C12 cells. To calculate the relationship between C2C12 cell area 
and volume we used data from 3D morphometric measurements of C2C12 cell (Slomka and Gefen, 2011). The 
relationship between area and volume was fitted using a linear equation (slope=1.78±0.08, p=0.001, R2=0.98). 
Dotted lines indicate 95% confidence limits. 
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Figure S7. Quantification of P/O ratio in permeabilized C2C12 cells. C2C12 cells were added to the 
respirometry chamber and permeabilized using the detergent digitonin (Dig). Subsequently, pyruvate/malate 
(PYR+MAL) and ADP (220 nM) were added. The total amount of O2 consumed (ΔO2) following ADP addition 
allowed calculation of the P/O ratio. Mitochondrial integrity was assessed by adding cytochrome-c (cyt-c). This 
figure depicts a representative example of 4 independent experiments.  
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Abstract 
Isolated complex I (CI) deficiency is among the most common mitochondrial 
oxidative phosphorylation (OXPHOS) disorders in humans. In Chapter 3 we 
demonstrated that chemical CI inhibition acutely stimulates the rate of glucose 
uptake in C2C12 mouse myoblasts. Here we quantified glucose uptake in primary 
myoblasts isolated from skeletal muscle of Ndufs4 knockout- (KO) mice with 
inherited CI deficiency. At high serum levels (41% of culture medium volume) and 
hyperglycemic external glucose concentration (25 mM), the rate of glucose uptake 
and mitochondrial O2 consumption was similar for wild-type (WT) and KO 
myoblasts. At low serum levels (2% of culture medium volume), ATP-linked O2 
consumption increased in media containing 5 mM glucose or galactose compared 
to 25 mM glucose, albeit to the same extend in WT as in KO myoblasts. 
Interestingly, single cell glucose measurements revealed that the rate of glucose 
uptake increased to a greater extent in KO than in WT myoblasts in media 
containing 5 mM glucose or galactose compared to 25 mM glucose. This 
upregulation was not due to increased expression levels of glucose transporters 
(Glut1 or Glut4) and paralleled by increased levels of hydroethium-oxidizing 
reactive oxygen species. Our results suggest that mouse myoblasts become more 
dependent on OXPHOS-derived ATP when cultured under conditions of low serum 
and low glucose or galactose. In KO but not in WT myoblasts, this increased 
OXPHOS dependency is paralleled by a higher glucose uptake rate, suggesting that 
CI deficiency triggers a compensatory mechanism.  
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Introduction 
Cellular energy metabolism is initiated by the uptake of metabolic substrates such 
as glucose. In most cells, glucose transporters (GLUTs) facilitate the passive 
transport of glucose across the plasma membrane. GLUTs are integral membrane 
proteins predicted to have 12 membrane spanning helices (Mueckler et al., 1985). 
Although 14 different Gluts have been described only some of them are localized 
to the plasma membrane and actually transport glucose (Joost et al., 2002, 
Carruthers et al., 2009). In skeletal muscle cells, GLUT1 is responsible for basal 
glucose uptake whereas insulin-stimulated glucose uptake is mediated by GLUT4 
translocation to the plasma membrane (Thorens et al., 1990, Marette et al., 1992). 
After glucose is taken up by the cell, it is phosphorylated by hexokinases to form 
glucose-6-phosphate (G6P). The glycolytic conversion of G6P into pyruvate has a 
net yield of 2 ATP molecules per glucose molecule. Subsequent mitochondrial 
uptake and oxidation of pyruvate by the tricarboxylic acid (TCA) cycle yields 
another 2 ATP molecules per glucose molecule and reduces the electron carriers 
NAD+ and FAD. Oxidation of NADH and FADH2 by respectively the first (CI) and 
second (CII) multi-subunit complex of the oxidative phosphorylation (OXPHOS) 
system, releases energy which is used by CI-CIV to generate an electrical (Δψ) and 
chemical (ΔpH) proton gradient over the mitochondrial inner membrane (MIM). 
The energy stored in this proton gradient is used by the fifth OXPHOS complex (the 
FoF1-ATPase) to form ATP from ADP and inorganic phosphate (Pi). Depending on 
the coupling efficiency between proton pumping and ATP production, the OXPHOS 
system can yield another 30-32 molecules of ATP per molecule of glucose. The first 
complex of the OXPHOS system (CI) consists of 44 subunits which are assembled 
into a 1 MDa holo-complex (Walker, 1992, Smeitink et al., 1998, Balsa et al., 2012, 
Dieteren et al., 2012). CI deficiency is the most common OXPHOS disorder in 
humans (Smeitink et al., 2001, Koopman et al., 2010). Patients with CI deficiency 
suffer from a progressive multi-systemic disorder with an often fatal outcome 
(Smeitink and van den Heuvel, 1999, Koene et al., 2012). One of the subunits 
frequently mutated in CI deficiency is the 18 kDa accessory subunit 
NADH:ubiquinone oxidoreductase iron-sulfur protein 4 (NDUFS4), which is located 
in the peripheral arm of CI (Budde et al., 2003, Iuso et al., 2006, Petruzzella et al., 
2001, Scacco et al., 2003, Calvaruso et al., 2012, Dieteren et al., 2012, Leshinsky-
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Silver et al., 2009). Mutations in the NDUFS4 gene generally results in truncation of 
the protein and absence of the C-terminal phosphorylation site, which is important 
for proper mitochondrial import and maturation of the precursor protein 
(Anderson et al., 2008, Papa et al., 2010, De Rasmo et al., 2008). As a consequence, 
mutations in NDUFS4 generally lead to the complete absence of NDUFS4 protein 
and the accumulation of a ~830 kDa late stage CI assembly intermediate instead 
of fully assembled complex (Ugalde et al., 2004, Leshinsky-Silver et al., 2009, 
Assouline et al., 2012). In fibroblasts from patients baring different mutations in 
this subunit, the residual CI activity ranges from 15-75% of the lowest control value 
(Koene et al., 2012, Verkaart et al., 2007b, Voets et al., 2012). NDUFS4 mutations 
cause a Leigh-like syndrome, which presents as encephalopathy, optic atrophy, 
hypotonia, ataxia, neuropathy, and myopathy (Leigh, 1951). Generally, these 
symptoms appear a few months after birth and patients usually die a few years 
after the onset of symptoms (van den Heuvel et al., 1998, Petruzzella et al., 2001, 
Budde et al., 2000, Budde et al., 2003, Scacco et al., 2003, Petruzzella and Papa, 
2002). Currently, there is no cure for CI deficiency and a better understanding of 
the metabolic consequences of NDUFS4 mutations is required for the development 
of treatment strategies. To study this in more detail, a whole body knockout (KO) 
mouse model was created by deletion of the second exon of the Ndufs4 gene 
(Kruse et al., 2008). This exon deletion causes complete absence of the Ndufs4 
protein, resulting in a reduced stability of CI (Kruse et al., 2008, Valsecchi et al., 
2012, Calvaruso et al., 2012). Although supercomplex formation with CIII provides 
partial CI stability and activity, the absence of Ndufs4 leads to a reduced 
expression level CI, suggesting unstable CI is degraded faster (Calvaruso et al., 
2012). At birth, KO mice have a lower body weight compared to wild-type (WT) 
mice but appear healthy (Kruse et al., 2008). From about 5 weeks of age onward, 
the KO mice start to develop ataxic signs, dysfunctions in motor coordination, and 
failure to thrive, after which they die around 7 weeks of age (Kruse et al., 2008). 
The brain of 30-day-old KO mice displays an abnormal metabolic profile that 
includes accumulation of pyruvate, lactate, and glycolytic intermediates, which is 
consistent with clinical symptoms of Leigh syndrome (Johnson et al., 2013). To 
study intracellular pathophysiology, immortalized mouse embryonic fibroblasts 
(iMEFs) and primary mouse muscle and skin fibroblasts were obtained from wild-
type (WT) and KO mice. Similar to patient fibroblasts, primary KO mouse muscle 
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and skin fibroblasts display increased reactive oxygen species (ROS) levels (based 
upon hydroethidium (HEt) oxidation) (Valsecchi et al., 2013). In contrast, HEt-
oxidizable ROS levels were not increased in iMEFs, which might be due to a 
different cellular status (cell type, immortalization) (Valsecchi et al., 2012). 
However, it is to be expected that mitochondrial dysfunction mostly affects tissues 
with a high energy demand, such as muscle, which for the greater part depend on 
mitochondrial ATP production (Koopman et al., 2012). One of the compensatory 
mechanisms could be a switch to a more glycolytic mode of ATP production, which 
requires an increase in glucose uptake rate. For instance, in primary fibroblasts, CI 
dysfunction induces a complete reliance on glucose for cell survival (Distelmaier 
et al., 2015).          
Here, primary myoblasts derived from M. Soleus from WT and KO mice were used 
to study the effect of inherited CI deficiency on glucose uptake. It was found that 
proliferating WT and KO myoblasts have similar rates of glucose uptake when 
cultured in proliferation medium containing high glucose and high serum levels. 
Switching to low serum and low glucose- or galactose-containing differentiation 
media increased ATP-linked oxygen consumption and revealed a significant 
increase in glucose uptake in KO myoblasts compared to WT. This increased 
glucose uptake rate in differentiating KO myoblasts is not due to upregulation of 
Glut1 or Glut4 expression and paralleled by increased levels of hydroethidium-
oxidizing ROS. 
 
Materials and Methods 
Animals and housing conditions 
Ndufs4 whole-body knockout (KO) and wild-type (WT) mice were generated by 
crossing heterozygote males and females with a mixed 129/sv x C57BL/6 
background (Kruse et al., 2008). Animals were fed with a standard rodent diet ad 
libitum and housed at 21.0 C, 60% humidity, and a standard light/dark (12 h/12 h) 
cycle. The Animal Experimentation Committee at the Radboud University Medical 
Centre approved, in accordance with Dutch laws and regulations regarding animal 
experimentation, breeding, and experiments.  
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Mouse behavioral studies  
Only males were used for the behavioral studies, of which each animal was tested 
at 3, 5, and 6 weeks of life. Behavioral analysis was carried out by performing 
rotarod, rope grip, and grip strength analysis. On testing days, animal(s) were 
placed in the testing room for a 30 minute acclimation period. Animals were tested 
in one paradigm/day over the course of 3 days. The order of testing was consistent 
(for example, all animals were tested first on the rotarod on day 1, then the rope 
grip on day 2 and grip strength on day 3).  After the day’s testing was completed, 
all animals were returned to the colony room. 
 
Rotarod  
The rotarod paradigm was used to provide a quantitative readout of motor 
capabilities. The test consisted of a training period, during which the animals are 
exposed to the rotating rod, set at a constant 10 RPM, for 3 minutes. After the 
training period, the animals were tested a total of 3 times on the accelerating 
rotarod, with a 3 minute resting period in between each trial. The average time to 
fall from the rod (sec) is used as the readout parameter. The rotarod test is 
complete when the animal falls from the rod or if the animal remains on the rod 
until the maximum RPM is reached (300 sec).   
 
Rope grip  
The rope grip paradigm was used as a measure of muscular endurance. It 
consisted of a rope, suspended approximately 30 cm above the floor and 
approximately 100 cm long. Animals were placed on the middle of the rope, and 
allowed to grasp it with their fore paws only. The animal may then try to escape 
from the rope for an interval of 2 min. Normal rodent behavior dictates that the 
animal will try to escape by gripping the rope with all 4 limbs and crawling to either 
end of the rope, where they can then crawl to the floor, and safety. Animals with 
muscular dysfunctions will be unable to grip the rope properly, and will fall to the 
padded apparatus floor before the conclusion of the 2-minute test. The number 
of escapes during the 2 minutes was quantified, as well as how long (sec) the 
animals remained on the rope. The test was automatically concluded if the animal 
falls from the rope. The rope grip test was repeated 3 times (with a resting interval 
of 3 minutes), and the average number of escapes and average time on the rope 
were used as the readouts.   
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Grip strength  
The grip strength paradigm was used as a measure for muscular forelimb 
strength. The device consisted of a single bar (TSE Systems, Germany). Animals will 
grasp the bar by instinct, which were gently retracted by the researcher until they 
were forced to release the bar. This was repeated 5 times for every animal and the 
average force exerted was used as the readout. Since body weight may play a role 
in the amount of force that was exerted, the measurements were corrected for 
body weight.  
 
Myofiber and primary myoblast isolation  
Female WT and KO mice (age: 38-42 days) were sacrificed by decapitation and M. 
soleus muscles were dissected. Individual myofibers were isolated as described in 
detail elsewhere (Collins and Zammit, 2009, Blanchet et al., 2014, Grefte et al., 
2015). Isolated myofibers were cultured in proliferation medium consisting of 
DMEM (Invitrogen HQ, San Diego, CA, USA) supplemented with 30% (v/v) fetal 
bovine serum (FBS, PAA Laboratories, Cölbe, Germany), 10% (v/v) horse serum (HS, 
PAA Laboratories), 1% (v/v) chick embryo extract (CEE, MP Biomedicals Europe, 
Illkirch Cedex, France), 10 ng/ml basic fibroblast growth factor (bFGF, Invitrogen), 
and 1% (v/v) p/s (PAA Laboratories) for 3 days at 37 C (95% air, 5% CO2). In this 
period satellite cells grew out of the myofibers, which were then removed. 
Proliferating satellite cells (a.k.a. myoblasts) were trypsinized, pre-plated for 10 
min in uncoated 6 wells-plate after which the non-adherent cells were transferred 
to a 6 wells-plate coated with Matrigel (1 mg/ml; MatrigelTM Basement Membrane 
Matrix, BD Bioscience, Bedford, MA, USA). WT and KO myoblasts were cultured for 
maximally one week and then used for experiments. 
 
Transfection with glucose sensor 
Myoblasts were electroporated with the glucose sensor FLII12Pglu-700μδ6 
(Addgene Plasmid #17866) (Takanaga et al., 2008) using the Neon® Transfection 
System (Life Technologies). Coverslips (∅24 mm) were first coated with 20 μg/ml 
fibronectin (Roche Diagnostics GmbH, Mannheim, Germany) for one hour and 
subsequently with 10 μl Matrigel to create a ‘Matrigel-spot’ for the cells. Cells were 
harvested, counted and washed with PBS. Per 10 μl Neon® Pipette Tip a 
suspension of 50,000-100,000 myoblasts in Resuspension Buffer R (Life 
Technologies) and 1 μg DNA was taken up. Cells were microporated in Electrolytic 
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Buffer E (Life Technologies) with a single pulse of 1350 V and a pulse width of 30 
ms. Cells were recovered in pre-warmed proliferation medium without p/s at a 
density of 5,000 cells per 10 μl (proliferation experiment) or 10,000 cells per 10 μl 
(differentiation experiment). Matrigel was removed from spots and 10 μl of 
microporated cells were seeded per spot. These spots were created to reduce the 
amount of cells necessary for microscopic analysis. After cell attachment (10 min), 
3 ml proliferation medium without p/s was gently added and cells were further 
maintained at 37 °C (95% air, 5% CO2).  
 
Glucose uptake measurements 
One day after transfection, the primary myoblasts were washed and incubated for 
3 min in HEPES-Tris (HT) buffer (adjusted to pH 7.4 with Tris) containing 4.2 mM 
KCl, 132 mM NaCl, 10 mM HEPES, 1.2 mM MgCl2 and 1 mM CaCl2. Next, the original 
HT buffer was replaced with HT buffer containing 500 μM iodoacetic acid (IAA, 
Sigma) and incubated for another 15 min. Subsequently, coverslips were mounted 
in an incubation chamber and placed on the stage of an inverted microscope 
(Axiovert 200 M, Carl Zeiss BV, Sliedrecht, The Netherlands) (Nooteboom et al., 
2012), equipped with a x40/1.3 NA Plan NeoFluar objective (Carl Zeiss) and a 
CoolSNAP HQ monochrome CCD-camera (Roper Scientific, Vianen, The 
Netherlands). Microscopy hardware was controlled using Metafluor 6.0 software 
(Universal Imaging Corporation, Downingtown, PA, USA). FLII12Pglu-700μδ6 was 
excited at 430 nm (CFP) for 300 ms using a Polychrome IV monochromator system 
(TILL Photonics, Gräfelfing, Germany). CFP fluorescence was detected using a 
455DRLP dichroic mirror (XF2034, Omega Optical Inc, Brattleboro, VT, USA) and a 
480AF30 (XF3075; Omega) emission filter. Citrine emission (CitrineFRET) was 
measured using 430 nm excitation light (during 200 ms) and emission was 
detected using the 455DRLP dichroic mirror and a 535AF26 emission filter (XF3079; 
Omega). Time-lapse recordings were performed using an acquisition interval of 
2.5 s. After a short baseline, HT buffer containing 4 mM glucose was added to the 
cells (1:1). Microscopy images were stored in native Metafluor format (12-bit; 
Universal Imaging Corporation) and analyzed off-line using Image Pro Plus 6.1 
software (Media Cybernetics, Rockville, USA). Individual images were background 
corrected for each wavelength by subtracting the average intensity of an 
extracellular region of interest (ROI). Next, cell-derived fluorescence signals were 
quantified using cytosolic circular regions of interest (ROIs).  
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High-resolution respirometry  
For every experiment, 2 ml of culture medium was collected. Myoblasts were 
trypsinized, washed and resuspended in the collected medium to 250,000 - 
500,000 cells per 2 ml to measure cellular oxygen consumption using a two-
chamber Oxygraph (Oroboros Instruments, Innsbruck, Austria) at 37 oC. First a 
basal oxygen consumption rate (basal) was obtained after which the complex V 
(CV)-inhibitor oligomycin A (OLI; 2.5 μM) was added to measure O2 consumption 
related to mitochondrial proton leak (leak). Next 0.5 μM Carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP) was added stepwise until the maximal 
O2 consumption (maximal) was reached. Finally, rotenone (0.5 μM) and antimycin 
A (2.5 μM) were added together to determine non-mitochondrial O2 consumption 
(ROX). This ROX value was subtracted from the basal, leak, and maximal oxygen 
consumption values. Finally, various derived parameters were calculated as 
follows (Dranka et al., 2011): non ATP-linked O2 consumption 
((leak/maximal)*100), ATP-linked O2 consumption (((basal-leak)/maximal)*100) 
and reserve capacity (((maximal-basal)/maximal)*100).  
 
Myoblasts differentiation  
Approximately 4 hours after cell seeding or electroporation, cells were washed 
with PBS and placed in differentiation medium consisting of either DMEM 
containing 25 mM glucose (DM-HG; Invitrogen) or glucose-free DMEM (Invitrogen) 
supplemented with 5 mM glucose (DM-LG) or 5 mM galactose (DM-GAL). All media 
contained 2% (v/v) dialyzed fetal bovine serum (diFBS, Invitrogen) and 1% (v/v) p/s.  
 
Quantitative PCR analysis  
Myoblasts were seeded at 200,000 cells/well on matrigel-coated 6 wells plates and 
placed in differentiation medium as described above. After 24 hours cells were 
washed with cold PBS. Next, cells were lysed on ice using 300 μl lysis buffer 
(PureLink® RNA Mini Kit, Life technologies) containing 1% (v/v) β-mercaptoethanol 
per well. Homogenization was carried out using a 21 Gauge needle (BD 
Bioscience). Subsequently, RNA was extracted according to the manufacturer’s 
protocol (PureLink® RNA Mini Kit, Life technologies). cDNA was generated from 1 
μg RNA using the IScript cDNA synthesis kit (Biorad, Hercules, CA, USA) using the 
manufacturer’s protocol. Quantitative real-time PCR was performed in a final 
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volume of 25 μl containing 12.5 μl SYBR®Green Supermix (Bio-Rad), 5 μl (10x 
diluted) cDNA, 4.5 μl RNAse-free water, 1.5 μl forward primer (2.5 μM) and 1.5 μl 
reverse primer (2.5 μM). Primers for GAPDH and Glut1-4 (see below) were 
obtained from Biolegio (Nijmegen, The Netherlands). Amplification of cDNA was 
performed using a C1000 Thermal Cycler (Bio-Rad) and fluorescence was analyzed 
using the CFX96TM Real-Time System (Bio-Rad). The PCR conditions were 95 ºC for 
3 minutes (1 cycle), 95 ºC for 15 s and 60 ºC for 30 seconds (39 cycles), and finally 
a temperature increase starting at 65 ºC to 95 ºC with 0.5 ºC intervals. RNA 
expression was normalized against the mRNA level of GAPDH (DCt).  
Glut1 TGCAGTTCGGCTATAACACTG and GGTGGTTCCATGTTTGATTG 
Glut2 TGTGATCAATGCACCTCAAG and TCATAGTTAATGGCAGCTTTCC 
Glut3 ACTCTTTGTCAACCGCTTTG and ATCTTGGCGAATCCCATAAG 
Glut4 CTTGGCTCCCTTCAGTTTG and CACGTTGCATTGTAGCTCTG 
GAPDH TGATGGGTGTGAACCACGAG and GGGCCATCCACAGTCTTCTG 
 
Western blot analysis  
Cells were scraped and centrifuged at 600g for 5 min at 4 ºC. Cell pellets were lysed 
in RIPA buffer consisting of 50 mM Tris-HCl (pH 7.4), 50 mM NaCl, 5 mM EDTA, 1% 
(w/v) deoxycholate, 1% (w/v) Triton X-100, 10 mM Na4P2O7, 50 mM NaF, 0.1 mg/ml 
DNase, and 1x protease inhibitor cocktail. After 30 min rotation at 4 ºC, cell 
suspensions were centrifuged at 15,000g for 10 min at 4 ºC and supernatants were 
used for protein concentration determination by measuring the absorption at 280 
nm using a Nanodrop 2000c spectrophotometer (Thermo Scientific). Proteins 
were denaturated in sample buffer (250 mM Tris-HCl (pH 6.8), 160 mM 
dithiothreitol, 2% (w/v) SDS, 12% (v/v) glycerol, and 0.03% (w/v) bromophenol blue) 
at 70 ºC for 10 min. Proteins (30 μg/lane) were separated on 10% SDS-PAGE gels 
and transferred to polyvinylidene difluoride (PVDF) membranes (Novex, Life 
Technologies). Membranes were blocked with Odyssey blocking buffer (Li-Cor, 
Lincoln, NE, USA) in PBS (1:1) and incubated with polyclonal anti-GLUT1 (07-1401), 
polyclonal anti-GLUT4 (07-1404) (Millipore, Billerica, USA), and monoclonal anti-β-
Actin (A5441) (Zwijndrecht, The Netherlands). For detection, IRDye 680RD-
Conjugated Goat Anti-Mouse IgG (Li-Cor) and IRDye 800CW-Conjugated Goat Anti-
Rabbit IgG (Li-Cor) secondary antibodies were used. Membranes were scanned 
and bands were quantified with Image Studio Lite version 4.0 software (Li-Cor). 
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Fluorescence microscopy of hydroethidium-oxidation, NAD(P)H 
autofluorescence, TMRM (ΔΨ)  
The levels of HEt-oxidizing ROS were determined as described in detail previously 
(Grefte et al., 2015). Briefly myoblasts were loaded with 10 μM HEt (Invitrogen) in 
culture medium for exactly 4.5 min, washed and transferred to a HT buffer. For 
NAD(P)H autofluorescence, cells were washed and transferred to a HT buffer. For 
TMRM fluorescence, cells were stained with 30 nM TMRM (Invitrogen) in the 
corresponding medium for exactly 25 min, washed and then transferred back to 
the original medium without TMRM. Coverslips were mounted in an incubation 
chamber and placed on the stage of an inverted microscope (Axiovert 200 M, Carl 
Zeiss). For HEt fluorescence, cells were excited at 490 nm for 100 ms using a 
monochromator (Polychrome IV, TILL Photonics). Fluorescence emission was 
directed to a CCD-camera using a 525DRLP dichroic mirror (Omega Optical Inc.) 
and a 565ALP emission filter (Omega Optical Inc.). For NAD(P)H autofluorescence, 
cells were excited at 360 nm for 1000 milliseconds using the Polychrome IV 
monochromator system and fluorescence emission was directed by a 430DCLP 
dichroic mirror (Omega Optical Inc, Brattleboro, VT, USA) and through a 480AF30 
emission filter (Omega Optical Inc.). For TMRM fluorescence, cells were excited at 
540 nm for 100 milliseconds and fluorescence emission was directed by a 
560DRLP dichroic mirror (Omega Optical Inc.) and through a 565ALP emission 
filter (Omega Optical Inc.). Quantitative analyses were performed with the 
Metamorph 6.0 software (Universal Imaging Corporation). The mean fluorescence 
intensity in a mitochondrial-dense intracellular region (at least 10 different 
microscopic fields) was determined and corrected for background using an 
extracellular region of the same size. 
 
Statistical analysis  
Average values are presented as mean ± standard error of the mean (SEM). Curve 
fitting was performed using Origin Pro 6.1 (OriginLab Corp., Northampton, USA) 
and statistical analysis was performed using GraphPad Prism 5 (Graphpad 
Software Inc., La Jolla, USA). Statistical significance relative to the indicated 
condition was determined using a One-way or Two-way ANOVA (followed by 
Bonferroni posttests) and marked by: *** (p<0.001), **(p<0.01), and *(p<0.05).  
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Results 
KO mice display decreased muscle endurance and strength  
All KO mice displayed a severe progressive phenotype including loss of hair, motor 
dysfunction, ataxia, and died before the age of 45 days after birth as described 
previously (Kruse et al., 2008). At 3, 5, and 6 weeks after birth, WT and KO animals 
were subjected to rotarod, rope grip, and grip strength paradigms to determine 
their motor capabilities, muscle endurance, and muscle strength, respectively (Fig. 
1). Three-weeks old KO mice displayed decreased motor capabilities and muscle 
endurance as indicated by the significant decreased time to fall during the rotarod 
and rope grip paradigms. At 5 and 6 weeks after birth these parameters in KO mice 
worsened confirming the progressive phenotype. Muscle (grip) strength of the KO 
mice was significantly decreased at 6 weeks of life. These data suggest that 5-6 
weeks old KO mice display muscle dysfunction and therefore we isolated primary 
myoblasts from these animals to study whether glucose uptake was affected.  
 
 
 
 
Figure 1. Rotarod, rope grip, and grip strength of WT and KO mice. WT and KO mice were tested at 3, 5, 
and 6 weeks of life for their motor capabilities, muscle endurance, and muscle strength using the rotarod, 
rope grip, and grip strength paradigms, respectively. Bar graphs represent mean values (WT, N=15 and KO, 
N=12 at 3 weeks; WT, N=14 and KO, N=9 at 5 and 6 weeks) and statistical significance between WT and KO is 
indicated by * (p<0.05). 
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KO myoblasts show normal glucose uptake and oxygen consumption when 
cultured in high-glucose proliferation medium  
For glucose uptake experiments primary myoblasts, derived from M. Soleus, were 
transfected with the glucose sensor FLII12Pglu-700μδ6 (FLII), which consists of a 
glucose binding domain attached to cyan fluorescent protein (CFP) and the yellow 
fluorescent protein mutant Citrine (Takanaga et al., 2008). Glucose binding to the 
sensor increases the emission of Citrine upon CFP excitation (CitrineFRET) and 
decreases the CFP emission upon CFP excitation (CFP). Glucose unbinding will 
induce the reverse effect and hence the emission ratio (CitrineFRET/CFP) can be 
used as a measure of the intracellular glucose concentration (Takanaga et al., 
2008). Glucose uptake was measured under zero-trans conditions in myoblasts 
pretreated with iodoacetic acid (IAA). The later was used to inhibit glucose 
consumption and allows for measurement of glucose uptake without 
underestimation due to glucose consumption (Chapter 3) (Liemburg-Apers et al., 
2015a). Upon extracellular addition of 2 mM glucose the initial rate of increase in 
CitrineFRET/CFP was quantified by fitting a linear equation to the steepest part of 
the CitrineFRET/CFP increase (Fig. 2A). The slope of CitrineFRET/CFP increase is a 
measure of the rate of glucose uptake (Chapter 3) (Liemburg-Apers et al., 2015a). 
The rate of glucose uptake was identical between WT and KO myoblasts cultured 
in proliferation medium containing 25 mM glucose (Fig. 2B). In addition, the 
average protein levels of Glut1, the primary Glut isoform in undifferentiated 
myoblasts (Al-Khalili et al., 2003), was not increased in lysates from KO myoblast 
compared to WT (Fig. 2C). Next, cellular O2 consumption rates were examined in 
WT and KO primary myoblasts. KO myoblasts showed normal ‘basal’, ‘leak’ (CV-
inhibitor OLI) and ‘maximal’ (CV-inhibitor OLI + mitochondrial uncoupler FCCP) O2 
consumption as compared to WT (Fig. 4A). Taken together, the above results 
suggest that KO myoblasts cultured in proliferation medium containing 25 mM 
glucose are not affected by the absence of Ndufs4. 
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Figure 2. Glucose uptake in primary myoblasts cultured in proliferation medium. (A) Typical example of 
a glucose uptake experiment. Myoblasts expressing FLII were incubated in HT buffer containing 0 mM glucose 
for 18 min and 500 μM IAA was added during the last 15 min. Next, 2 mM glucose was added to the cells. The 
CitrineFRET/CFP was plotted in time. (B) The glucose uptake rate was quantified by fitting a linear equation to 
the part of steepest increase upon glucose addition as indicated by the dotted lines in panel B. Bar graphs 
represent the mean glucose uptake rate for WT (n=6 experiments) and KO (n=6 experiments). N=1 day. (C) 
Representative Western blot analysis of whole cell Glut1 expression in lysates from WT (2 mice) and KO (2 
mice). Graph shows the average Glut1 optical densities normalized on actin optical densities for WT (6 mice) 
and KO (4 mice) myoblasts.  
 
KO myoblasts show increased glucose uptake in low glucose and galactose 
differentiation medium  
Empirical evidence suggests that proliferating cells rely less on OXPHOS-based ATP 
production than differentiated cells (Agathocleous et al., 2012). Therefore, we 
hypothesized that differentiation could make myoblasts more oxidative and reveal 
a higher glucose uptake rate in KO myoblasts. Myoblasts were cultured in 
differentiation medium (DM) containing 2% (low) FBS for 24 hours. The various 
differentiation media contained: 25 mM glucose (high glucose, DM-HG), 5 mM 
glucose (low glucose, DM-LG) or 5 mM galactose (DM-GAL). It is expected that cells 
become more dependent on OXPHOS-based ATP generation in DM-LG and DM-
GAL (Elkalaf et al., 2013, Voets et al., 2012, Moran et al., 2010, van der Westhuizen 
et al., 2003). Reducing serum levels is known to induce myoblasts differentiation 
(Lawson and Purslow, 2000, Lattanzi et al., 2000, Columbaro et al., 2001, Faenza et 
al., 2003). However, visual inspection revealed that after 24 hours in differentiation 
medium, the majority of the myoblasts were not yet fully differentiated into 
multinuclear myotubes (Fig. 3A,B).  
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Figure 3. Typical images of FLII expressing WT and KO myoblasts cultured for 24 hours in (A) proliferation 
medium or in (B) DM-HG, DM-LG, or DM-GAL. Images show Citrine fluorescence intensities. 
 
Basal, leak and maximal O2 consumption did not differ between WT and KO 
myoblasts in DM-HG, DM-LG, and DM-GAL (Fig. 4B). However, both WT and KO 
myoblasts tended to display a higher basal O2 consumption in DM-LG and DM-
GAL. In the latter condition, leak O2 consumption appeared slightly reduced. From 
these data the non-ATP linked (i.e. oligomycin-insensitive) and ATP-linked (i.e. 
oligomycin-sensitive) O2 consumption and reserve capacity (i.e. FCCP-stimulated 
minus basal consumption) relative to the maximal O2 consumption were 
calculated (Dranka et al., 2011) (Fig. 4C). The reserve capacity is considered an 
estimate of the amount of O2 consumption available during conditions of 
increased ATP demand (Dranka et al., 2011). Switching to DM-GAL significantly 
increased ATP-linked O2 consumption and decreased reserve capacity in both WT 
and KO myoblasts.  
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Figure 4. Oxygen consumption in primary myoblasts cultured in proliferation and differentiation 
medium. (A) Basal, leak and maximal oxygen consumption rates corrected for non-mitochondrial oxygen 
consumption rate of WT and KO myoblasts cultured in proliferation medium. Bar graphs represents mean 
values of 3 independent experiments. (B) Basal, leak and maximal oxygen consumption rates corrected for 
non-mitochondrial oxygen consumption rate of WT and KO myoblasts cultured for one day in DM-HG, DM-
LG, DM-GAL. Bar graphs represents mean values of 3-4 independent experiments. (C) Proton leak, ATP linked 
oxygen consumption and reserve capacity were calculated from the values and conditions described in B. Bar 
graphs represent mean values of 3-4 independent experiments. One-way ANOVA Bonferroni posttests.  
* (p<0.005). 
 
Next, the rate of glucose uptake was measured in WT and KO myoblasts 
differentiated for 24 hours in DM-HG, DM-LG, or DM-GAL (Fig. 5A). Glucose uptake 
was significantly increased in DM-LG and DM-GAL conditions in both WT and KO 
myoblasts (p<0.01 for WT; p<0.001 for KO) (Fig. 5B). Under these conditions, 
glucose uptake was significantly faster in KO than in WT myoblasts (p<0.05 for LG; 
p<0.001 for galactose) (Fig. 5B). As shown in figure 2 of the general introduction, 
Glut4 expression is induced during C2C12 myoblasts differentiation. Therefore, it 
was determined which Gluts were expressed after 24 hours of differentiation and 
how DM-LG, and DM-GAL affected Glut expression in WT and KO myoblasts. QPCR 
analysis was unable to detect Glut2 and Glut3 but revealed that Glut1 and Glut4 
were expressed in differentiating myoblasts (Fig. 5C). Although the protein levels 
of Glut1 were significantly increased in DM-GAL medium (p<0.05), expression of 
this protein was not differentially affected (Fig. 5D). Glut4 expression was similar 
for DM-HG, DM-LG and DM-GAL condition and not significantly different between 
WT and KO myoblasts (Fig. 5E). These results suggest that KO myoblasts cultured 
in DM-LG or DM-GAL undergo a compensatory switch to a more glycolytic mode 
of ATP production. 
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Figure 5. Glucose uptake in primary myoblasts cultured in differentiation medium. (A) Typical example 
of a glucose uptake experiment. Myoblasts expressing FLII were incubated in HT buffer containing 0 mM 
glucose for 18 min and 500 μM IAA was added during the last 15 min. Next, 2 mM glucose was added to the 
cells. The CitrineFRET/CFP was plotted in time. (B) The glucose uptake rate was quantified by fitting a linear 
equation to the part of steepest increase upon glucose addition as indicated by the dotted lines in panel A. 
Bar graphs represent the mean glucose uptake rate for WT HG (n=6 experiments), LG (n=6 experiments), GAL 
(n=6 experiments), and KO HG (n=6 experiments), LG (n=6 experiments), GAL (n=7 experiments). N=3 days.  
Two-way ANOVA Bonferroni posttest. (C) A qPCR with primers against mouse Glut1, Glut2, Glut3, and Glut4 
was performed on cDNA generated from myoblasts cultured in DM-HG, DM-LG, and DM-GAL for 24 hours. 
Only mRNA of Glut1 and Glut4 were detected. N=1 (D) Representative Western blot analysis of whole cell 
Glut1 expression in lysates from WT and KO myoblasts cultured in DM-HG, DM-LG, or DM-GAL. Graph shows 
Glut1 optical densities normalized on actin optical densities for WT HG (4 mice), LG (3 mice), GAL (4 mice), and 
KO HG (4 mice), LG (3 mice), GAL (4 mice). (E) Representative Western blot analysis of whole cell Glut4 
expression in lysates from WT and KO myoblasts cultured in DM-HG, DM-LG, or DM-GAL. Graph shows Glut4 
optical densities normalized on actin optical densities for WT HG (4 mice), LG (3 mice), GAL (4 mice), and KO 
HG (4 mice), LG (3 mice), GAL (4 mice). Two-way ANOVA Bonferroni posttest *** = p<0.001, ** = p< 0.01, * = 
p<0.05. 
 
KO myoblasts show increased hydroethidium oxidation in low glucose and 
galactose differentiation medium  
In order to see how the different culturing conditions affected cellular pathology, 
NAD(P)H, HEt-oxidizable ROS levels and ΔΨ were measured in differentiating 
myoblasts. KO myoblasts were shown to have significantly increased NAD(P)H 
levels (Fig. 6A) and decreased ΔΨ (Fig. 6B) in DM-HG, DM-LG, and DM-GAL. HEt-
oxidizable ROS levels (Fig. 6C) were similar between WT and KO myoblasts when 
differentiated in DM-HG. However, it is significantly increased (p<0.001) in KO 
myoblasts when differentiated in DM-LG and DM-GAL. 
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Figure 6. Cellular pathology in primary myoblasts cultured in differentiation medium. WT and KO 
myoblasts were differentiated for one day in DM-HG, DM-LG, DM-GAL after which (A) NAD(P)H 
autofluorescence, (B) TMRM fluorescence (ΔΨ) (C) the fluorescence of HEt-oxidation products were measured 
in myoblasts using live-cell microscopy. Bar graphs represent mean values (WT HG: n=127, 212, and 170 cells; 
WT LG: n= 141, 218, and 144 cells; WT GAL: n= 100, 230, and 125 cells; KO HG; n= 137, 204, and 163 cells; KO 
LG: n= 104, 176, and 140 cells; KO GAL: n= 140, 190, and 123 cells for NAD(P)H, HEt-oxidation, and TMRM 
respectively; all of 3 independent experiments) and statistical significance between the culturing conditions is 
indicated by *** (p<0.001). 
 
Discussion 
To gain a better understanding of the cellular consequences and adaptation to CI 
dysfunction, glucose uptake was studied in proliferating and differentiating 
primary myoblasts from Ndufs4 KO mice. In contrast to immortalized cells, primary 
cells still display some of their in vivo characteristics (Berggren et al., 2007). 
Because the absence of Ndufs4 reduces CI stability and activity (Kruse et al., 2008, 
Calvaruso et al., 2012, Valsecchi et al., 2012), it was expected that KO myoblasts 
would display a more glycolytic mode of ATP production. However, in proliferation 
medium, no difference in the rate of glucose uptake and oxygen consumption was 
observed between WT and KO myoblasts. This could at least in part be due to the 
fact that proliferating cells are more glycolytic and rely less on OXPHOS for their 
ATP production than differentiated cells (Agathocleous et al., 2012). In addition, in 
order to keep primary myoblasts in an undifferentiated state, high serum levels 
(41%) and the growth factor basic fibroblasts growth factor (bFGF) were required. 
The latter induces HIF-1α stabilization, leading to Glut1 upregulation and a 
glycolytic phenotype (Kihira et al., 2011). This glycolytic phenotype could mask the 
effects of CI deficiency on bioenergetics. To overcome the above potential 
drawbacks, myoblasts were cultured for 24 hours in differentiation medium in the 
absence of bFGF and in the presence of low serum levels (2%). Although the latter 
is known to induce myoblasts differentiation (Lattanzi et al., 2000, Lawson and 
Purslow, 2000, Columbaro et al., 2001, Faenza et al., 2003), we did not observe that 
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the majority of the WT and KO myoblasts fused into multinuclear myotubes within 
24 hours. In differentiating KO myoblasts, intracellular pathophysiology was 
observed as a reduced ΔΨ and an increased NAD(P)H autofluorescence. To further 
stimulate OXPHOS activity, next to a high external glucose concentration (25 mM; 
DM-HG), myoblasts were cultured in differentiation medium with a lower external 
glucose (5 mM; DM-LG), or glucose was displaced by galactose (DM-GAL). Culturing 
C2C12 myoblasts/myotubes at a normal external glucose concentration (5 mM) 
stimulates mitochondrial oxidative metabolism (Elkalaf et al., 2013). In addition, 
culturing in galactose medium stimulates OXPHOS-mediated ATP production 
(Moran et al., 2010, van der Westhuizen et al., 2003, Voets et al., 2012). The latter 
probably results from the fact that conversion of galactose into glucose-1-
phosphate is very slow, thereby forcing cells to generate ATP from mitochondrial 
pyruvate oxidation (Reitzer et al., 1979). Our experimental results demonstrate 
that primary WT and KO mouse myoblasts display increased ATP-linked oxygen 
consumption and a decreased reserve capacity in DM-GAL compared to DM-HG, 
suggesting a shift from glycolytic towards mitochondrial ATP production. 
Furthermore, HEt-oxidation was higher in KO myoblasts compared to WT in both 
DM-LG and DM-GAL. Moreover, culturing in DM-LG and DM-GAL medium revealed 
a significant higher rate of glucose uptake in KO compared to WT myoblasts. We 
propose a mechanism in which KO myoblasts cultured in DM-HG mainly use 
glycolysis for their ATP production (Fig. 7A). Switching to DM-LG and especially DM-
GAL forces KO myoblasts to use their mitochondria for ATP production, which 
increases HEt-oxidizing ROS (Fig. 7B). This ROS might be involved in the stimulation 
of glucose/galactose uptake to meet a higher pyruvate demand. However, basal 
O2 consumption was not higher in KO myoblasts compared to WT, suggesting that 
mitochondrial pyruvate consumption is not increased. Alternatively, the increased 
glucose/galactose uptake could serve to produce more NADPH via the pentose 
phosphate pathway (PPP) for ROS scavenging (Le Goffe et al., 2002, Andrisse et al., 
2014). However, the latter would suggest normal HEt-oxidation in KO myoblasts, 
which was not observed, suggesting that the increased glucose uptake was not 
able to fully reduce the ROS levels. However, it is not known whether HEt-oxidation 
would be even higher in KO myoblasts if glucose uptake was not stimulated.  
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Figure 7. Proposed mechanism of cellular adaptation in KO myoblasts. (A) In high glucose differentiation 
medium (DM-HG) myoblasts mainly use glycolysis for their ATP production. (B) In low glucose (DM-LG) or 
galactose (DM-GAL) differentiation medium ATP-linked O2 consumption and ROS levels are increased. This 
ROS might be involved in the stimulation of glucose uptake. Increased glucose uptake can increase NADPH 
production for ROS scavenging. GAL, galactose; GLC, glucose; PYR, pyruvate; ROS, reactive oxygen species. 
 
ROS can stimulate glucose uptake via various different mechanisms (see General 
introduction). The increased HEt-oxidation in KO myoblasts cultured in DM-LG and 
DM-GAL compared to DM-HG, suggests that ROS might be involved in the 
regulation of glucose uptake under these conditions. Using anti-oxidants the role 
of ROS in the regulation of glucose uptake in KO myoblasts cultured in DM-LG and 
DM-GAL could be further investigated. Interestingly, the increased rate of glucose 
uptake in KO myoblasts cultured in DM-LG and DM-GAL is not due to upregulation 
of Glut1 or Glut4. This is compatible with the fact that the magnitude of the rate 
of glucose uptake not always correlates with Glut1 expression levels (Abbud et al., 
2000, Barnes et al., 2002, Hamrahian et al., 1999, Shetty et al., 1993, Shi et al., 
1995). One explanation is that ROS induces a translocation of Glut1 and/or Glut4 
to the plasma membrane in KO myoblasts as a response to an increased energy 
demand (see General introduction) (Chambers et al., 2009, Liemburg-Apers et al., 
2015b). On the other hand, it could also be that ROS increases the intrinsic activity 
of Glut1 and/or Glut4 in KO myoblasts. Changes in the intrinsic activity of Glut1 
upon OXPHOS inhibition have been reported previously and metabolic regulation 
by AMPK has been suggested to play a role in this (Abbud et al., 2000, Barnes et 
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al., 2002). Remarkably, both WT and KO myoblasts died after culturing for 24 hours 
in DM-GAL containing the AMPK inhibitor compound C (data not shown), 
suggesting that AMPK activity is essential for the survival of myoblasts. 
Nevertheless, the role of AMPK in the regulation of glucose uptake in KO myoblasts 
is not clear.  
In conclusion, the glycolytic phenotype of primary myoblasts cultured in high 
serum- and bFGF-containing medium can be reversed by switching to DM-LG and 
especially DM-GAL. Under these conditions KO myoblasts display an increased 
level of HEt-oxidizing ROS and an increased rate of glucose uptake compared to 
WT myoblasts. The latter is not due to upregulation of Glut1 or Glut4 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgements 
This work was supported by equipment grants of ZonMW (Netherlands 
Organization for Health Research and Development, No: 903-46-176) and NWO 
(Netherlands Research) initiative from ZonMW (Grant: #CSBR09/013V) and the 
Dutch Energy4All foundation. 
   
 
CHAPTER 5 
Stimulation of glucose influx by acute mitoenergetic 
dysfunction requires LKB1, AMPK and Sirt2  
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Abstract 
Mitochondrial oxidative phosphorylation (OXPHOS) plays a central role in cellular 
energy production. We recently demonstrated using C2C12 myoblasts that acute 
mitoenergetic dysfunction triggers a compensatory increase in steady-state 
glucose flux to maintain ATP homeostasis. Here we aimed to highlight the 
mechanism by which acute OXPHOS inhibition stimulates glucose uptake in these 
cells. Treatment (30 min) with the OXPHOS inhibitors piericidin A or antimycin A 
greatly increased the maximal rate of glucose uptake. This uptake was mediated 
by Glut1, the mRNA level and plasma membrane abundance of which was not 
increased by inhibitor treatment. Piericidin A and antimycin A stimulated 
phosphorylation of AMP-activated protein kinase (AMPK) and, to a lesser extent, 
phosphorylation of serine-threonine liver kinase B1 (LKB1). Knockdown (KD) or 
chemical inhibition of AMPK greatly reduced the inhibitor-induced stimulation of 
glucose uptake. KD of LKB1 reduced the piericidin A- and antimycin A-induced 
increase in pAMPK levels and glucose uptake. Activated AMPK mediated the novo 
synthesis of NAD(H), maintaining a constant level of this nucleotide under 
conditions of mitochondrial inhibition. Inhibition of the NAD+-dependent 
deacetylating enzyme Sirt2 diminished the increased rate of glucose uptake, 
suggesting its activity - which is preserved by NAD+-synthesis - is necessary for the 
stimulation of glucose uptake. However, Sirt2 activity does not appear to be the 
driving force as the NAD+ precursor NMN only moderately stimulated glucose 
uptake. In addition, although Glut1 was found to be acetylated, mitochondrial 
inhibition did not appear to modulate the acetylation status. Our findings support 
a model in which acute mitoenergetic dysfunction stimulates Glut1-mediated via 
a LKB1-, AMPK-, and Sirt2-dependant mechanism.  
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Introduction 
Glucose is one of the major substrates for ATP production and is passively taken 
up by cells via a family of facilitative glucose transporters (Gluts). Glut-mediated 
glucose transport depends on the gradient between the concentration of 
extracellular glucose ([GLC]ext) and cytosolic glucose ([GLC]c). In the cytosol glucose 
is phosphorylated by hexokinase (HK) to form glucose-6-phosphate (G6P). This 
means that the magnitude of the glucose gradient across the plasma membrane, 
and thereby the rate of Glut-mediated glucose influx, is largely determined by HK 
activity (Barros, Glia, 2007). Glucose is converted by the glycolysis pathway into 
pyruvate, a process yielding two ATP per glucose molecule. Pyruvate can be 
converted into lactate and released from the cell or taken up by mitochondria. In 
the latter case, pyruvate oxidation by the tricarboxylic acid (TCA) cycle yields 
another ATP and reduces four NAD+ (into NADH) and one FAD molecule (into 
FADH2). NADH and FADH2 are oxidized by complex I (CI) and complex II (CII) of the 
mitochondrial electron transport chain (ETC), respectively. The electrons released 
by these oxidations are subsequently transported to complex III (CIII; by coenzyme 
Q10) and complex IV (CIV; by cytochrome-c). At CIV, the electrons are donated to 
molecular oxygen (O2). Within the ETC, the energy released by the electron 
transport is used to drive proton transport out of the mitochondrial matrix (by CI, 
CIII and CIV). The resulting matrix-directed proton-motive force (PMF) is then used 
by the mitochondrial FoF1-ATPase (CV) to drive ATP production via chemiosmotic 
coupling (Mitchell, 1961). Together, CI-CV constitute the mitochondrial oxidative 
phosphorylation (OXPHOS) system, which has a maximal yield of 32 ATP per 
molecule glucose. 
Each OXPHOS complex consists of multiple subunits and requires the assistance 
of proteinaceous assembly factors to catalyze its biogenesis (Nouws et al., 2012, 
Acin-Perez and Enriquez, 2014). Mutations in structural subunits or assembly 
chaperones induce mitochondrial disease in humans (van den Heuvel and 
Smeitink, 2001, Koene et al., 2012, Loeffen et al., 2000). Interestingly, inherited CI 
deficiencies are the most common OXPHOS disorders (Skladal et al., 2003), 
whereas statin-induced myopathy was linked to its off-target effect on CIII (Schirris 
et al., 2015). Moreover, empirical evidence suggests that CI inhibition mediates the 
action of the antidiabetic drug metformin and is relevant in cancer treatment 
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(Schockel et al., 2015, Zhang et al., 2014, Chen et al., 2007, Vatrinet et al., 2015). In 
addition to inborn errors of energy metabolism, mitoenergetic dysfunction has 
also been linked to diabetes, obesity and neurodegenerative disorders (Koopman 
et al., 2013, Chandra and Singh, 2011, Correia et al., 2012, Costa and Scorrano, 
2012, Martin, 2011, Patti and Corvera, 2010, Ritov et al., 2010, Swerdlow, 2012, 
Finsterer and Mahjoub, 2013).  
To cope with mitoenergetic dysfunction and prevent energy crisis, cells can 
increase their glycolytic ATP production (Elstrom et al., 2004, Epstein et al., 2014, 
Liemburg-Apers et al., 2015a). In this respect, an increased glycolytic rate was 
observed in fibroblasts from patients with myoclonic epilepsy and ragged-red 
fibers (MERRF) syndrome (Wu and Wei, 2012) and cells chronically treated with the 
CI inhibitor rotenone (Distelmaier et al., 2015). Also silencing of the CI gene NDUFS3 
triggered a glycolytic switch (Suhane et al., 2013). Increasing the glycolytic rate in 
some cases requires an increase in Glut-mediated glucose uptake capacity (Barros 
et al., 2007). The Glut family consists of 14 members of which Glut1 is the best 
studied and most abundant isoform in proliferating cells (Mann et al., 2003). Glut1 
is an integral membrane glycoprotein consisting of 12 membrane spanning α-
helices (Mueckler et al., 1985). Although monomeric Glut1 is a functional 
transporter, dimeric and tetrameric structures greatly accelerate its catalytic 
activity (Hebert and Carruthers, 1992, Zottola et al., 1995). Long-term upregulation 
of glucose uptake usually involves an increased level of Glut1 protein at the plasma 
membrane (Wang et al., 2013, Wu and Wei, 2012). However, the Glut1 transport 
activity can also be increased within 2 hours in response to oxidative stress (Prasad 
and Ismail-Beigi, 1999), metabolic stress (Barnes et al., 2002, Jing and Ismail-Beigi, 
2007, Mercado et al., 1989, Shetty et al., 1993, Shi et al., 1995, Hamrahian et al., 
1999, Koseoglu and Beigi, 1999, Cura and Carruthers, 2012, Abbud et al., 2000) and 
anoxia (Wheeler, 1988). Mechanistically, Glut1 transport capacity can be 
stimulated by: (i) increasing the translocation of Glut1-containing vesicles from the 
cytosol to the plasma membrane (Cura and Carruthers, 2012, Jing et al., 2008, 
Wheeler, 1988) or (ii) ‘unmasking’ of Glut1 transporters already present at the 
plasma membrane (i.e. enhancing the accessibility of Glut1 to glucose) (Abbud et 
al., 2000, Barnes et al., 2002, Hamrahian et al., 1999, Shetty et al., 1993, Shi et al., 
1995, Mercado et al., 1989). 
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In chapter 3 we demonstrated that acute (30 min) inhibition of CI by piericidin A 
(PA) or CIII by antimycin A (AA) increased glucose uptake and consumption in 
C2C12 myoblasts (Liemburg-Apers et al., 2015a). The latter fully compensated for 
the loss in mitochondrial ATP production and thereby maintained ATP 
homeostasis, as supported by the fact that the amount of total cellular ATP was 
not significantly altered in cells treated for 24 hours with PA- and AA (Liemburg-
Apers et al., 2015a). Combining the above experimental strategy with 
mathematical modeling led us to propose that mitoenergetic dysfunction evokes 
a rapid compensatory increase in steady-state glucose uptake and consumption 
to prevent energy crisis in cells with a compromised mitochondrial ATP 
generation. In this study we investigate the mechanism by which acute CI and CIII 
inhibition stimulate glucose uptake in C2C12 cells.  
Our results show that the amount of Glut1 at the plasma membrane remains 
constant upon inhibition of CI/CIII, suggesting activation of Glut1 transporters 
already present at this site. This activation of Glut1 requires the activity of LKB1, 
AMPK, and Sirt2. 
 
Materials and methods 
Chemicals  
Sodium iodoacetic acid (IAA), Antimycin A (AA),  5-Aminoimidazole-4-carboxamide 
ribonucleotide (AICAR), 2-cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-
quinolinyl-2-propenamide (AGK2), β-nicotinamide mononucleotide (NMN), 
trichostatin A (TSA), 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (4-Hydroxy-
TEMPO or Tempol), and 4-amino-5-(4-chlorophenyl)-7-
(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2) were obtained from Sigma-Aldrich 
(Zwijndrecht, The Netherlands). Piericidin A (PA) was obtained from Enzo Life 
Sciences (Raamsdonksveer, The Netherlands). 6-[4-[2-(1-
Piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidine (Compound C) 
was obtained from Calbiochem (Billerica, MA). 6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid (Trolox) was obtained from Fluka (Buchs, 
Switzerland). 2-morpholino-6-(thianthren-1-yl)-4H-pyran-4-one (KU55933) was 
obtained from Abcam (Cambridge, UK).  
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Cell culture  
C2C12 myoblasts were cultured at 37 oC (95% air, 5% CO2) in Dulbecco’s modified 
eagle’s medium (DMEM-32430; Life Technologies Invitrogen, Bleiswijk, The 
Netherlands), supplemented with 10% (v/v) fetal bovine serum (FBS) (10270-106; 
Life Technologies Invitrogen). For glucose measurements myoblasts were seeded 
in Fluorodishes® (#FD35-100; World Precision Instruments, Sarasota, USA) at a 
density of 40,000 cells/dish.   
 
Transfection   
One day after seeding, 1 μg DNA was mixed with 6 μl lipofectamine (Life 
Technologies Invitrogen) in 0.5 ml FBS-free DMEM. Following 20 min incubation at 
room temperature the transfection mix was added to the cells in FBS-free DMEM. 
After 6 hours this medium was replaced by DMEM containing 10% FBS. The 
glucose sensor FLII12Pglu-700μδ6 (FLII) (Addgene Plasmid #17866) (Takanaga et al., 
2008) was a gift from Dr. Wolf Frommer (Department of Plant Biology, Carnegie 
Institution for Science, CA, USA). 
 
Single cell glucose uptake measurements  
These experiments were carried out using a protocol described in detail previously 
(Liemburg-Apers et al., 2015a). Cells were washed and incubated for 3 min in 
HEPES-Tris (HT) buffer (adjusted to pH 7.4 with Tris) containing 4.2 mM KCl, 132 
mM NaCl, 10 mM HEPES, 1.2 mM MgCl2 and 1 mM CaCl2. Next, cells were placed 
on an inverted microscope (Axiovert 200 M, Carl Zeiss BV, Sliedrecht, The 
Netherlands). FLII was excited at 430 nm (CFP) for 300 ms, CFP fluorescence was 
detected using a 455DRLP dichroic mirror and a 480AF30 emission filter. Citrine 
emission (CitrineFRET) was measured using 430 nm excitation light (during 200 ms) 
and emission was detected using the 455DRLP dichroic mirror and a 535AF26 
emission filter. Time-lapse recordings were performed using an acquisition 
interval of 2.5 s. Individual images were background corrected for the individual 
wavelengths by subtracting the average intensity in an extracellular region of 
interest (ROI). Next, cell-derived fluorescence signals were quantified using 
cytosolic circular regions of interest (ROIs).  CitrineFRET/CFP emission ratios were 
converted to [GLC]c using a previously generated in situ calibration curve 
(Liemburg-Apers et al., 2015a). Per experiment a minimum of 15 cells was 
analyzed. 
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Quantitative PCR analysis 
This was carried out as described previously (Liemburg-Apers et al., 2015a). The 
primer sequences were:  
Glut1: TGCAGTTCGGCTATAACACTG and GGTGGTTCCATGTTTGATTG,   
Glut2: TGTGATCAATGCACCTCAAG and TCATAGTT-AATGGCAGCTTTCC,  
Glut3: ACTCTTTGTCAACCGCTTTG and ATCTTGGCGAATCC-CATAAG,  
Glut4: CTTGGCTCCCTTCAGTTTG and CACGTTGCATTGTAGCTCTG,  
Actin: CTAAGGCCAACCGTGAAAAG and TACGACCAGAGGCATACAGG. 
 
Preparation of whole cell lysates  
After treatment cells were scraped and centrifuged at 600 g for 5 min at 4 oC. Cell 
pellets were lysed in RIPA buffer containing 50 mM Tris-HCl (pH 7.4), 50 mM NaCl, 
5 mM EDTA, 1% (w/v) deoxycholate, 1% (w/v) Triton X-100, 10 mM Na4P2O7, 50 mM 
NaF, 0.1 mg/ml DNase, and 1x protease inhibitor cocktail. For pSrc analysis 
vanadate (1 mM) was added to the RIPA buffer. After 30 min incubation under 
gentle rotation at 4 oC, cell suspensions were centrifuged at 15,000g for 10 min at 
4 oC and supernatants were used for protein concentration determination by 
measuring the absorption at 280 nm using a Nanodrop 2000c spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA, USA). 
 
Western blot analysis  
Proteins were denaturated in sample buffer containing 250 mM Tris-HCl (pH 6.8), 
160 mM dithiothreitol, 2% (w/v) SDS, 12% (v/v) glycerol, and 0.03% (w/v) 
bromophenol blue at 70˚C for 10 min. Proteins (30 μg/lane) were separated on 
10% SDS-PAGE gels and transferred to polyvinylidene difluoride (PVDF) or 
nitrocellulose membranes (Novex, Thermo Fisher Scientific). Membranes were 
blocked with Odyssey blocking buffer (Li-Cor, Lincoln, NE, USA) diluted 1:1 in PBS 
(v/v) and incubated with primary antibodies. Polyclonal anti-Glut1 (07-1401), 
monoclonal anti-LKB1 (05-832), and polyclonal anti-phosphoLKB1(Ser431) (09-
495) were obtained from Millipore (Billerica, USA). Polyclonal anti-AMPK (2532L), 
monoclonal anti-phosphoAMPK (Thr172) (2535L), and anti-phospho-Acetyl-CoA 
Carboxylase (Ser79) (3661S) were obtained from Cell Signaling (Bioke, Leiden, the 
Netherlands). Monoclonal anti-β-Actin (A5441) was obtained from Sigma. 
Polyclonal anti-phosphoSrc (Tyr418) (44-660G) was obtained from Invitrogen. For 
detection, IRDye 680RD-Conjugated Goat Anti-Mouse IgG and IRDye 800CW-
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Conjugated Goat Anti-Rabbit IgG (Li-Cor, Lincoln, NE, USA) secondary antibodies 
were used. Membranes were scanned and band intensities were quantified with 
Image Studio Lite version 4.0 software (Li-Cor). Recombinant Src (14-117; Upstate, 
Millipore) was phosphorylated in vitro (Weigand et al., 2012). 
 
Cell surface protein biotinylation  
Biotinylation was performed using the Pierce Cell Surface protein isolation kit 
(89881; Thermo Fisher Scientific) according to the manufacturer’s protocol. For 
each condition two confluent T175 culture flasks were used. After treatment cells 
were incubated with Sulfo-NHS-SS-Biotin and biotinylated proteins were purified 
using NeutrAvidin Agarose Resin. Purified biotinylated proteins were loaded on a 
Western blot and visualized using an anti-Glut1 antibody (see above).  
 
Gene knock-down  
AMPK knock-down was performed by transfecting 75,000 cells with 60 ng siRNA 
directed against AMPKα1 and AMPKα2 subunits (sc-45313) or scramble siRNA (sc-
37007) (Santa Cruz Bioconnect Life Sciences, Huissen, The Netherlands). LKB1 
knock-down was performed by transfecting 75,000 cells with 100 nM siRNA 
directed against LKB1 (s74499) or scramble (Silencer select negative control No. 1) 
(Life Technologies Invitrogen). Transfection with siRNA was performed using the 
Neon® Transfection System (Life Technologies Invitrogen) according to 
manufacturer’s protocol for C2C12 myoblasts. One day after siRNA addition cells 
were transfected with FLII using lipofectamine (see the above section on 
transfection). Two day after siRNA addition cells were used for experiments. 
 
NAD(H) measurements   
Per sample 50,000 cells were seeded in a 6 well plate and used the next day for 
measurements. For AMPK knock-down experiments cells were transfected with 
siRNA, seeded in 6 wells plates and used for measurement 2 days later. After 
treatment cells were scraped and NAD+ and NADH were quantified using the 
EnzyFluoTM NAD+/NADH Assay Kit (EFND-100, BioAssay Systems, Hayward, CA, 
USA) according to the manufacturer’s protocol. Upon the addition of reagent the 
optical density (OD) at 560 nm was measured using a 2 min interval on the Synergy 
2 multi-mode reader (Biotek, Abcoude, The Netherlands). The ΔOD (10 min) values 
were normalized to vehicle per experiment. 
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Hydroethidium oxidation   
The levels of hydroethidium (HEt)-oxidizing ROS were determined as described in 
detail previously (Grefte et al., 2015, Forkink et al., 2015). Cells were pretreated for 
30 min with mitochondrial inhibitors followed by an 18 min incubation in the 
absence of glucose of which the last 15 min where in the presence of IAA were and 
the last 5 min in the presence of 10 μM HEt (Life Technologies Invitrogen). Next, 
the cells were washed with HT buffer and Fluorodishes® were mounted in an 
incubation chamber and placed on the stage of an inverted microscope (Axiovert 
200 M, Carl Zeiss). Cells were excited at 490 nm for 100 ms using a 
monochromator (Polychrome IV, TILL Photonics). Fluorescence emission was 
detected by a 565ALP emission filter. Quantitative analyses were performed using 
Metamorph 6.0 software (Universal Imaging Corporation). The mean fluorescence 
intensity in a mitochondria-dense and nuclear region was determined for at least 
10 different microscopic fields and corrected for background intensity using an 
extracellular region of identical size. 
 
Immunoprecipitation  
For protein acetylation analysis, lysate preparation and immuno-precipitation (IP) 
were performed in the presence of nicotinamide (NAM; 10 mM) and trichostatin A 
(TSA; 1 μM). IP of acetylated proteins was performed by incubating 1 g of protein 
cell lysate with 5 μg mouse anti-acetyl-lysine (clone 4G12, Millipore) overnight 
under gentle rotation at 4 oC. On the following day 100 μl Dynabeads® Protein G 
(Novex, Thermo Fisher Scientific) were added and incubated for 2 hours under 
gentle rotation at 4 oC. The beads were washed 3x with PBS and proteins were 
eluted in 30 μl 4x sample buffer at 70 oC for 10 min and loaded on Western blot. 
Acetylated-Glut1 was quantified by correcting the Glut1 signal for the loading 
control anti-acetyl-lysine heavy chain (HC). IP of Glut1 was performed by covalently 
cross-linking rabbit anti-Glut1 (ab32551, Abcam, Cambridge, UK) to Dynabeads® 
Protein G. After a 10 min incubation under gentle rotation of 50 μl Dynabeads® 
Protein G with 5 μg anti-Glut, beads were washed 3x in conjugation buffer 
containing 20 mM sodium phosphate, 0.15 M NaCl (pH 7-9) and incubated for 30 
min under gentle rotation at RT in conjugation buffer containing 5 mM of the 
amine-to-amine crosslinker bis(sulfosuccinimidyl)suberate (BS3; Thermo Fisher 
Scientific). Cross-linking was quenched by adding 16 mM Tris (pH 7.5) and 
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incubated for 15 min under gentle rotation at RT. Next, beads were washed 3x in 
PBS-T (PBS + 0.01% Tween) and incubated with 2 g protein cell lysate for 15 min 
under gentle rotation at RT. Beads were washed 3x with PBS and proteins were 
eluted in 30 μl 4x sample buffer at 70 oC for 10 min and loaded on Western blot. 
The amount of acetylated-Glut1 was quantified by normalizing the acetylation 
signal to the Glut1 signal. 
 
Statistical analysis  
Average values are presented as mean ± standard error of the mean (SEM). Curve 
fitting and statistical analysis were performed using Origin Pro 6.1 (OriginLab 
Corp., Northampton, USA) and GraphPad Prism 5 (Graphpad Software Inc., La Jolla, 
USA). Unless stated otherwise, statistical significance relative to the indicated 
condition was determined using a Kruskal-Wallis (followed by a Dunn’s post hoc 
test) or a Two-way ANOVA (followed by Bonferroni post hoc test) and marked by: 
*** (p<0.001), **(p<0.01) or *(p<0.05).  
 
Results 
Acute OXPHOS inhibition stimulates glucose uptake  
To quantify glucose uptake, C2C12 myoblasts were transfected with the glucose 
sensor FLII12Pglu-700μδ6 (FLII) (Takanaga et al., 2008) and imaged using 
epifluorescence microscopy. FLII consists of a glucose binding domain attached to 
CFP and the YFP-variant Citrine. The binding and unbinding of glucose triggers 
conformational changes within the sensor that affects the efficiency of 
fluorescence resonance energy transfer (FRET) from CFP to Citrine. The 
CitrineFRET/YFP emission ratio is a measure of the free cytosolic intracellular 
glucose concentration ([GLC]c) and was previously calibrated in situ in C2C12 cells 
(Liemburg-Apers et al., 2015a). To study the effects of acute OXPHOS inhibition on 
glucose uptake, cells were first pretreated (30 min) with vehicle (0.01% ethanol), 
the CI inhibitor PA (100 nM), or the CIII inhibitor AA (20 nM). Importantly, we 
demonstrated previously that these inhibitor regimes fully blocked mitochondrial 
O2 consumption and mitochondrial ATP production in C2C12 cells (Liemburg-
Apers et al., 2015a). Next, the cells were depleted of glucose by placing them in a 
glucose-free medium for 18 min. During the last 15 min of incubation, this medium 
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contained the Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) inhibitor 
iodoacetic acid (IAA) to inhibit glucose consumption. IAA (500 μM) was required to 
prevent underestimation of glucose uptake due to glucose consumption 
(Liemburg-Apers et al., 2015a). Then, glucose uptake was measured by adding 2 
mM of glucose to the cells. Quantification of the maximal rate of linear increase 
(Fig. 1A; lines), which is a measure of the rate of glucose uptake (Liemburg-Apers 
et al., 2015a), demonstrated that PA- and AA-treatment increased glucose uptake 
from 0.4 mM/min (vehicle) to 3 mM/min (Fig. 1B).  
 
 
 
Figure 1. Acute OXPHOS inhibition stimulates Glut1-mediated glucose uptake in C2C12 myoblasts. (A) 
Myoblasts were incubated for 30 min with vehicle (Veh), PA or AA. Glucose uptake was analyzed using 
fluorescence microscopy of cells expressing the glucose sensor FLII. Prior to imaging, myoblasts were 
incubated for 18 min in the absence of glucose, the last 15 min of which was in the presence of the glucose 
consumption inhibitor IAA. Next, the FLII fluorescence emission ratio (CitrineFRET/YFP) was measured during 
addition of 2 mM extracellular glucose. CitrineFRET/YFP was calibrated, allowing calculation of [GLC]c in mM. 
The maximal rate of [GLC]c increase (lines), was quantified and taken as a measure of glucose uptake rate. (B) 
The maximal rate of glucose uptake in vehicle, PA- and AA-treated cells. (C) QPCR analysis of Glut1-Glut4 
expression in cells pretreated with vehicle (Veh), PA, AA or the positive control CoCl2. Expression levels were 
normalized on actin expression. (D) Western blot analysis of Glut1 protein levels for the conditions depicted 
in panel C. Protein levels were normalized on actin protein and the vehicle condition levels. Statistics: Mean 
values (+SEM) represent 7 independent experiments (Panel B) or 3 independent experiments (Panel C, D). 
Significant differences with the indicated columns/conditions are marked by *p<0.05 and ***(p<0.001).  
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Stimulation of glucose uptake by acute OXPHOS inhibition is mediated by 
Glut1 in C2C12 myoblasts  
QPCR analysis revealed the presence of Glut1 mRNA, whereas Glut2, Glut3 and 
Glut4 were not detected (Fig. 1C). The faster rate of glucose uptake in PA- and AA-
treated cells was neither paralleled by elevated levels of Glut1 mRNA, nor by 
appearance of the other Glut isoforms. As a positive control cells were exposed to 
CoCl2 (250 μM, 4.5 h), a treatment previously demonstrated to increase GLUT1 
expression (Barnes et al., 2002, Behrooz and Ismail-Beigi, 1997). CoCl2 greatly 
increased the levels of Glut1 mRNA without inducing expression of the other Glut 
isoforms (Fig. 1C). In case of Glut1, a Western blot analysis of whole cell 
homogenates was performed under conditions mimicking the microscopy assay 
(i.e. myoblasts were pretreated for 30 min with mitochondrial inhibitors followed 
by an 18 min incubation in the absence of glucose of which the last 15 min where 
in the presence of IAA). Glut1 protein was detected as smeared bands (Fig. 1D), 
probably due to glycosylation (Asano et al., 1991). Quantification of Glut1 protein 
levels yielded no significant differences between the vehicle, PA and AA conditions 
whereas CoCl2 clearly increased these levels (Fig. 1D). Taken together, these 
results are compatible with our previous findings (Liemburg-Apers et al., 2015a) in 
suggesting that PA and AA stimulate Glut1-mediated cellular glucose uptake and 
that this stimulation is not due to Glut1 upregulation.  
 
Acute OXPHOS inhibition does not increase plasma membrane Glut1 levels  
Since the Western blot analysis in Figure 1D was carried out using whole cell 
homogenates, it cannot be ruled out that PA- and AA-treatment increase Glut1 
levels at the plasma membrane. To analyze these levels we performed 
biotinylation of cell surface Glut1 using non cell-permeable biotin (Barnes et al., 
2002). We also assessed the effect of IAA, since GAPDH is known to play a role in 
vesicular transport (Zala et al., 2013). To this end, myoblasts were pretreated for 
30 min with vehicle, PA, or AA. Next cells were incubated in HT buffer without 
glucose for 18 min, the last 15 min of which were in the absence or presence of 
IAA. The levels of biotinylated Glut1 were not affected by PA, AA, or IAA treatment 
(Fig. 2). This suggests that the inhibitor-induced stimulation of glucose uptake is 
not due to increased levels of Glut1 at the plasma membrane.  
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Figure 2. Acute inhibition of OXPHOS or glucose consumption does not affect Glut1 levels at the plasma 
membrane. (A) Levels of biotinylated Glut1 in vehicle- (in the absence and presence of IAA), PA- and AA-
treated cells. (B) Mean levels (+SEM) of biotinylated Glut1 representing 3 independent experiments. No 
significant differences were observed.  
 
Stimulation of Glut1-mediated glucose uptake by acute OXPHOS inhibition 
is paralleled by Thr172-phosphorylation of AMPK  
Increased Glut1-mediated glucose uptake during metabolic dysfunction has been 
linked to increased Thr172-phosphorylation (activation) of the energy stress 
sensor AMP-activated protein kinase (AMPK) (Abbud et al., 2000, Barnes et al., 
2002, Cura and Carruthers, 2012, John et al., 2008, Wu et al., 2013). To determine 
whether AMPK activation plays a role in our model system, myoblasts were first 
pretreated for 30 min with vehicle, PA, or AA. Next, cells were incubated in HT 
buffer without glucose for 18 min, the last 15 min of which were in the presence 
of IAA. Relative to vehicle, PA- and AA-treatment induced a 3-fold increase in the 
levels of Thr172-phosphorylated AMPK (pAMPK) without affecting the level of 
AMPK (Fig. 3A). Also phosphorylation of acetyl-CoA carboxylase 1 at Ser79 (from 
ACC1 to pACC1), which is stimulated by pAMPK, was slightly increased in PA- and 
AA-treated cells (p=0.06; Fig. S1A). This suggests that the increase in pAMPK level 
represents active pAMPK. Exogenous AMPK activation using 5-aminoimidazole-4-
carboxamide ribonucleotide (AICAR; 500 μM, 30 min) increased both pAMPK levels 
(Fig. S1B) and glucose uptake (Fig. 3B). However, AICAR stimulated glucose uptake 
to a lesser extent than PA. Co-incubation of AICAR and PA revealed no additive 
effect on glucose uptake (Fig. 3B), suggesting AICAR and PA stimulate glucose 
uptake via the same mechanism. 
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Figure 3. Stimulation of Glut1-mediated glucose uptake by acute OXPHOS inhibition requires AMPK. 
(A) Western blot analysis of the levels of AMPK and pAMPK in vehicle-, PA- and AA-treated cells. Protein levels 
were normalized on actin protein and the vehicle condition levels. (B) Effect of AICAR alone and in combination 
with PA on the rate of glucose uptake. (C)  Effect of the AMPK-inhibitor Compound C on the rate of glucose 
uptake for the conditions depicted in panel A. (D) Typical Western blot showing the effects after 2 days of 
transfection with scramble or AMPK-α1/α2 siRNA (AMPK KD) for vehicle-, PA- and AA-treated cells. Actin was 
used as a loading control. (E) Effect of scramble and AMPK-α1/α2 siRNA transfection on the rate of glucose 
uptake in vehicle-, PA- and AA-treated cells. Statistics: Mean values (+SEM) represent 3 independent 
experiments (Panel F), 4 independent experiments (Panel B, D) or 7 independent experiments (Panel A). 
Significant differences with the indicated columns/conditions are marked by *p<0.05, **p<0.01 and 
***(p<0.001). 
 
Stimulation of Glut1-mediated glucose uptake by acute OXPHOS inhibition 
is prevented by chemical AMPK inhibition and AMPK knockdown  
To determine whether AMPK activity was required for PA- and AA-induced 
stimulation of glucose uptake, cells were pretreated with the cell permeable AMPK 
inhibitor Compound C (20 μM, 2 hours). This compound binds to the AMPK α2 
catalytic subunit in a pocket that partially overlaps with the putative ATP-binding 
pocket (Handa et al., 2011). Pretreatment with Compound C did not significantly 
affect glucose uptake in the vehicle condition (Fig. 3C). However, compound C 
greatly reduced the PA- and AA-stimulated increase in glucose uptake (Fig. 3C) and 
lowered AA-stimulated ACC phosphorylation (Fig. S1C). These findings suggest that 
AMPK activity is required for inhibitor-induced stimulation of Glut1-mediated 
glucose uptake. However, evidence was provided that Compound C also displays 
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off-target effects (Bain et al., 2007, Vogt et al., 2011, Liu et al., 2014). Therefore, we 
next used a knockdown (KD) strategy using siRNAs co-targeting the α1 and α2 
catalytic subunits of AMPK. KD of AMPK reduced the levels of pAMPK in vehicle-, 
PA- and AA-treated cells (Fig. 3D). AMPK KD did not affect glucose uptake in the 
vehicle condition (Fig. 3E). Similar to Compound C, AMPK KD greatly reduced the 
stimulated glucose uptake in PA- and AA-treated cells (Fig. 3E). This reduction was 
not due to AMPK KD lowering Glut1 protein levels (Fig. S1D). The above findings 
suggest that acute OXHOS inhibition activates glucose uptake by a mechanism 
involving Thr172-phosphorylation and ensuing activation of AMPK.  
 
Stimulation of Glut1-mediated glucose uptake by acute OXPHOS inhibition 
involves LKB1  
In mammals, Thr172-phosphorylation of AMPK is primary mediated by two 
upstream kinases (Hardie et al., 2012): (i) the LKB1-STRAD-MO25 complex, which 
was originally identified as a tumor suppressor, and (ii) Ca2+/calmodulin-activated 
protein kinase kinase β (CaMKK or CaMKK2). Mechanistically, LKB1-STRAD-MO25 
induces a high basal-level of Thr172-phosphorylation that is modulated by the 
binding of AMP to the AMPK γ-subunit. The latter stimulates AMPK 
phosphorylation and inhibits its dephosphorylation (Hawley et al., 1995, Davies et 
al., 1995). LKB1 is activated by Ser431-phosphorylation (yielding pLKB1) during a 
variety of conditions (Gan and Li, 2014). This activation results in binding of pLKB1 
to AMPK and its subsequent Thr172-phosphorylation and activation (Xie et al., 
2006). To investigate the potential role of LKB1 in our model system, cells were 
pretreated for 30 min with vehicle, PA, or AA. Next, they were incubated in HT 
buffer without glucose for 18 min, the last 15 min of which were in the presence 
of IAA. PA- and AA-treatment slightly increased the levels of pLKB1 (Fig. 4A). 
Knockdown of LKB1 reduced the inhibitor-induced stimulation of AMPK Thr172-
phosphorylation (Fig. 4B). LKB1 knockdown did not affect glucose uptake in 
vehicle- or PA-treated cells but reduced this parameter in AA-treated cells (Fig. 4C). 
These results suggest that LKB1 is involved in mediating the stimulation of glucose 
uptake in AA-inhibited cells.  
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Figure 4. Stimulation of Glut1-mediated glucose uptake by acute OXPHOS inhibition involves 
LKB1. (A) Western blot analysis of the levels of pLKB1 in vehicle-, PA- and AA-treated cells. Protein 
levels were normalized on actin protein and the vehicle condition levels. (B) Typical Western blot 
showing the effects after 2 days of transfection with scramble or LKB1 siRNA (LKB1 KD) on LKB1 
and pAMPK levels for vehicle-, PA- and AA-treated cells. Protein levels were normalized on actin 
protein and the vehicle condition levels. (C) Effect of scramble and LKB1 siRNA transfection on the 
rate of glucose uptake in vehicle-, PA- and AA-treated cells. (D) Effect of the ATM-inhibitor KU55933 
on the rate of glucose uptake for vehicle- and PA-treated cells. (E) The effect of the antioxidants 
Trolox and Tempol on the rate of glucose uptake for vehicle- and PA-treated cells. Statistics: Mean 
values (+SEM) represent 2 independent experiments (Panel E), 3 independent experiments (Panel 
A, B, C), or 4 independent experiments (Panel D). Significant differences with the indicated 
columns/conditions are marked by *p<0.05, **p<0.01 and ***(p<0.001). 
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Stimulation of Glut1-mediated glucose uptake by acute OXPHOS inhibition 
does not involve ATM, Src or ROS 
The above suggests that additional modes of regulation are involved in PA-induced 
stimulation of glucose uptake. The kinase ataxia-telangiectasia mutated (ATM) was 
demonstrated to activate AMPK by an LKB1-independent mechanism in AICAR 
treated cells (Sun et al., 2007). However, pre-treatment with the ATM inhibitor 
KU55933 (1 μM, 1 hour (Hickson et al., 2004)) did not prevent the PA-induced 
increase in glucose uptake (Fig. 4D) arguing against involvement of ATM.  
Inhibitor-induced and inherited mitochondrial dysfunction are generally 
associated with an increase in ROS levels (Koopman et al., 2013, Koopman et al., 
2012, Willems et al., 2015, Zorov et al., 2014) and hydrogen peroxide has been 
suggested to play a role in LKB1-independent AMPK activation by inducing 
oxidative modification of the AMPK α subunit (Mungai et al., 2011, Zmijewski et al., 
2010). Previous studies provided evidence that antioxidants diminished hydrogen 
peroxide-associated activation of AMPK (Colombo and Moncada, 2009) and that 
Trolox and Tempol reduce hydrogen peroxide levels in living cells (Chen et al., 
2013b, Peus et al., 2001). Although PA treatment increased the levels of 
hydroethidium (HEt)-oxidizing ROS (Fig. S1E), co-incubation with the antioxidants 
Trolox (30 μM, 30 min) or Tempol (400 μM; 30 min), were unable to prevent the 
PA-induced increase in pAMPK (Fig. S1F) and glucose uptake (Fig. 4E). This suggest 
that HEt-oxidizing and/or Trolox/Tempol-sensitive ROS are not mediating the 
stimulation of AMPK phosphorylation and glucose uptake. In leukemic cells, 
glucose uptake was increased by ROS-stimulated Glut1 phosphorylation mediated 
by the tyrosine kinase Src (Prata et al., 2008). ROS-induced activation of Src was 
suggested to be mediated by oxidation of the Cys245 and Cys487 residues, 
followed by an increase in Src autophosphorylation (Giannoni et al., 2005). 
Myoblasts were pretreated for 30 min with vehicle, PA, or AA. Next, cells were 
incubated in HT buffer without glucose for 18 min, the last 15 min of which were 
in the presence of IAA. Inhibitor treatment did not stimulate Tyr418 
phosphorylation of Src (Fig. S1G). Compatible with this result, the Src inhibitor PP2 
(20 μM, 30 min) did not affect the PA-induced increase in glucose uptake (Fig. S1H). 
These results argue against involvement of Src in mediating the stimulation of 
glucose uptake in OXPHOS-inhibited cells. 
 
118 Chapter 5 
Total cellular NADH and NAD+ amount is increased and NAD+/NADH ratio is 
decreased in PA- and AA-treated cells  
Finally, it was assessed how AMPK activation leads to stimulation of Glut1-
mediated glucose uptake. Because AMPK activity is involved in NAD+ synthesis 
(Canto et al., 2009, Fulco et al., 2008) and CI oxidizes NADH, the effect of PA and 
AA treatment on NAD+ and NADH levels was assessed. Myoblasts were pretreated 
for 30 min with vehicle, PA, or AA and then incubated in HT buffer without glucose 
for 18 min, the last 15 min of which were in the presence of IAA. PA- and AA-
treatment increased total cellular NADH content (Fig. 5A), whereas NAD+ content 
also appeared elevated (Fig. 5B). As a consequence, inhibitor-treated cells 
displayed a reduced NAD+/NADH ratio (Fig. 5C), compatible with the previously 
reported increased lactate release by these cells (Liemburg-Apers et al., 2015a). 
The increase in NADH without a decrease in NAD+ suggests the novo synthesis of 
NAD+ upon PA or AA treatment. Knockdown of AMPK prevented the PA- and AA-
induced increase in total cellular NADH (Fig. 5D) and lowered total cellular NAD+ 
(Fig. 5E). However, the inhibitor-induced drop in NAD+/NADH ratio was not 
affected by AMPK knockdown (Fig. 5F). These results suggest that AMPK is involved 
in the novo synthesis of NAD+ upon PA or AA treatment.  
 
 
 
Figure 5. NAD+/NADH is decreased by acute OXPHOS inhibition. (A) NADH levels (B) NAD+ and (C) 
NAD+/NADH in vehicle-, PA- and AA-treated cells. (D) NADH, (E) NAD+ and (F) NAD+/NADH after 2 days of 
transfection with scramble or AMPK-α1/α2 siRNA (AMPK KD) in vehicle-, PA- and AA-treated cells. Statistics: 
Mean values (+SEM) represent 4 independent experiments (Panel D, E, F), or 5 independent experiments 
(Panel A, B, C). Significant differences with the indicated columns/conditions are marked by *p<0.05, **p<0.01 
and ***(p<0.001). 
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Sirt2 activity is necessary for the PA- and AA-induces stimulation of glucose 
uptake 
The NAD+-dependent deacetylating enzymes Sirtuins are involved in metabolic 
regulation. In order to assess a possible role of NAD+ and NADH in glucose uptake, 
myoblasts were treated with the NAD+ precursor nicotinamide mononucleotide 
(NMN; 1 mM, 24 hours (Yoshino et al., 2011)). This treatment increased total 
cellular NAD+ levels (Fig. S2A), but did not affect NADH levels (Fig. S2B). Under 
vehicle conditions, NMN slightly increased glucose uptake by itself (p=0.09; Fig. 
6A), whereas in PA-treated cells, stimulation of glucose uptake was not affected. 
In order to assess the possible role of Sirtuins in our model system, we specifically 
inhibited the cytosolic Sirtuin 2 (i.e. Sirt2) (Poulose and Raju, 2015). In vehicle-
treated cells, the Sirt2 inhibitor AGK2 (5 μM, 2 hours; (Outeiro et al., 2007)) 
stimulated glucose uptake (Fig. 6B). This suggests that active Sirt2 prevents 
glucose uptake. Enigmatically, AGK2 inhibited the increased glucose uptake in PA- 
and AA-treated cells, suggesting that Sirt2 activity is required for stimulation of 
glucose uptake in inhibitor-treated cells. AGK2-treatment did not prevent PA- and 
AA-induced AMKP phosphorylation (Fig. S2C). This suggests that the AGK2 effects 
occur downstream of AMPK activation.  
 
 
 
Figure 6. Stimulation of Glut1-mediated glucose uptake by acute OXPHOS inhibition involves Sirt2. (A) 
Effect of the NAD+ precursor NMN on the rate of glucose uptake for vehicle- and PA-treated cells. (B) Effect of 
the Sirt2-inhibitor AGK2 on the rate of glucose uptake for vehicle-, PA-, and AA-treated cells. Statistics: Mean 
values (+SEM) represent 3 independent experiments (Panel A) or 5 independent experiments (Panel B). 
Significant differences with the indicated columns/conditions are marked by *p<0.05 and ***(p<0.001). 
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Glut1 acetylation is not affected by PA or AA treatment 
The acetylation status of Glut1 was reported to be increased by sodium byturate 
inhibition of HDACs (Chen et al., 2015). In order to assess whether Sirt2 regulates 
Glut1-acetylation, acetylated-lysine residues were immunoprecipitated and the 
level of Glut1 was detected on Western blot. The acetylation status of Glut1 was 
not affected by PA or AA treatment (Fig. 7A). To confirm Glut1 acetylation, Glut1 
was immunoprecipitated and acetyl-lysine was analyzed on Western blot. A band 
specific for anti-acetyl-lysine was found to colocalize with Glut1 (Fig. 7B). Again, the 
acetylation status of Glut1 was not affected by PA or AA treatment (Fig. 7B). These 
results ague against regulation of Glut1-mediated glucose uptake by Glut1 
deacetylation. 
 
 
 
Figure 7. Acetylation status of Glut1. (A) Western blot analysis of the level of Glut1 in anti-acetyl-lysine (anti-
acK)-immunoprecipitated samples from vehicle-, PA- and AA-treated cells. Protein levels were normalized on 
the heavy chain (HC) levels and the vehicle condition levels. (B) Western blot analysis of Glut1 (upper panel) 
and anti-acK (lower panel) in Glut1-immunoprecipitated samples from vehicle-, PA-, and AA-treated cells. 
Acetylated-Glut1 levels were normalized on total Glut1 levels and on vehicle condition levels. Statistics: Mean 
values (+SEM) represent 4 independent experiments (Panel B) or 6 independent experiments (Panel A). No 
significant differences were observed.  
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Discussion 
Regulation of Glut1-mediated glucose uptake upon metabolic stress is an 
important cellular adaptation and a more detailed understanding of its molecular 
mechanism is relevant in a broad spectrum of metabolic disorders including 
mitochondrial dysfunction, cancer, and diabetes. Here we show that a 30 min 
incubation of mitochondrial CI or CIII increases the rate of glucose uptake without 
an increase in Glut1 membrane abundance, suggesting activation of Glut1 
preexisting at the plasma membrane. This activation requires the activity of LKB1, 
AMPK, and Sirt2.   
 
Stimulation of glucose uptake by short-term inhibition of OXPHOS complexes has 
been described before (Hamrahian et al., 1999, Jing et al., 2008, Koseoglu and 
Beigi, 1999, Mercado et al., 1989, Shetty et al., 1993, Shi et al., 1995). As already 
expected from the short time frame in which this increased glucose uptake rate 
occurred, this was not due to upregulation of Glut1 expression. Furthermore, the 
fact that Glut1 plasma membrane abundance was not affected by CI- or CIII-
inhibition suggests that the rate of Glut1 internalization was not decreased and/or 
the rate of Glut1-vesicle translocation to the plasma membrane was not increased. 
In line with this, inhibition of ATM, which promotes plasma membrane localization 
of Glut1 in myoblasts (Andrisse et al., 2013), did not diminish the increased rate of 
glucose uptake induced by PA. Activation of Glut1 preexisting at the plasma 
membrane upon metabolic stress has been described before in other cell types 
(Abbud et al., 2000, Barnes et al., 2002, Koseoglu and Beigi, 1999, Shetty et al., 
1993, Shi et al., 1995). In Chapter 3 we showed that the increased rate of glucose 
uptake induced by PA and AA was mediated by an increase in the Vmax of glucose 
transport, whereas the Km was not affected (Liemburg-Apers et al., 2015a). This 
suggests activation or unmasking of inactive Glut1 at the plasma membrane. Glut1 
is allosterically inhibited by ATP and under conditions of reduced ATP levels, the 
Vmax of Glut1 increases (Carruthers, 1986). This may suggest that the increased 
rate of glucose uptake induced by mitochondrial inhibition is mediated by the 
release of ATP-mediated inhibition. However, Glut1 activity continued to be 
increased after the ATP levels return to normal in CI-inhibited clone 9 cells 
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(Mercado et al., 1989). This suggests that although reduced ATP levels could 
initially play a role in Glut1 regulation, other modes of regulation are involved.  
 
Acute metabolic stress was reported to stimulate Glut1-mediated glucose uptake 
in an AMPK-dependent manner (Abbud et al., 2000, Barnes et al., 2002, Jing et al., 
2008). We found that both PA and AA induced AMPK activation. In addition, AMPK 
activation by AICAR stimulated the rate of glucose uptake under vehicle 
conditions. Importantly, inhibition of AMPK activity or knockdown (AMPK KD) of 
the α1- and α2-subunits of AMPK (partially) diminished the increased rate of 
glucose uptake induced by PA and AA. The incomplete inhibition of glucose uptake 
by AMPK KD could be because pAMPK was not fully reduced. Since glucose uptake 
was measured by single cell microscopy it is likely that part of the cells that were 
measured were not transfected with siRNA. Nevertheless, a significant decrease 
in the rate of glucose uptake under PA and AA conditions was observed by AMPK 
KD.  
 
Next it was assessed how AMPK is activated in response to mitochondrial 
inhibition. Acute mitochondrial inhibition is known to increase the AMP/ATP ratio 
(Jing and Ismail-Beigi, 2007, Mercado et al., 1989, Shetty et al., 1993). Increased 
binding of AMP to the γ-subunit of AMPK was shown to enhance phosphorylation 
of the α-subunit by the upstream AMPK kinase LKB1 (Woods et al., 2003, Shaw et 
al., 2004, Hardie, 2014, Hardie and Ashford, 2014). We found a moderate increase 
in the level of phosphorylated LKB1 upon PA and AA treatment. This is in 
agreement with a model proposed by Hardie, which suggests a high basal LKB1 
activity leading to a continuous phosphorylation of AMPKα at Thr172, which in the 
absence of AMP, is rapidly dephosphorylated (Hardie, 2011). However, the binding 
of AMP causes a conformational change that inhibits the dephosphorylation of 
AMPK (Sanders et al., 2007, Davies et al., 1995). Knockdown of LKB1 (LKB1 KD), 
significantly reduced PA- and AA-induced phosphorylation of AMPK and AA-
induced stimulation of glucose uptake. Interestingly, LKB1 KD did not reduce PA-
induced stimulation of the glucose uptake. It is possible that in the absence of 
LKB1, PA activates AMPK via an alternative route. Although PA increased ROS 
levels, which can activate AMPK directly or via ATM (Guo et al., 2010, Kurz et al., 
2004, Zmijewski et al., 2010), two anti-oxidants and ATM inhibition did not diminish 
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the increased rate of glucose uptake. Of note, the anti-oxidants Trolox and Tempol 
only partially diminished the PA-induced HEt-oxidation (data not shown). Hence it 
is possible that the remaining ROS is sufficient to activate AMPK and/or Glut1. 
Alternatively, AMPK-independent signaling could be involved although this is not 
expected because AMPK KD completely diminished PA-induced stimulation of 
glucose uptake.  
 
The mechanism by which AMPK stimulates Glut1-mediated glucose uptake under 
conditions of metabolic stress has been the topic of research for over a decade 
(Abbud et al., 2000, Barnes et al., 2002, Jing and Ismail-Beigi, 2007). Co-
immunoprecipitation studies showed that Glut1 is not associated with pAMPK 
under conditions of metabolic stress, suggesting Glut1 is not a direct 
phosphorylation target of AMPK. More likely, AMPK indirectly modulates Glut1 
activity. AMPK stimulates Sirt1 activity via the novo synthesis of its co-substrate 
NAD+ (Canto et al., 2009, Fulco et al., 2008, Brandauer et al., 2013). Sirtuins sense 
the energy status of the cell and deacetylate proteins involved in many cellular 
processes such as cell cycle regulation, genomic stability, and energy metabolism 
(Choudhary et al., 2009, Choudhary et al., 2014). PA and AA increased NADH levels, 
which is expected to be due to glycolysis-mediated reduction of NAD+ and the 
absence of OXPHOS-mediated oxidation of NADH. This was expected to reduce 
NAD+ levels. However, NAD+ levels were not decreased, suggesting the novo 
synthesis of NAD+. A similar observation was made in CI-deficient myoblasts of the 
heart, where upregulation of nicotinamide phosphoribosyl transferase (Nampt) 
was found to be responsible for the increased NAD+ levels (Karamanlidis et al., 
2013). Nampt is the rate-limiting enzyme in NAD+ synthesis and its expression is 
regulated by AMPK (Fulco et al., 2008). Hence is was assessed whether NAD+ 
synthesis was decreased by AMPK KD. Indeed, AMPK KD reduced NAD+ levels upon 
PA/AA treatment, suggesting that AMPK is involved in maintaining equal NAD+ 
levels and perhaps preserving Sirtuins activity under conditions of mitochondrial 
dysfunction. However, although AMPK mediated regulation of Nampt expression 
takes place at the level of translation, it takes at least 8 hours before Nampt 
protein levels are increased in muscle cells upon AICAR treatment (Brandauer et 
al., 2013). This is much longer compared to the 30 min treatment with PA or AA. In 
addition, AMPK can increase the NAD+ level by stimulation of mitochondrial fatty 
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acid oxidation, but this takes at least 4 hours (Canto et al., 2009). Although it is 
possible that these mechanisms occur faster in PA and AA treated myoblasts, it is 
expected that other modes of regulation are involved in the AMPK-mediated NAD+ 
synthesis. In order to assess the effect of NAD+ on glucose uptake, the Nampt 
product NMN was used. As expected, under vehicle conditions NMN treatment 
increased NAD+ levels. This increase in NAD+ slightly although not significantly 
increased the rate of glucose uptake.  Based on the above described effects we 
speculated that AMPK-mediated preservation of Sirtuin activity is necessary for 
the stimulation of glucose uptake under PA and AA conditions. To test this 
hypothesis, Sirt2 was specifically inhibited. In contrast to other Sirtuins, Sirt2 
localizes predominantly in the cytosol, where is has specific targets such as tubulin 
(North et al., 2003, Rauh et al., 2013). Inhibition of Sirt2 activity diminished both 
PA- and AA-induced glucose uptake, suggesting its function is necessary for the 
stimulation of glucose uptake. Interestingly, Sirt2 inhibition stimulated glucose 
uptake under vehicle conditions suggesting Sirt2 has a dual effect of glucose 
uptake. Under basal conditions it may prevent excessive glucose uptake whereas 
under metabolic stress it mediates the stimulation of glucose uptake. In the 
nucleus Sirt1 deacetylates LKB1, leading to AMPK activation (Lan et al., 2008). 
However, we found that Sirt2 inhibition did not diminish PA and AA induced AMPK 
phosphorylation, indicating that Sirt2 operates downstream of AMPK. A great 
number of glycolytic enzymes are found to be heavily acetylated and reversible 
acetylation is believed to fine tune metabolic adaptation and insulin signaling in 
muscle (Philp et al., 2014, LaBarge et al., 2015). Moreover, Sirt2 is critical for Akt 
activation by insulin (Ramakrishnan et al., 2014). Although Glut1 was found to be 
acetylated, the degree of acetylation was not altered by PA- or AA-treatment. 
Although Sirt2 activity is necessary for the stimulation of glucose uptake, it is not 
the driving force because: (i) PA and AA induced activation of AMPK preserves but 
does not increase NAD+ levels and (ii) increasing the level of NAD+ with NMN only 
moderately stimulated glucose uptake. We propose a mechanism as depicted in 
figure 8 in which acute OXPHOS inhibition increases the AMP/ATP ratio, leading to 
inhibition of AMPK dephosphorylation and stimulation of LKB1-mediated AMPK 
phosphorylation. While glycolysis reduces NAD+, phosphorylated AMPK stimulates 
NAD+ synthesis, maintaining equal levels of this nucleotide. NAD+ is necessary for 
basal Sirt2 activity, which function is to deacetylate an unknown target ‘X’. The fact 
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that AMPK activity is sufficient to stimulate Glut1 activity whereas Sirt2 activity is 
not, suggests an additional AMPK-mediated phosphorylation of ‘X’. Sequential 
phosphorylation and deacetylation has also been described for the activation of 
peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1α (Canto et 
al., 2009). Phosphorylated and deacetylated ‘X’ would activate Glut1 via a yet 
unknown mechanism. 
 
 
Figure 8. Proposed mechanism for Glut1 activation by acute OXPHOS inhibition. See discussion for more 
details. AA, antimycin A; Ac; acetylated; comp C, compound C; GLC, glucose; NAM; nicotinamide; NMN, 
nicotinamide mononucleotide; P, phosphorylated; PA, piericidin A. 
 
A possible candidate for ‘X’ is Akt, which promotes a glycolytic phenotype in various 
cell types (Elstrom et al., 2004, Higaki et al., 2008). Acetylation of Akt at the Lys20 
residue prevents plasma membrane localization and activation of Akt by PI3K 
(Sundaresan et al., 2011), whereas Akt deacetylation by Sirt2 was reported to 
promote its activity (Dan et al., 2012, Chen et al., 2013a). Importantly, 
phosphorylation of Sirt2 by AMPK at residue Thr101 was found necessary for Akt-
Sirt2 interaction and subsequent activation by PI3K (Ramakrishnan et al., 2014). 
However, AMPK-mediated phosphorylation of Akt has not been described. 
Interestingly, one of the down-stream targets of Akt is mTOR/RAPTOR, which 
stimulates glucose uptake without increasing Glut1 plasma membrane abundancy 
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(Wieman et al., 2007). Interestingly, inhibition of mTOR/RAPTOR by rapamycine 
reduced HK expression and the glycolytic flux in mice lacking the CI-subunit 
Ndufs4 (Johnson et al., 2013), suggesting mTOR/RAPTOR activity promotes 
glycolysis.  
 
In summary, LKB1, AMPK, and Sirt2 activity appears to be necessary for the 
stimulation of glucose uptake by acute OXPHOS inhibition but the exact mode of 
regulation remains unclear. Further research should focus on which protein(s) 
activate Glut1 and how they are affected by reversible acetylation and 
phosphorylation.  
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Supplementary figures 
 
 
 
Figure S1. (A) Western blot analysis of the levels of pACC in vehicle-, PA- and AA-treated cells. Protein levels 
were normalized on actin protein and the vehicle condition levels. (B) Western blot analysis of the levels of 
pAMPK in vehicle-, AICAR-, PA- and PA+AICAR-treated cells. Protein levels were normalized on actin protein 
and the vehicle condition levels. (C) Typical Western blot showing the effects of compound C on pACC levels 
for AA-treated cells. Actin was used as a loading control. (D) Typical Western blot showing the effects after 2 
days of transfection with scramble or AMPK-α1/α2 siRNA (AMPK KD) on Glut1 levels for vehicle-, PA- and AA-
treated cells. Actin was used as a loading control. (E) Nuclear and mitochondrial HEt-oxidation levels in vehicle- 
and PA-treated cells. HEt-oxidation levels were normalized on nuclear signal in vehicle. (F) Western blot 
analysis of the effect of Trolox and Tempol on the levels of pAMPK in vehicle-, PA- and AA-treated cells. Protein 
levels were normalized on actin protein and the vehicle condition levels. (G) Typical Western blot of pSrc in 
vehicle-, PA-, and AA-treated cells. Phosphorylated recombinant Src was used as a positive control. Actin was 
used as a loading control. (H) Effect of the Src-inhibitor PP2 on the rate of glucose uptake for vehicle- and PA-
treated cells. Mean values (+SEM) represent 3 independent experiments (Panel A, B, F) or 5 independent 
experiments (Panel E). Significant differences with the indicated columns/conditions are marked by *p<0.05 
and **p<0.01. 
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Figure S2. (A, B) Effect of NMN on (panel A) NAD+ and (panel B) NADH levels in vehicle-treated cells. (C) Typical 
Western blot showing the effects of AGK2 on pAMPK levels for vehicle-, PA- and AA-treated cells. Actin was 
used as a loading control.  Statistics: Mean values (+SEM) represent 2 independent experiments (Panel A, B). 
Significant differences with the indicated columns/conditions are marked by *p<0.05. 
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General discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Partially published in:  
Liemburg-Apers DC, Willems PH, Koopman, WJ, Grefte S.  
Arch Toxicol. (2015) 89(8):1209-26  
 
Sander Grefte#, Dania C. Liemburg-Apers#, Ganesh R. Manjeri, Megan E. 
Breuer, Jori A.L. Wagenaars, Leanne H.J. de Ronde, Jan A.M. Smeitink, Peter 
H.G.M. Willems, Werner J.H. Koopman  
[#These authors contributed equally] 
(Submitted)
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  General discussion 131 
Introduction 
Glucose is an important source of energy for ATP production by glycolysis in the 
cytosol and the oxidative phosphorylation (OXPHOS) system in the mitochondria. 
OXPHOS dysfunction often triggers an increase in the rate of glucose uptake and 
glycolysis (Jing et al., 2008, Shetty et al., 1993, Shi et al., 1995, Wu and Wei, 2012). 
The aim of this thesis was to assess the role of glucose in OXPHOS dysfunction. In 
order to do so the FRET-based glucose sensor FLII12Pglu-700μδ6 (FLII) described in 
Chapter 2 was used to develop a microscopic assay for live-cell quantitative 
glucose uptake measurements (Chapter 3). This assay was used to study the 
regulation (Chapter 4 and 5) and biochemical consequences (Chapter 3) of 
enhanced glucose uptake in CI- and CIII-dysfunctional myoblasts. In this chapter 
the findings from the studies in chapter 3, 4, and 5 will be integrated and discussed 
in a broader perspective. 
 
Metabolic consequences of glucose uptake stimulation 
by OXPHOS dysfunction 
Both pharmacologic inhibition of CI or CIII in C2C12 myoblasts (Chapter 3) and 
genetic deletion of the CI subunit Ndufs4 in primary mouse myoblasts (Chapter 
4) triggered an increase in the rate of glucose uptake. This enhanced glucose 
uptake has several cellular biochemical consequences. In this section the effect of 
glucose uptake stimulation on the production of ATP, lactate, and reactive oxygen 
species (ROS) will be discussed. 
 
Glucose uptake stimulation and ATP production 
Dysfunction of one of the components of the OXPHOS system can lower the 
mitochondrial ATP production rate (Porteous et al., 1998, Janssen et al., 2006, 
Jonckheere et al., 2010, Gajewski et al., 2003). Since OXPHOS generates the 
majority of total ATP produced from glucose catabolism, an increase in the 
glycolytic ATP production is required to compensate for a reduced mitochondrial 
ATP production. In Chapter 3 the glycolytic flux and ATP production were 
predicted using a mathematical model, which was parameterized using glucose 
uptake and glucose consumption kinetic data. The model predicted a 2-fold 
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increase in the steady-state glucose flux and ATP production rate under the 
condition of OXPHOS inhibition, which was confirmed empirically. Comparing this 
increased ATP production rate to the mitochondrial ATP production rate under 
normal conditions revealed that this 2-fold increase was sufficient to compensate 
for the lack of mitochondrial ATP production. This full compensation by glycolytic 
ATP was confirmed by the absence of a reduction in total ATP levels after 24 hours 
of OXPHOS inhibition. Importantly, malignant cells such as the C2C12 myoblast 
cell line generally have a high glycolytic flux compared to the mitochondrial flux, 
allowing only a 2-fold increase in glycolytic ATP production to be compensatory. 
However, in (primary) cells with a higher basal mitochondrial flux, the increase in 
glycolytic flux required to compensate for mitochondrial ATP production is 
expected to be higher. On the other hand, although OXPHOS activity is usually 
reduced in patient cells, it is not zero as is the case for full OXPHOS inhibition 
(Jonckheere et al., 2010). This suggests less compensation by glycolytic ATP is 
required in patient cells. Thus, ATP might not be a problem as the glycolytic ATP 
production can compensate and the ATP consumption is minimal under resting 
condition. However, under conditions of increased ATP demand, such as hormone 
or electrical stimulation (Visch et al., 2006b, Koopman et al., 2003), even a small 
reduction in the total ATP production capacity may induce problems such as 
disturbed calcium homeostasis (Willems et al., 2008). In addition, the 
compensatory increase in glycolytic ATP production is important to maintain the 
mitochondrial membrane potential (ΔΨ) (Nicholls, 1977). Glycolytic ATP can be 
used by CV operating in reverse-mode in order to pump protons out of the 
mitochondrial matrix. In this manner ΔΨ, which is necessary for osmotic 
homeostasis, is preserved and necrotic cell death is prevented (Elstrom et al., 
2004, Huber et al., 2011, Nicholls, 1977). Interestingly, in skeletal muscle from 
Ndufs4 KO mice which has 20-30% residual CI activity (Calvaruso et al., 2012, Alam 
et al., 2015), mitochondrial ATP production after ischemic reperfusion was not 
significantly reduced (Kruse et al., 2008). This might be due to overcapacity of CI 
as will be discussed in more detail in another section.  
 
Glucose uptake stimulation and lactate production  
Another biochemical consequence of the increased glycolytic flux is an elevation 
of pyruvate and lactate production (Chapter 3). In addition, OXPHOS dysfunction 
increases the NADH/NAD+ ratio (Chapter 5), which inhibits pyruvate 
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dehydrogenase (PDH) and shifts the reaction of the NADH-oxidizing lactate 
dehydrogenase (LDH) towards lactate production. This results in an increased 
lactate secretion and decreased pyruvate secretion upon OXPHOS inhibition (Fig. 
1). Hence one of the hallmarks of mitochondrial dysfunction is an elevated 
lactate/pyruvate ratio in blood, which is termed hyperlactatemia (Robinson, 2006). 
Lactate secretion appears to crucial for reducing ETC electron input as inhibition 
of LDH enhanced oxidative stress and cell death in tumor cells (Le et al., 2010), 
whereas stimulating pyruvate-to-lactate conversion reduced oxidative stress 
(Brand, 1997). However, when the liver is unable to process the elevated lactate 
levels, fatal lactic acidosis can follow (Loeffen et al., 2000). 
 
Figure 1. C2C12 myoblasts were incubated in culture medium (25 mM glucose) containing the CI inhibitor 
piericidin A (100 nM), the CIII inhibitor antimycin A (20 nM), or vehicle (0.01% ethanol). After 30 min the lactate 
(LAC) and pyruvate (PYR) levels in the medium were measured as described in Chapter 3.  
 
Glucose uptake stimulation and ROS production  
As described in the general introduction, mitochondrial dysfunction can cause 
excessive ROS production and even oxidative stress. In CI inhibited C2C12 
myoblasts (Chapter 5) and Ndufs4 KO primary myoblasts cultured in low glucose 
or galactose (Chapter 4), both the rate of glucose uptake and the level of HEt-
oxidizable ROS were increased, whereas these parameters were both normal in 
Ndufs4 KO myoblasts cultured in high glucose. This suggests a causal relation 
between ROS and glucose uptake. ROS-induced signaling can stimulate glucose 
uptake via various different mechanisms (Fig. 2; arrow 1) (Liemburg-Apers et al., 
2015b). However, pretreatment with different antioxidants or inhibition of the 
ROS-activated GLUT1 activators ATM and Src, did not diminish the stimulation of 
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glucose uptake in CI-inhibited C2C12 myoblasts (Chapter 5). This suggests ROS is 
not involved in the stimulation of glucose uptake under CI-inhibited condition. Vice 
versa, a high glycolytic flux was associated with increased ROS levels (Talior et al., 
2003, Zhou et al., 2005), whereas inhibition of mitochondrial pyruvate uptake 
lowered ROS levels (Nishikawa et al., 2000, Yu et al., 2006). Increased glycolytic flux 
is generally associated with and increased TCA cycle flux (Ishihara et al., 1996). The 
latter results in accumulation of OXPHOS substrates and elevated NADH/NAD+ 
and FADH2/FAD ratios (Ido, 2007, Ying, 2008). A high level of mitochondrial NADH 
leads to a fully reduced FMN site in CI, potentially stimulating superoxide 
production (Kussmaul and Hirst, 2006). Similarly, a more reduced ETC might 
stimulate superoxide formation by CIII (Turrens et al., 1985). Reduced ubiquinone, 
in combination with a highly negative (hyperpolarized) Δψ, favors reverse electron 
transfer from CII to CI, which also stimulates superoxide production (Batandier et 
al., 2006, Murphy, 2009). Hyperglycemic conditions induced mitochondrial 
fragmentation in clone 9 liver cells, H9c2 cardiomyoblasts, and smooth muscle 
cells, which was strictly required to allow increased ROS production (Yu et al., 
2011). However, induction of mitochondrial fragmentation by over-expression of 
the fission-promoting protein Drp1 (Dynamin-related protein 1), did not stimulate 
ROS levels in HeLa cells, suggesting that increased ROS levels are not a de facto 
consequence of mitochondrial fragmentation (Distelmaier et al., 2012). It was 
proposed that fragmented mitochondria might produce more ROS due to a bigger 
relative membrane surface (allowing better uptake of metabolic substrates) and 
ensuing Δψ hyperpolarization (Yu et al., 2006). High extracellular glucose levels 
stimulate TXNIP expression (Stoltzman et al., 2008), which can aggravate oxidative 
stress by binding Trx via disulfide bridges and thereby inhibiting its reducing 
potential (Hwang et al., 2014, Kaimul et al., 2007, Li et al., 2015, Nishiyama et al., 
1999, Schulze et al., 2004). Taken together, the current experimental evidence 
suggests that increased glucose uptake and glycolytic conversion to pyruvate can 
increase ROS levels (Fig. 2; arrow 2). The above raises the question whether the 
increased ROS levels in CI dysfunction cells are a consequence of the increased 
rate of glucose uptake and glycolytic flux. Based on the fact that the majority of 
pyruvate produced by glycolysis is converted to lactate and the mitochondrial flux 
is relatively low in CI-/CIII-inhibited cells (Chapter 5), a high ETC electron input is 
not expected. However, for the primary KO myoblasts this might be different. In 
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order to answer this question, HEt-oxidation levels should be measured in CI- 
inhibited cells with a diminished stimulation of glucose uptake. If diminishing the 
increased rate of glucose would lower or even normalize the ROS levels, it is likely 
that the increased rate of glucose uptake contributes to mitochondrial ROS 
production in CI-dysfunctional myoblasts. Alternatively, because glucose can be 
used by the pentose phosphate pathway (PPP) to produce the antioxidant 
recycling cofactor NADPH (Fig. 2; arrow 3), ROS levels might even be higher in the 
absence of increased glucose uptake. 
 
Figure 2. ROS stimulates glucose uptake (1). Glycolytic conversion of glucose into pyruvate and subsequent 
pyruvate entry into the mitochondria (2) stimulates ROS production by hyperpolarizing the mitochondrial 
membrane potential (Δψ↑). Glucose flux through the pentose phosphate pathway generates NADPH (3), which 
is an important cofactor in ROS scavenging. GLC, glucose; PYR, pyruvate; ROS, reactive oxygen species. 
 
Interestingly, in Ndufs4 KO mice, rapamycin treatment induced a metabolic shift 
away from glycolysis towards amino acid catabolism, whereas oxidative stress 
markers were not reduced (Johnson et al., 2013). Moreover, rapamycin enhanced 
survival and attenuated disease progression (Johnson et al., 2013). Although it is 
not clear whether reduced glycolysis is a cause or consequence of the attenuated 
disease progression upon rapamycin treatment, this suggests that oxidative stress 
is not affected by the glucose metabolism. Furthermore, it suggests that oxidative 
stress plays a minor role in the pathological symptoms of the Ndufs4 KO mice. On 
the other hand, in Drosophila, overexpression of either GLUT3, the glycolytic 
enzyme PFK or the PPP enzyme G6PDH, rescued the reduced lifespan induced by 
down-regulation of the CI subunit ND3 (Besson et al., 2015). In addition, in a 
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Drosophila model of Huntington’s disease, overexpression of G6PDH but not PFK 
increased the fly survival (Besson et al., 2015), suggesting NADPH-mediated ROS 
scavenging is involved in survival. In conclusion, it appears that an increased 
glycolytic flux has both favorable and unfavorable consequences and the balance 
between these consequences are organism- and/or cell type-specific. 
 
Regulation of glucose uptake by mitochondrial 
dysfunction 
The increased rate of glucose uptake observed in primary differentiating Ndufs4 
KO myoblasts cultured in low glucose or galactose was not due to upregulation of 
Glut1 or Glut4 (Chapter 4). Because of the limited availability of these primary 
Ndufs4 KO myoblasts, the mechanism of this regulation was studied in C2C12 
myoblasts. In order to induce CI dysfunction, this complex was pharmacologically 
inhibited with piericidin A (PA). Of note, the CI-inhibitor rotenone kills 
dopaminergic neurons and inhibits myoblasts differentiation in a CI- and OXPHOS-
independent manner (Choi et al., 2015, Grefte et al., 2015). The fact that the CIII 
inhibitor antimycin A (AA) induced similar effects on cell signaling compared to PA 
(Chapter 5), suggests that the PA-/AA-induced glucose uptake stimulation is at 
least OXPHOS-dependent. For optimal comparison of the mode of Glut1-
regulation in PA-treated myoblasts with the primary KO myoblasts, upregulation 
of Glut1 expression was prevented by performing a short-term (30 min) CI-
inhibition. Indeed, this short-term inhibition of CI did not trigger an upregulation 
of Glut1 (Chapter 5). As further shown in Chapter 5, Glut1 stimulation by 
mitochondrial dysfunction is regulated by LKB1, AMPK and Sirt2 activity. The role 
of protein acetylation in the regulation of energy metabolism is emerging. 
However, the exact role reversible acetylation on protein function remains to be 
elucidated (LaBarge et al., 2015). We found that although Glut1 is acetylated, it is 
not a direct deacetylation target of Sirt2 (Chapter 5). Interestingly, hexokinase (HK) 
was also found to be heavily acetylated (Lundby et al., 2012, Choudhary et al., 
2009), suggesting a common regulatory mechanism for both HK and Glut1 activity.  
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Figure 3. The rate of glucose (GLC) uptake in primary skin fibroblasts (C5120) and mouse embryonic 
fibroblasts (MEF) treated for 30 min with vehicle (Veh; 0.01% ethanol), piericidin A (PA; 100 nM), or antimycin 
A (AA, 20 nM). The rate of glucose uptake was measured as described in Chapter 3. N=1 independent 
experiment. 
 
Remarkably, in Chapter 3, calculation of the flux control coefficient of glucose 
uptake on the glucose flux was close to zero under both control and OXPHOS 
inhibited conditions. Of note, stimulation of glucose uptake by OXPHOS inhibitors 
is not cell type specific as it was also observed in control primary human skin 
fibroblasts (Fig. 3A) and mouse embryonic fibroblasts (MEFs) (Fig. 3B). Therefore, 
it seems counter intuitive that while stimulation of glucose uptake is so well 
regulated and occurs is various cell types, it has no effect on the glucose flux. In 
order to assess whether the increased glucose uptake capacity indeed has no 
effect on the glucose flux, lactate secretion was measured under AMPK 
knockdown (KD) conditions (i.e. diminished glucose uptake stimulation). 
Preliminary data suggests that lactate secretion is lower under AMPK KD 
conditions compared to scramble in PA- and AA-treated cells (Fig. 4). This argues 
against the low flux control coefficient for glucose uptake. However, the fact that 
lactate secretion is also reduced in the vehicle-treated cells, suggests that this 
AMPK KD-mediated reduction in lactate secretion is independent of glucose 
uptake. Of note, AMPK-mediated stimulation of HK activity cannot be excluded.  
 
 
Figure 4. C2C12 myoblasts were transfected with scramble or AMPK α1/α2 siRNA. After 2 days myoblasts 
were incubated in HT buffer (2 mM glucose) containing the CI-inhibitor PA (100 nM), the CIII-inhibitor AA (20 
nM), or vehicle (0.01% ethanol). After 60 min the lactate (LAC) levels in HT buffer were measured as described 
in Chapter 3. N=1 independent experiment. 
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Knowing the exact residues of Glut1 that are modified by mitochondrial inhibition, 
allows for more specific targeting of Glut1 and a better understanding of the role 
of glucose uptake stimulation on the glycolytic flux. In addition, it would be 
interesting to investigate whether the same signaling events also regulate the 
increased rate of glucose uptake in primary Ndufs4 KO myoblasts. Moreover, it is 
of great interest whether mitochondrial dysfunction also triggers an increase in 
glucose uptake in CI patient cells and whether the same signaling events as in 
C2C12 myoblasts are involved. Murine Glut1 is highly similar to human GLUT1 
(97% sequence identity), suggesting they are regulated in the same manner. 
However, since the CI-/CIII-inhibitors were used at concentrations that fully inhibit 
mitochondrial respiration, it is possible that they triggers a different mode of 
regulation compared to a genetic model with residual CI activity. In addition, is 
possible that in mitochondrial patient cells, long term adaptation triggers both 
upregulation of GLUT expression and activation of GLUTs at the plasma 
membrane. 
 
Model systems for studying mitochondrial dysfunction 
Fibroblasts derived from CI-deficient patients are extensively studied and show 
several cellular pathophysiological consequences such as decreased ΔΨ, 
increased levels of ROS and NAD(P)H, and aberrant calcium and ATP handling and 
mitochondrial morphology (Distelmaier et al., 2009b, Koopman et al., 2005, 
Verkaart et al., 2007b, Visch et al., 2006a). In addition, several mouse models have 
been created to study the pathophysiology of CI dysfunction (Breuer et al., 2013b). 
The Ndufs4 whole-body KO mouse shows similar clinical phenotypes as compared 
to human patients and ultimately dies before the age of 50 days (Kruse et al., 
2008). To study intracellular pathophysiology, immortalized mouse embryonic 
fibroblasts (iMEFs) and primary mouse muscle and skin fibroblasts were 
previously obtained from WT and KO mice. Similar to patient fibroblasts, primary 
KO mouse muscle and skin fibroblasts display increased HEt-oxidizable ROS level 
(Valsecchi et al., 2013). In contrast, HEt-oxidizable ROS levels were not increased 
in iMEFs, which might be due to a different cellular status (cell type, 
immortalization) (Valsecchi et al., 2012). However, CI deficiency generally affects 
high-energy demanding tissues that rely on mitochondrial ATP production 
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(skeletal muscle, heart, brain) (Koopman et al., 2012). Therefore, in Chapter 4 
primary myoblasts derived from skeletal muscles of WT and KO mice were used 
as a cellular model. Because a glycolytic phenotype could potentially mask CI-
dysfunction and (intra)cellular pathophysiology in KO myoblasts, the effect of 
different culturing conditions on the rate of glucose uptake and O2 consumption 
was assessed (Chapter 4). In order to prevent differentiation of primary myoblast, 
proliferation medium contained the growth factor bFGF. In this medium, no 
differences in the rate of glucose uptake and O2 consumption between WT and KO 
myoblast were observed. Because bFGF stabilizes HIF-1α, it promotes a glycolytic 
phenotype (Kihira et al., 2011). Switching to differentiation medium containing 
high glucose (25 mM), low glucose (5 mM), or galactose (5 mM) and no bFGF, 
revealed that low glucose and especially galactose instead of glucose increased 
the ATP-linked O2 consumption rates in KO myoblasts (Chapter 4). The rate of 
glucose uptake was also significantly higher in KO myoblasts cultured in 
differentiation medium containing low glucose or galactose, suggesting CI 
dysfunction triggers a compensatory mechanism. This improves the study of the 
(intra)cellular pathophysiology as a consequence of CI dysfunction. Interestingly, 
in C2C12 myoblasts cultured in 25 mM glucose, the rate of glucose uptake was 
significantly increased by CI inhibition (Chapter 3). This difference might be due 
to residual CI activity (KO myoblasts) versus no residual CI activity (PA treatment). 
In differentiating KO myoblasts intracellular pathophysiology was observed as a 
reduced ΔΨ, an increased NAD(P)H and HEt-oxidizable ROS levels (Chapter 4). 
Most of these changes are in accordance to previous results using primary skin 
fibroblasts from CI-deficient patients (Distelmaier et al., 2009a, Koopman et al., 
2007, Verkaart et al., 2007b) and primary fibroblasts derived from these KO mice 
(Valsecchi et al., 2013). This suggests a uniform cellular CI-dysfunctional 
pathophysiology between fibroblasts and skeletal muscle cells derived from mice 
and between human and murine fibroblasts. To our surprise, however, basal O2 
consumption rate of KO myoblasts were normal (Chapter 4). In order to analyze 
whether this basal O2 consumption was CI-driven, two CI inhibitors (PA and 
rotenone) were used. Surprisingly, these CI inhibitors acutely reduced basal O2 
consumption rates in KO myoblasts derived from extensor digitorum longus (EDL) 
muscle (Fig. 5). This suggests that sufficient amount residual CI activity is still 
present in KO myoblasts.  
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Figure 5. O2 consumption rates of EDL-derived KO myoblasts. After reaching a steady basal O2 consumption 
rate, 100 nM rotenone (ROT) or 100 nM piericidin A (PA) was added to inhibit CI. Dotted line indicates non-
mitochondrial O2 consumption rate (ROX). 
 
However, previous studies showed absence of the Ndufs4 subunit and thereby 
less stable complex I (Calvaruso et al., 2012, Valsecchi et al., 2013). This altogether 
suggests that these KO myoblasts are not CI deficient but rather have a 
dysfunctional CI. This might also explain the intracellular pathophysiology 
regarding HEt-oxidizable ROS and mitochondrial membrane potential in KO 
myoblasts in the absence of decreased basal O2 consumption rates (Chapter 4). 
But how could a normal CI-sensitive basal O2 consumption rate be observed in 
these KO myoblasts? Most likely, an over-capacity of CI exists and therefore a 
critical level of CI inhibition needs to be reached before any effects on 
mitochondrial ATP production and/or O2 consumption rate can be observed. 
Recently, it was shown that skeletal muscle mitochondria derived from these KO 
mice had 20% residual CI activity while having normal ATP production capacity 
(Alam et al., 2015). Using an in silico model it became clear that this (and other) 
parameter is severely affected when CI activity is decreased by more than 90% 
(Alam et al., 2015). In accordance to these results, O2 consumption rate and ATP 
production in skeletal muscle-derived mitochondria was only affected when CI 
activity was decreased by more than 80% (using rotenone) (Rossignol et al., 1999). 
Moreover, the O2 consumption rate and ATP production were only affected in 
brain mitochondria derived from a non-synaptic region when CI activity was 
reduced by 60-72% (Davey et al., 1997, Davey and Clark, 1996). However, this value 
was 25% in brain mitochondria derived from a synaptic region (Davey et al., 1997, 
Davey et al., 1998) indicating tissue- and regional-specific differences. These 
  General discussion 141 
findings all support a biochemical (mitochondrial) threshold effect (Rossignol et 
al., 2003). The above (i.e. absence of aberrant O2 consumption rate and ATP) 
suggests that a metabolic problem (based on O2 consumption rate and ATP 
production) does not occur in skeletal muscle tissue of the KO mice, which might 
also not be the primary tissue being affected by CI dysfunction (i.e. normal 
functioning of myoblasts) (Quintana et al., 2010). However, in vivo limited substrate 
(nutrient) availability and/or increased cellular activity could still result in restricted 
ATP levels and muscle pathology.  
 
Outlook 
OXPHOS dysfunction leads to a wide variety of both multi-systemic and tissue-
specific disorders and has been linked to many age-related diseases such as 
Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, amyotrophic 
lateral sclerosis (ALS), diabetes type II, and cancer (Breuer et al., 2013a, Chandra 
and Singh, 2011, Martin, 2011, Ritov et al., 2010, Swerdlow, 2012, Thorburn, 2004). 
Besides inherited disorders, OXPHOS dysfunction can be a consequence of drug 
off-target effects (Wallace, 2008). Currently there is no cure for patients suffering 
from an OXPHOS disorder. More in depth knowledge of the adaptive responses 
triggered by OXPHOS dysfunction can aid a rational design of intervention 
strategies. Although mitochondrial disorders comprise a phenotypically and 
genetically heterogeneous group of disorders, based on studies performed in this 
thesis and current literature (Abbud et al., 2000, Barnes et al., 2002, Besson et al., 
2015, Distelmaier et al., 2015, Hamrahian et al., 1999, Haran and Gross, 2014, Jing 
and Ismail-Beigi, 2007, Koseoglu and Beigi, 1999, Shetty et al., 1993, Shi et al., 1995, 
Suhane et al., 2013, Wu and Wei, 2012), stimulation of glucose uptake seems to be 
a general adaptive response. Moreover, the key role that both glucose uptake and 
mitochondria play in energy metabolism makes this knowledge applicable to a 
large group of metabolic-related diseases. For instance, in the case of type II 
diabetes, induction of enhanced glucose uptake could aid in lowering blood 
glucose levels. However, additional strategies might be necessary to prevent 
excessive lactate or ROS formation. In the case of cancer, inhibition of enhanced 
glucose uptake by tumor cells might reduce tumor growth. This thesis provides 
new insights in the regulation of glucose uptake by CI dysfunction and the cellular 
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consequences of enhanced glucose metabolism on which future research can 
build. For instance, a more detailed understanding of the role of AMPK and Sirt2 
in Glut1 stimulation could lead to more selective targeting. 
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Summary 
Glucose is one of the major energy sources for our body. In the majority of cells 
glucose is taken up by glucose transporter (GLUT)-mediated facilitated diffusion. 
Inside the cell, glucose is used to produce ATP and pyruvate by the enzymes of the 
glycolytic pathway in the cytosol. Pyruvate is taken up by mitochondria where it is 
converted by pyruvate dehydrogenase (PDH) to acetyl-coenzyme A. The latter is 
oxidized by the tricarboxylic acid (TCA) cycle, yielding reduced electron carriers 
that serve as substrates for the oxidative phosphorylation (OXPHOS) system in the 
mitochondria to produce ATP. The OXPHOS system consists of five multi-subunit 
complexes (CI-CV) and produces the majority of total ATP. Mutations in one of the 
subunits of the OXPHOS system can cause mitochondrial dysfunction leading to a 
wide variety of pathological conditions. Currently there is no cure for patients 
suffering from a mitochondrial disorder and a better understanding of the 
metabolic consequences is required for the development of treatment strategies. 
One of the frequently observed adaptive responses to OXPHOS dysfunction is a 
switch to a more glycolytic mode of ATP production. This often requires an 
increase in the rate of glucose uptake and glycolysis. In this thesis, the role of 
glucose in OXPHOS-dysfunctional myoblasts was assessed. 
 
Chapter 1 gives an introduction about GLUT-mediated glucose uptake and the 
modes of GLUT regulation. Furthermore, OXPHOS disorders and their effect on 
the production of reactive oxygen species (ROS) are presented. Finally, the 
interplay between ROS and glucose uptake is discussed.  
 
Because the current methods for glucose uptake measurements are limited in 
their spatial and temporal resolution, we developed a new microscopy assay for 
live, single-cell, quantitative glucose uptake measurements. In this assay, a 
protein-based sensor was used to visualize the intracellular glucose concentration. 
In Chapter 2, different fluorescence resonance energy-transfer (FRET)-based 
glucose sensors are compared and their applications are discussed. In Chapter 3, 
the glucose sensor with the highest dynamic range was used to develop the 
glucose uptake assay and to determine the kinetic parameters of glucose uptake 
and consumption in C2C12 myoblasts. Using this assay we found that a short-term 
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inhibition of CI or CIII induced a significant increase in the Vmax of glucose uptake 
and consumption. The kinetic parameters of glucose uptake and consumption 
were used to construct a mathematical model, which predicted a 2-fold increase 
in the steady-state glucose flux under CI-/CIII-inhibited conditions. Combining 
model predictions and empirical evidence, we found that this compensatory 
increase in glycolytic flux was sufficient to compensate for the lack of 
mitochondrial ATP production in CI-/CIII-inhibited C2C12 myoblasts. However, the 
fold increase necessary to compensate for reduced mitochondrial ATP production 
might vary depending on the cell type, the basal glycolytic and mitochondrial flux 
values, the residual ATP production rate after OXPHOS inhibition, and the ATP 
demand. Importantly, the combined approach of kinetic modeling and 
experimental analysis presented in this chapter, provides a tool to determine the 
glycolytic flux rate, which can help to answer various research questions. 
 
Opposed to the full chemical OXPHOS inhibition, patient cells usually display 
residual OXPHOS activity. Therefore, in Chapter 4 the effect of OXPHOS-
dysfunction on glucose uptake was studied in a primary myoblasts isolated from 
Ndufs4 knockout (KO) mice, a genetic model of isolated CI-deficiency. It was found 
that the glycolytic phenotype of myoblasts cultured in proliferation medium could 
be reversed by switching to differentiating medium containing 5 mM glucose or 
galactose. Under these conditions, KO myoblasts displayed a higher rate of 
glucose uptake compared to wild-type. Interestingly, this increased rate of glucose 
uptake was not due to upregulation of Glut1 or Glut4. 
 
Because of the limited availability of the primary KO myoblasts, the mode of 
regulation of Glut1-mediated glucose uptake was studied in CI-/CIII-inhibited 
C2C12 myoblasts in Chapter 5. For optimal comparison with the primary KO 
myoblasts, Glut1 upregulation was prevented by performing a short-term (30 min) 
inhibition of CI/CIII. It was found that while the amount of Glut1 at the plasma 
membrane remained the same, Glut1 activity was increased by a signaling cascade 
involving LKB1, AMPK, and Sirt2. Glut1 did not appear to be a direct target of Sirt2-
mediated deacetylation, although Glut1 was found to be acetylated. The role of 
Sirt2 in the stimulation of Glut1 activity has not been described before and may 
provide a target for future research and possible treatment strategies. 
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Finally, Chapter 6 integrates the findings from the studies in chapter 3, 4, and 5 
and discusses these in a broader perspective. The biochemical consequences of 
enhanced glucose uptake, such as the production of ATP, lactate, and ROS are 
discussed. In addition, the physiological relevance of the regulation of Glut1 
activity is assessed. In addition, the suitability of primary myoblasts derived from 
Ndufs4 KO mice as a model for CI-dysfunction is discussed. In conclusion, in this 
thesis I gained insight into the interplay between OXPHOS-dysfunction and 
glucose uptake. These insights can be used in future research for the treatment of 
a wide variety of metabolic disorders.  
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Samenvatting 
De enkelvoudige suiker glucose is een van de voornaamste energiebronnen voor 
ons lichaam. In de meeste lichaamscellen wordt glucose passief opgenomen met 
behulp van glucose transporters (GLUTs). Deze GLUTs faciliteren de glucose 
diffusie van buiten de cel (hogere glucose concentratie) naar binnen in de cel 
(lagere glucose concentratie). In de cel wordt de energie die is opgeslagen in de 
chemische verbindingen van glucose vrijgemaakt met behulp van de enzymen van 
1) de glycolyse, 2) het pyruvaat dehydrogenase complex, 3) de citroenzuurcyclus 
en 4) het oxidatieve fosforylering systeem. De vrijgekomen energie wordt gebruikt 
om adenosine trifosfaat (ATP) te maken. ATP is de energie valuta van de cel. Het 
merendeel van de ATP wordt gemaakt door het oxidatieve fosforylering systeem. 
Dit systeem bestaat uit vijf grote eiwitcomplexen (complex I-V) die zich bevinden 
in het binnenste membraan van de mitochondriën, de energiefabrieken van de 
cel. Mutaties in een van deze eiwitcomplexen leidt tot mitochondriële dysfunctie 
en een breed scala aan klachten en symptomen. Tot op heden is er geen genezing 
mogelijk voor patiënten met een mitochondriële aandoening. Betere kennis over 
de cellulaire consequenties van mitochondriële aandoeningen kan bijdragen aan 
de ontwikkeling van medicijnen. Een van de veel voorkomende 
aanpassingsmechanismes van de cel, is de overgang naar een meer glycolytische 
manier van ATP productie. Dit vereist vaak een verhoging van de glucose opname 
en glycolyse snelheid. Dit proefschrift gaat over de rol die glucose speelt in 
spiercellen met een verminderde activiteit van het oxidatieve fosforylering 
systeem. 
 
Hoofdstuk 1 geeft een introductie over GLUT gemedieerde glucose opname en 
de regulatie van GLUTs. Hierbij is vooral gefocust op GLUT1 omdat dit de enige 
glucose transporter is die voorkomt in de in dit onderzoek gebruikte spiercellen. 
Ook wordt mitochondriële dysfunctie en het effect hiervan op de productie van 
reactieve zuurstof moleculen besproken. Verder wordt de relatie tussen deze 
reactieve zuurstof moleculen en glucose opname bediscussieerd.  
 
Omdat de huidige methoden voor glucose opname metingen gelimiteerd zijn in 
hun ruimtelijke- en tijdsresolutie, hebben we een nieuwe microscopie methode 
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ontwikkelt om glucose opname in levende cellen te kwantificeren. In dit protocol 
wordt gebruik gemaakt van een sensor om de glucose concentratie in de cel te 
kunnen visualiseren. In hoofdstuk 2 worden verschillende glucosesensoren met 
elkaar vergeleken en de toepassingen worden besproken. Deze sensoren zijn 
eiwitten die glucose-binding rapporteren door middel van veranderingen in 
‘fluorescentie resonantie energie overdracht’. In hoofdstuk 3 is de glucosesensor 
met het grootste dynamische bereik gebruikt voor de ontwikkeling van de glucose 
opname methode. Met behulp van deze methode zijn de kinetische parameters 
van glucose opname en consumptie bepaald in de spiercellijn C2C12. Hierbij is 
gevonden dat de maximale snelheid van glucose opname en consumptie 
significant toenam door remming van complex I of III. De gemeten kinetische 
parameters zijn gebruikt om een wiskundig model de bouwen. Dit model 
voorspelde een verdubbeling van de glucose snelheid (flux) in complex I of III 
geremde C2C12 spiercellen. Door voorspellingen en experimenten te combineren 
vonden we dat deze verdubbeling van de glucose flux voldoende was om te 
compenseren voor het gebrek aan mitochondriële ATP productie in complex I of 
III geremde C2C12 cellen. Hoeveel de glucose flux moet toenemen om te 
compenseren hangt echter af van het celtype, de basale glycolyse en 
mitochondriële snelheid, de ATP productie na mitochondriële remming en het ATP 
verbruik. Van belang is dat de glucose flux goed bepaald kan worden door de 
gecombineerde aanpak van modeleren en experimentele data. Deze aanpak kan 
helpen bij het beantwoorden van een breed scala aan biologische vraagstukken. 
 
In tegenstelling tot (volledige) chemische remming van de oxidatieve fosforylering, 
hebben patiënten cellen meestal een restactiviteit. Daarom hebben we in 
hoofdstuk 4 gebruikt gemaakt van een genetisch muismodel met complex I-
deficiëntie. Deze muis mist het complex I-eiwit Ndufs4 en vertoont veel van de 
symptomen die patiënten ook vertonen. We hebben spiercellen uit deze muis 
geïsoleerd en gebruikt om het effect van complex I-deficiëntie op glucose opname 
te bestuderen. Het bleek dat de conditie waaronder deze spiercellen gekweekt 
werden van cruciaal belang was voor de balans tussen glycolyse en oxidatieve 
fosforylering. Om een zo groot mogelijk effect van complex I-deficiëntie te zien 
kozen we voor de conditie waarbij cellen voornamelijk afhankelijk zijn van 
oxidatieve fosforylering voor hun ATP productie. Onder deze conditie vonden we 
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dat de glucose opname snelheid significant hoger was in complex I-deficiënte 
spiercellen vergeleken met spiercellen van gezonde muizen. Opmerkelijk was dat 
deze verhoogde glucose opname snelheid niet kwam door een toename van het 
aantal glucose transporters dat tot expressie kwam.  
 
Omdat de spiercellen uit de muis schaars waren, hebben we gekozen om de 
regulatie van glucose opname in de complex I geremde C2C12 cellijn te 
bestuderen in hoofdstuk 5. Om de glucose opname regulatie in de geremde 
cellijn zo goed mogelijk te kunnen vergelijken met de spiercellen uit de complex I-
deficiënte muis was het van belang om te voorkomen dat de Glut expressie 
toenam. Dit hebben we voorkomen door te kiezen voor een korte (30 min) 
remming van complex I. We vonden dat de hoeveelheid beschikbare Glut1 op het 
celmembraan niet toenam door complex I-remming. De activiteit van Glut1 bleek 
echter wel toe te nemen en dit werd geïnduceerd door een signaleringscascade 
waar de eiwitten LKB1, AMPK en Sirt2 bij betrokken waren. Glut1 bleek 
geacetyleerd te zijn en omdat Sirt2 acetylgroepen van eiwitten kan verwijderen 
was de hypothese dat Sirt2 Glut1 deacetyleert door complex I-remming. Dit bleek 
echter niet het geval. Het lijkt erop dat er nog meer signaleringseiwitten betrokken 
zijn bij Glut1 activatie. Echter, de betrokkenheid van Sirt2 is een bevinding die 
nieuwe aanknopingspunten verschaft voor toekomstig onderzoek. Bovendien kan 
Sirt2 een nieuw doelwit zijn voor de ontwikkeling van medicijnen tegen een breed 
scala van metabole ziektes.  
 
Uiteindelijk wordt in hoofdstuk 6 de bevonden resultaten samengebracht en in 
een breder perspectief geplaatst. De biochemische consequenties van verhoogde 
glucose opname voor de cel worden besproken. Voorbeelden hiervan zijn de 
productie van ATP, lactaat en reactieve zuurstof moleculen. Ook wordt de 
fysiologische relevantie van de regulatie van Glut1 besproken. Verder wordt de 
geschiktheid van de spiercellen uit het complex I-deficiënte muismodel als een 
nieuw celmodel voor complex I-deficiëntie besproken. In dit proefschrift heb ik 
inzicht gekregen in de wisselwerking tussen een mitochondriële dysfunctie en 
glucose opname. Deze informatie kan gebruikt worden voor toekomstig 
onderzoek. 
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